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Abstract 
 Enantiopure nitrogen and oxygen containing heterocycles are prominently 
displayed in a variety of important pharmaceuticals and biologically active products. As 
such accessing these scaffolds in an enantioselective and efficient manner is an 
interesting challenge. We envisioned that novel asymmetric carboamination and 
carboetherification reactions would be powerful methods to synthesize these 
enantiopure heterocycles, as you can generate a library of enantiopure compounds in a 
facile manner with this approach. While these enantioselective carboamination and 
carboetherification reactions are robust methods of accessing enantiopure heterocycles, 
at the onset of the work detailed in this thesis all of the efforts in this area were related 
to the formation of 5-membered rings bearing a single nitrogen heteroatom. 
As such, this thesis entails the development of new enantioselective 
carboamination and carboetherification reactions meant to address the above 
limitations. Chapter 2 details the development of an enantioselective carboamination 
reaction to access enantiopure imidazolidin-2-ones in up to 97:3 er. This work also 
shows how reaction conditions, namely the choice of aryl halide, use of water additive 
and substrate electronics, affect the final enantioselectivity observed in the products. 
Chapter 3 details the development of a general procedure to access 
tetrahydroquinolines, tetrahydroisoquinolines and tetrahydroquinoxalines all in > 95:5 er. 
Furthermore, these reactions in chapter 3 are rare transformations of this type that allow 
for the synthesis of quaternary centers in high enantioselectivity. Chapter 4 details the
xiii 
 
 development of a novel carboetherification reaction, and how using a modular TADDOL 
ligand scaffold allowed us to rationally design a ligand that afforded our desired 
products in >95:5 er. Lastly, Chapter 5 entails the initial results looking into the 
synthesis of enantiopure benzofused oxygen heterocycles.  
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Chapter 1 
Enantioselective Transition Metal Catalyzed Alkene Di-
Functionalization Reactions 
1.1 Introduction 
 Chemical transformations of alkenes by transition metal catalysis have proven to 
be highly effective reactions for a variety of processes. A few examples of these 
powerful reactions include hydrogenations and the Wacker oxidation.1,2 These 
aforementioned transformations are utilized to form a range of useful chemical products 
and intermediates, not to mention a variety of consumer goods such as margarines and 
diesel fuel.1,2 
 Due to the synthetic utility of transition metal catalyzed reactions of alkenes,1,2 
using these transformations to afford new and interesting products is of importance to 
the chemical community. One specific area of significance is in the formation of new 
heterocyclic compounds. The importance of these heterocycles stems from the wide 
array of these motifs in biologically active compounds, natural products, and 
pharmaceuticals.3 Also, many of these biologically active heterocycles are chiral, with 
the compounds possessing stereocenters adjacent to the heteroatom in the ring (Figure 
1.1).3 As such, the development of new reactions to access these chiral heterocycles 
from simple alkene precursors is of extreme importance to new methodological 
2 
 
advances in this area. 
Figure 1.1 Biologically relevant enantiopure heterocycles 
 
1.2 Stereoselective Synthesis of Heterocycles via Palladium Catalyzed 
Oxyarylation and Aminoarylation Reactions 
 Demonstrating the powerful nature of transition metal catalyzed reactions of 
alkenes, our group developed a new series of methods to form a variety of oxygen and 
nitrogen containing heterocycles via Pd-catalyzed di-functionalization reactions of 
alkenes (Scheme 1.1).4 This chemistry was developed over the past decade or so, and 
these reactions have allowed us to access compounds that possess privileged motifs, 
which are noted in an array of biologically active compounds (Figure 1.1).3 As shown in 
Scheme 1.1, we start with readily accessible substrates bearing a heteroatom tethered 
to an alkene. We subject these substrates to the reaction conditions noted in Scheme 
1.1 to yield a product bearing a new heterocyclic ring, a new carbon-heteroatom bond, a 
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new carbon-carbon bond, and depending on alkene substitution up to 2 new 
stereocenters. This methodology has yielded a variety of interesting heterocycles 
including pyrrolidines, tetrahydrofurans, pyrazolidines, morpholines, and 
benzodiazapenes.4 These products are afforded in high yields and excellent 
diastereoselectivities. Moreover, we can readily access libraries of compounds by 
simply changing the aryl or alkenyl electrophile in the reaction. 
Scheme 1.1 Stereoselective synthesis of heterocycles by the Wolfe group 
 
 Through some well-designed experiments and deuterium labeling studies, our 
group was able to determine that these heterocycles are produced through a cis 
addition of the alkene into the Pd-heteroatom bond.5,6 In terms of how the complete 
mechanism progresses, we envision that initially Pd(0) undergoes oxidative addition to 
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afford the Pd(II) intermediate 1-A. After deprotonation of the substrate, subsequent 
coordination of the heteroatom to the palladium yields the intermediate 1-B.  1-B 
undergoes a syn-migratory insertion of the alkene into the Pd-N bond to afford 
intermediate 1-C. Carbon-carbon bond forming reductive elimination from 1-C affords 
the desired heterocyclic product and regenerates the Pd(0) catalyst.6 
Figure 1.2 Catalytic cycle for Pd-catalyzed carboamination reaction 
 
1.3 Enantioselective Carboamination Reactions of Alkenes Catalyzed by 
Transition Metals: A Recent Timeline of Relevant Events 
A variety of research is directed towards the enantioselective addition of 
heteroatoms to alkenes via transition metals, and recent reviews highlight this field in 
depth.7 However, our group is specifically interested in enantioselective di-
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functionalization reactions of alkenes via Pd-catalyzed carboamination and 
carboetherification reactions. Although we reported our initial racemic carboamination 
and carboetherification reactions before 2005, an enantioselective variant of our 
chemistry was not published until 2010. During this time, related enantioselective 
transformations that form a C-N bond and a C-C bond across an alkene were published. 
 In 2006, a report from the Yang group detailed an enantioselective synthesis of 
indolines through an intramolecular Pd(II) catalyzed oxidative cyclization reaction.8 This 
reaction proceeds through an amidopalladation followed by an intramolecular olefin 
insertion into a Pd(II) alkyl intermediate. Subsequent beta-hydride elimination affords 
the final product (Scheme 1.2). However, it is of note that this reaction is limited by the 
necessity of an intramolecular olefin addition for the C-C bond formation, which impedes 
the synthesis of a library of enantioenriched compounds. 
Scheme 1.2 Enantioselective oxidative cyclization reaction 
 
 Following the above reaction, in 2007 the Chemler group reported a Cu(II) 
catalyzed enantioselective carboamination reaction to afford enantioenriched sultams 
(Scheme 1.3).9 Through some mechanistic work, they determined that their reaction 
proceeded via a syn aminocupration of the alkene.9 That being said, their mechanism is 
quite different from ours displayed in Figure 1.2. Notably, after the syn aminocupration 
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step in their mechanism, the Cu-C alkyl intermediate undergoes homolysis to afford an 
alkyl radical intermediate.9 This alkyl radical is then trapped by an intramolecular 
addition into a nearby pi bond in the nitrogen protecting group. As shown in Scheme 
1.3, this reaction works well to afford chiral sultams in good yields and 
enantioselectivities. However, like the aforementioned reaction in Scheme 1.2, this 
method relies on an intramolecular addition to form the C-C bond, which limits the facile 
synthesis of a library of compounds.  
Scheme 1.3 Copper catalyzed enantioselective carboamination reaction 
 
 In 2010, Dr. Peter Mai from our group reported the Pd-catalyzed enantioselective 
synthesis of pyrrolidines via an asymmetric carboamination reaction (Scheme 1.4).10 
This reaction worked well to form a variety of different products in moderate to good 
yields and good enantioselectivities. Our carboamination reaction differs from the two 
reactions mentioned above in the fact that an external component (aryl or alkenyl 
halide) is used in the C-C bond forming step. This allows the user to quickly form a 
variety of new enantioenriched products by simply changing the aryl or alkenyl halide 
used in the reaction. 
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Scheme 1.4 Pd-catalyzed enantioselective synthesis of pyrrolidines 
 
 During our work in this area, we noted that chiral monodentate ligands were 
essential to achieving high enantioselectivities.10 This is interesting as similar reactions, 
such as the reports by Yang and Chemler mentioned above, utilize bi-dentate ligands to 
afford the enantioenriched products.8,9 True to this statement, a recent review stated 
that our reaction (Scheme 1.4) was the only successful application of a monodentate 
chiral ligand to an enantioselective alkene nucleopalladation reaction.7b We believe that 
these monodentate chiral ligands are vital to our reaction, as some recent mechanistic 
studies from our group illustrated that one arm of a bi-dentate ligand disassociates prior 
to the aminopalladation step.6 Therefore, in our enantioselective carboamination 
reactions, a large portion of the bi-dentate chiral ligand would be placed away from the 
reaction site, potentially lowering the asymmetric induction in the products. Indeed this 
is what was observed by our group, and low levels of asymmetric induction were noted 
with chiral bi-dentate ligands in these reactions (Scheme 1.5). 
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Scheme 1.5 Poor enantioinduction with bi-dentate chiral ligands 
 
 After this report by our group, the Chemler group came out with another 
enantioselective Cu(II) catalyzed carboamination reaction in 2012 (Scheme 1.6).9c This 
work differed from their previous methodology, as it used an external agent, in this case 
a styrene, to trap the alkyl radical. Thus, this reaction now more closely resembles our 
carboamination methodology, with the potential to afford an array of products by 
switching out the styrene moiety that is used. However, changing the styrene from 1,1-
diphenylethylene typically afforded products in lower enantioselectivities for this 
transformation. 
Scheme 1.6 Copper catalyzed enantioselective carboamination reaction 
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1.4 Application of Enantioselective Carboamination Reactions to Natural Product 
Synthesis 
 Although the above reactions were useful at synthesizing enantiopure 
heterocycles,8,9,10 applying these new methodologies to access more complex targets 
was of interest as well. As such, our group and Chemler’s group both utilized these 
carboamination reactions to access natural products and related derivatives. As noted 
in Figure 1.3, Chemler was able to afford (S)-tylophorine in 81% ee in 9 linear steps.11a 
The need for Chemler’s group to attach the reacting arene to the substrate substantially 
added to their step count. A few years later, we were able to afford (R)-tylophorine in 
88% ee in just 3 linear steps with our Pd-catalyzed carboamination reaction.10 Our 
group was also able to show the utility of our methodology to afford (+)-aphanorphine in 
81% ee.10b 
Figure 1.3 Natural products synthesized via enantioselective carboamination reactions 
 
 Additionally, it would be interesting to utilize similar carboamination 
methodologies to help streamline other synthetic approaches to complex targets. Thus, 
in 2013 Dr. Nick Babij in our group elegantly displayed the utility of our enantioselective 
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carboamination reactions to do just that (Scheme 1.7).12 He was able to develop an 
enantioselective desymmetrization reaction of substrate 1-1 to afford the complex 
bicyclic urea 1-2 with three new stereocenters in good yield and enantiomeric ratio. The 
work outlined in Scheme 1.7 below was a beautiful expansion of a similar reaction that 
will be discussed in chapter 2. This enantioselective desymmetrization reaction 
streamlined the synthesis of the bicyclic urea 1-2 and it was afforded in just 5 steps, 
compared to 10 steps needed to generate a similar intermediate in a previous synthesis 
of bicyclic ureas by our group.13 Additionally, this reaction allowed access to 
enantiopure bicyclic ureas without the need of a stoichiometric chiral auxiliary. This 
method was also the first example of enantioselective six-membered ring forming 
reactions with our chemistry, and intermediate 1-2 was utilized to synthesize the tricyclic 
guanidine 9-epi-batzelladine K. 
Scheme 1.7 Enantioselective Pd-catalyzed desymmetrization reactions 
 
1.5 Enantioselective Copper Catalyzed Carboetherification Reactions 
 Recently in 2014, the Chemler group reported a Copper catalyzed 
enantioselective carboetherification reaction capable of generating products in up to 95 
% ee.14 The reactions were shown to work best when utilizing a system similar to that in 
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Scheme 1.6, where a styrene derivative can intercept the alkyl radical that is generated 
in the reaction (Scheme 1.8). This publication came out when we were in the middle of 
our own studies to afford tetrahydrofuran products enantioselectivly via a Pd-catalyzed 
carboetherification reaction. We will elaborate further in chapter 4 on our studies, but it 
is imagined that the two methods will be complimentary to each other as different 
products are formed during the course of the reactions. 
Scheme 1.8 Copper catalyzed enantioselective carboetherification reactions 
 
1.6 Application of Enantioselective Pd-Catalyzed Alkene Di-Functionalization 
Reactions to New Scaffolds 
 The initial enantioselective carboamination reaction by our group proved to be 
very successful for the synthesis of enantioenriched pyrrolidines.10a Similar 
enantioselective methodologies from other groups were successful as well,8,9 and these 
reactions were even extended to the synthesis of a few natural products.10b,11,12 That 
being said, there was still a lot of chemistry to explore in this area. We were uncertain if 
enantioselective carboamination reactions would have a broad application to an array of 
heterocycles. For instance, at the outset of my thesis there were no enantioselective 
carboamination methodologies that formed heterocycles bearing more than one 
nitrogen in the ring. Furthermore, carboamination reactions to form heterocyclic ring 
systems larger than five members in high enantioselectivity were unknown at this time 
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as well. Moreover, we desired to learn more about how reaction conditions and 
substrate structure affect the enantioselectivity of the products. As such, the following 
work outlined in chapters two through five will depict our recent efforts towards the 
expansion of carboamination and carboetherification reactions to form an array of 
enantioenriched heterocycles. Also, we will note how the substrate structure and 
reaction conditions affect the enantioselectivity of our carboamination products. 
Furthermore, we wanted to synthesize enantioenriched oxygen heterocycles, as at the 
outset this thesis research no groups had reported these reactions in high 
enantioselectivity.14 
 Chapter two details our studies into the synthesis of enantiomerically enriched 
cyclic ureas via an asymmetric Pd-catalyzed alkene carboamination reaction. In this 
chapter we note the importance of reactions conditions in achieving high 
enantioselectivities, and suggest that the enantiodetermining step in these reactions 
appears to be C-C bond forming reductive elimination. Chapter three explains our 
approach to the enantioselective synthesis of six membered benzo-fused heterocycles. 
We were able to form 3 distinct classes of benzo-fused products all in >95:5 er. Also, to 
the best of our knowledge, the reactions in chapter three are the first highly 
enantioselective transition metal catalyzed C-N bond forming reactions involving 
addition to a 1,1-disubstituted alkene. 
 To further expand the utility of our enantioselective reactions, our studies in 
chapter four entail the expansion into enantioselective carboetherification reactions. A 
key point in this chapter is the development of TADDOL ligands inspired by nature to 
help form the desired products in better enantioselectivities. Chapter 5 is an expansion 
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of the enantioselective carboetherification reactions to afford benzo-fused heterocycles. 
Promising yields and enantioselectivities are noted for these compounds, and further 
ligand and substrate development will be required to afford these products in better 
enantioselectivities and yields. 
 In all, it is believed that the reactions developed in chapters two through five will 
find a use in the synthesis of biologically relevant scaffolds.3 Furthermore, it is 
envisioned that the data gathered on substrate electronics, enantiodetermining step, 
ligand structure, and reaction additives will help guide similar reaction development in 
the future.  
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Chapter 2 
Enantioselective Synthesis of Imidazolidin-2-ones via Pd-Catalyzed 
Carboamination Reactions 
2.1 Introduction 
The imidazolidin-2-one core is displayed in a variety of biologically active 
molecules,1 and it is also used in other applications such as a precursor to 1,2-
diamines2  and as a monomer unit in biomaterials.3 More specifically, chiral 4-
substituted imidazolidin-2-ones have proven to be potent HIV-1 protease inhibitors 
(Figure 2.1),1a and other chiral imidazolidin-2-ones display an array of biological 
activities as well.1d  
Figure 2.1 HIV-1 protease inhibitors 
 
As is typical with many of the syntheses of chiral imidazaolidin-2-ones,1a,3 the 
construction of the imidazolidin-2-one cores in Figure 2.1 commences with  the chiral 
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precursor 2-6 (Scheme 2.1). Access to chiral imidazolidin-2-one 2-8 requires 4 synthetic 
steps from 2-6. Furthermore, the synthesis of different imidazolidin-2-ones with varied 
aryl groups in the 4 position is limited to amino acid precursors that fit the necessary 
synthetic profile. As such, the ability to afford imidazolidin-2-ones from achiral 
precursors via transition metal catalysis would improve upon these aforementioned 
methods to access chiral imidazolidin-2-ones. Also, starting from achiral precursors 
allows for the synthesis of imidazolidin-2-ones from cheaper and more readily 
accessible achiral precursors.  
Scheme 2.1 Synthesis of precursor 2-8 from boc-phenylalanine 
 
2.2 Previous Results 
 Due to the utility of the imidazolidin-2-one core,1-3 the Wolfe group developed a 
method to access racemic imidazolidin-2-ones in good yields and 
diastereoselectivities.4 Due to our interest in the development of novel enantioselective 
reactions,5 the bioactivity of chiral imidazolidin-2-ones,1-3 and the lack of methods 
available to afford enantioenriched imidazolidin-2-ones catalytically,2,6  we decided it 
would be essential to develop an enantioselective variant of our carboamination 
reaction to access imidazolidin-2-ones.  
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 Previous members of the Wolfe lab probed the enantioselective synthesis of 
imidazolidin-2-ones. Dr. Johnathon Fritz was able to afford enantioenriched 
imidazolidin-2-ones in up to 86% yield and 66:34 er with (S)-Phanephos, 2-
bromotoluene, and substrate 2-9.7 However, it was not until after these initial reactions 
were completed that we understood the importance of monodentate ligands for 
achieving high enantioselectivities in our carboamination reactions.5,8 
 Dr. Peter Mai screened a broader variety of ligands with substrate 2-9, and was 
able to show that ligand 2-L1 worked best, affording product 2-10 in 82:18 er and 52% 
yield. Furthermore, he also showed that ligand 2-L2 afforded the product in a similar 
enantiomeric ratio as well (Scheme 2.2).9 
Scheme 2.2 Enantioselective carboamination reaction of substrate 2-9
 
2.3 Initial Optimization of Reaction Conditions and Substrate 
 The anticipation at the outset of our studies into the enantioselective formation of 
imidazolidin-2-ones was that the ability to synthesize substrates in a straightforward 
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manner would be essential to the overall success of this project. Therefore, utilizing 
readily available allylamines and isocyanates to access the N-allyl urea substrates 
afforded us the opportunity to test a variety of different compounds for this methodology 
(Scheme 2.3).  This was important to us as we wanted to amass more information on 
how substrate structure and reaction conditions affect enantioselectivity in 
carboamination reactions. More specifically we wanted to determine the role of the 
protecting group, reactants, and reaction additives in terms of how each piece affects 
enantioselectivity.  
Scheme 2.3 Synthesis of N-allylurea substrates 
 
 We decided to undertake an initial ligand screen with substrate 2-11 to observe 
how the reaction progressed with a more electron rich benzyl protecting group. 
However, as noted in Table 2.1 the more electron rich protecting group led to the 
formation of the hydroamination side product 2-13. The low yields shown below in Table 
2.1 are indicative of the difficulty in separating the two products 2-12 and 2-13. 
 
 
 
 
19 
 
Table 2.1 Initial ligand screen with substrate 2-11a 
 
a
 Conditions: Reactions were conducted on a 0.15 mmol scale using 1.0 equiv substrate, 1.5 equiv Ar-Br, 
1.5 equiv NaO
t
Bu, toluene (0.2 M), 90 °C, 12-14 h. Yields and enantiomeric ratios refer to isolated 
compound 2-12 unless noted otherwise. 
 
Changing to substrate 2-14 led to the sole formation of the carboamination 
product 2-15 (Table 2.2), with no competing hydroamination. Furthermore, use of 1-
Bromo-4-tert-butylbenzene as the electrophile allowed for easier analysis of the 
products via HPLC. A few of the ligands tested for these reactions are shown in Table 
2.2 below. The optimal ligand proved to be (S)-Siphos-PE (2-L2) affording the desired 
product in 99% yield and 81:19 er. Although 2-L10 afforded a promising result, a screen 
of similar ligand scaffolds did not lead to any improvement in enantioselectivity or yield. 
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Table 2.2 Initial ligand screen with substrate 2-14a 
 
 
 
   
 
 
 
 
a
 Conditions: Reactions were conducted on a 0.10 mmol scale using 1.0 equiv substrate, 2.0 equiv Ar-Br, 
2.0 equiv NaO
t
Bu, toluene (0.2 M), 90 °C, 12-14 h. Yields and enantiomeric ratios refer to isolated 
compound 2-15. 
 
 With the optimal ligand (S)-Siphos-PE (2-L2) in hand further investigation of the 
protecting groups was initiated. We decided to alter the protecting group on the non-
cyclizing nitrogen as noted in Table 2.3. Changing the protecting group to other phenyl 
based systems such as substrates 2-16 and 2-18, afforded the products in lower yields 
and comparable enantioselectivities to substrate 2-14. The optimal protecting group on 
the non-cyclizing nitrogen was found to be methyl, and when substrate 2-23 was 
subjected to the reaction conditions, product 2-24 was afforded in 93% yield and 89:11 
er. Other alterations such as allyl (2-21) as the protecting group or using an unprotected 
nitrogen (2-20) afforded poorer results than 2-23 in the reaction. Since substrate 2-23 
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bearing the N-methyl group afforded the best results in this system, we decided to use 
this structure for future investigations. 
Table 2.3 Varying non-cyclizing nitrogen protecting groupa 
 
 
a
 Conditions: Reactions were conducted on a 0.10 mmol scale using 1.0 equiv substrate, 2.0 equiv Ar-Br, 
2.0 equiv NaO
t
Bu, toluene (0.2 M), 90 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated 
compounds. 
c
 Used 4-bromobenzophenone. 
 
 To further improve the asymmetric induction of this reaction, we wanted to 
determine if the nucleophilicity of the nitrogen would affect the enantioselectivity of the 
products. As shown in Table 2.4, we synthesized a variety of substrates bearing 
electron poor and electron rich phenyl groups on the cyclizing nitrogen. The data in 
Table 2.4 shows that the enantioselectivity of the products increases when the 
nucleophilicity of the cyclizing nitrogen decreases. Unfortunately, under standard 
reaction conditions at 90 °C low chemical yields were noted for substrates 2-31 and 2-
33, with unreacted starting material still present in the crude reaction mixtures. 
However, simply heating the reaction up to 120 °C afforded the products in good yields, 
with little effect on the enantioselectivity. The best result was obtained with substrate 2-
33, affording the desired product 2-34 in 81% yield and 96:4 er.  
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Table 2.4 Electronic effects of cyclizing nitrogena 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv Ar-Br, 2.0 equiv NaO
t
Bu, 
toluene (0.2 M), 90 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated compounds (average of 
two or more runs). 
c
 Reactions were conducted at 120 °C in xylenes. 
 
 Next, we wanted to explore scope of the reaction with different aryl halide 
electrophiles.  Interestingly, when substrate 2-31 was subjected to the reaction 
conditions noted in Table 2.5 we observed that the enantioselectivity changed 
depending on the choice of aryl halide. The use of aryl iodides afforded products with 
lower enantioselectivities when compared to the use an aryl bromide (entries 1-6). 
However, this was only true when electron rich and electron neutral electrophiles were 
employed. When an electron poor aryl halide was subjected to the reaction conditions 
(entries 7-8), the use of the aryl iodide or the aryl bromide led to the same 
enantioselectivity for 2-38. Employing aryl chlorides for these reactions led to no 
formation of the desired product, and the use of phenyl triflate led to the formation of a 
hydroamination product in 70% yield. Furthermore, extensive screening of other bases, 
solvents, palladium sources, and even halide abstraction agents such as silver salts 
failed to produce products in better enantioselectivities. 
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Table 2.5 Scope of asymmetric carboamination with 2-31a 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv Ar-X, 2.0 equiv NaO
t
Bu, 
xylenes (0.2 M), 120 °C, 14-18 h. 
b
Yields and enantiomeric ratios refer to isolated compounds (average of 
two or more runs).  
 
 In order to further optimize the reaction, we wanted to test the electrophile scope 
with 2-33, which gave higher enantioselectivity than substrate 2-31 in preliminary 
screens. Initially, electron poor aryl bromides afforded irreproducible results under our 
reaction conditions. We assumed that this variability must be due to one of the reaction 
components. The most inconsistent component of our reaction mixture is NaOtBu, as 
this base is very hygroscopic. As such, we believed the quality of the base (i.e. amount 
of water retained) may be affecting the enantioselectivity of product 2-41. We tested this 
theory by adding water to the reaction. As noted in Table 2.6, reactions utilizing electron 
poor aryl halides always benefited from the addition of 2.0 equivalents  
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Table 2.6 Scope of asymmetric carboamination with 2-33a 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv Ar-X, 2.0 equiv NaO
t
Bu, 
xylenes (0.2 M), 115 °C, 14-18 h. 
b 
Additive is either 2.0 equiv of H2O or 40% TFA. 
c 
Yields and 
enantiomeric ratios refer to isolated compounds (average of two or more runs).  
 
 of water to the reaction (entries 1-12). Other amounts of water were tested under the 
reaction conditions, and although 0.50 equivalents of water was able to afford higher 
enantioselectivities, the use of 2.0 equivalents of water led to better reproducibility. Also, 
we realized that any water added to the reaction mixture would result in the formation of 
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a hydroxide ion. Thus, we tested the reaction with NaOH as the base (entry 3) and 2-41 
was afforded in high enantioselectivity, albeit with a slightly lower yield. Furthermore, 
the carboamination reaction with 2-33 also showed the same halide ion effect that was 
previously mentioned in Table 2.5, and lower enantioselectivities were noted when an 
aryl iodide was used in place of an aryl bromide (Table 2.6 entries 13-14). The reaction 
also performs well with electron neutral and electron rich aryl bromides (entries 13-19).  
 We also explored the use of disubstituted alkenes under our reaction conditions. 
The reaction with the 1,1-disubstituted alkene  2-53 worked well to afford  2-54 in 72% 
yield and 88:12 er (Scheme 2.4 a). However, conversion of 2-53 to form the quaternary 
carbon in 2-54 required heating the reaction up to 135 °C. The use of the 1,2-
disubstituted alkene 2-55 afforded no product, even under higher temperatures. To 
determine the stereochemistry of the addition to the alkene, we synthesized the Z-
deuterioalkene 2-56 and subjected it to our reaction conditions. This reaction proceeded 
via a net syn-addition to the alkene to afford the 2-57 in 85% yield, 95:5 er, and 7:1 dr 
(Scheme 2.4 c).10 
Scheme 2.4 Reactivity of disubstituted alkenes 
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2.4 Determination of Absolute Stereochemistry 
 In order to determine the absolute stereochemistry of the imidazolidin-2-one 
products from our asymmetric carboamination reactions (Tables 2.5 and 2.6), and to 
show the feasibility of deprotecting the p-nitrophenyl group, 2-48 was subjected to the 
reaction conditions noted in Scheme 2.5 a. A simple and efficient procedure involving 
the reduction of the nitro group, acylation, and then oxidative cleavage with CAN 
afforded 2-58 in 88% yield and 93:7 er. This 3 step procedure required only a single 
chromatographic step. In order to determine the absolute stereochemistry of 2-58, we 
needed to synthesize an authentic sample from a compound with a known absolute 
configuration. Thus, 2-59 was synthesized from the readily available amino acid L-
phenylalanine.11 Heating 2-59 with CDI afforded 2-60, and chiral HPLC and optical 
rotation data confirmed that 2-60 and 2-58 are the same enantiomer. 
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Scheme 2.5 Deprotection and determination of absolute configuration of 2-48 
 
2.5 Explanation of Electronic, Additive, and Halide Ion Effects on 
Enantioselectivity 
 In Tables 2.4, 2.5, and 2.6, a number of interesting effects on product 
enantioselectivity were observed based on slight changes to the substrate and reaction 
conditions. Interestingly, previous asymmetric carboamination reactions that afforded 
pyrrolidine products did not note any of these effects under very similar reaction 
conditions.5 Additionally, the imidazoldin-2-one product 2-51 and pyrrolidine product 2-
62 proceed with opposite absolute asymmetric induction under identical reaction 
conditions (Scheme 2.6). Furthermore, formation of pyrrolidine products is inhibited by 
the addition of water, and no product was formed with water added to the system. Also, 
the pyrrolidine products show no difference in asymmetric induction when changing 
from aryl bromides to aryl iodides.5 
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Scheme 2.6 Stereochemistry of imidazolidin-2-one versus pyrrolidine products 
 
 Although there are differences in the absolute product stereochemistry in the 
carboamination reactions of 2-33 compared to 2-61, these reactions also have 
similarities. Both reactions from Scheme 2.6 have been shown to proceed through a 
syn-addition to the alkene based on deuterium labeling studies. Also, the asymmetric 
induction in the above reactions is not effected in either case by the Pd to ligand ratio. 
Furthermore, both reactions undergo the same mechanism, initiating with oxidative 
addition of the aryl halide to Pd(0) followed by substrate deprotonation to afford 
complexes 2-63a,b and 2-68a,b (Scheme 2.7). These complexes undergo syn-insertion 
into the Pd-N bond to yield 2-64 and 2-70 respectively, which undergo reductive 
elimination to afford the major enantiomers 2-66 and 2-72. 
 We believe that a change in the enantiodetermining step is the cause of 
difference in the absolute stereochemistry of the imidazolidin-2-one (2-51) versus the 
pyrrolidine (2-62). The stereocenter of both products is generated in the migratory 
insertion step, but there are two steps that could be enantiodetermining: 1.) migratory 
insertion (i.e., 2-68a to 2-70) or 2.) reductive elimination (i.e., 2-64 to 2-66), but only if 
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the insertion step is reversible. In the case of the formation of the pyrrolidine products, 
the relatively electron rich N-boc pentenylamine 2-61 likely undergoes an irreversible 
migratory insertion,5 and then a relatively fast reductive elimination from 2-7012 to afford 
the major pyrrolidine enantiomer 2-72.  
Scheme 2.7 Mechanism of imidazolidin-2-one versus pyrrolidine formation 
 
 However, we believe that the electronic effect in the N-allyl urea substrates 
(Table 2.4) and the effect of anionic ligands (see Tables 2.5 and 2.6) are consistent with 
a mechanism that proceeds through a reversible migratory insertion followed by an 
enantiodetermining reductive elimination. One of the main reasons for the change in the 
enantiodetermining step for the formation of the imidazolidin-2-one products has to do 
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with the relative electron richness of the cyclizing nitrogen in substrate 2-33. The pka of 
2-33 is approximately 17.0 compared to 23.0 for substrate 2-61,13 and thus 2-33 is a lot 
less nucleophilic than 2-61. The use of a more electron poor cyclizing nitrogen in 
complexes related to 2-64,65 and 2-69,70 has been shown to decrease the rate of 
reductive elimination8 and  promote  beta-amidate elimination14 (retroaminopalladation) 
from these complexes. Therefore, the more electron poor N-allylurea substrates 2-31 
and 2-33 likely have a more facile equilibration from 2-65→2-63a→2-63b→2-64. 
Reductive elimination then occurs faster from 2-64 than from 2-65 based on the chirality 
of the ligand to yield the major product 2-66. The equilibration of 2-65→2-63a occurs 
less readily for the more electron rich N-allyl urea substrates 2-23,25,27 leading to more 
formation of the minor enantiomer 2-67, and therefore a lower enantioselectivity in the 
corresponding products in Table 2.4. 
 We also believe that the effect of anionic ligands (i.e. the hydroxide from added 
water and the iodide from aryl iodides) is due to their ability to alter the rate of the 
reductive elimination step, and thus affect the equilibration of 2-65→2-63a. The 
combination of the small hydroxide ligand and electron-poor aryl halides leads to 
improved enantioselectivities in the formation of imidazolidin-2-ones. This result is 
consistent with the electron rich hydroxide ligand slowing down the reductive elimination 
(and thereby facilitating equilibration of 2-65→2-63a) of electron-poor aryl halides, 
which typically undergo a relatively quick C-C bond forming reductive elimination.15 
Likewise, the addition of water to related reactions with electron-rich and electron-
neutral aryl bromides led to no change in the enantioselectivity of the products (in most 
cases), as these groups already undergo relatively slow reductive eliminations. 
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Furthermore, we believe that the relatively large iodide ligand may help to increase the 
rate of reductive elimination through a steric effect,16 and thus afford more of the minor 
enantiomer which erodes the enantioselectivity (Table 2.5). We believe that these 
anionic ligand effects arise through binding to the metal center after the 
aminopalladation step, as related aminopalladation reactions have been shown to 
proceed through 4-coordinate Pd complexes such as 2-63a,b and 2-68a,b.8,17 
2.6 Conclusions 
 We have shown the utility of our asymmetric carboamination reactions to afford 
enantioenriched imidazolidin-2-ones from readily accessible N-allyl urea derivatives. 
Products are generated in good yields and good enantiomeric ratios up to 97:3. More 
importantly, we noted that the enantiodetermining step is likely influenced by the 
substrate structure, and we have shown that substrate electronics and additives greatly 
affect the levels of enantioselectivity in the products. This information will likely be very 
useful in the development of future enantioselective carboamination reactions. 
 
The work in this chapter was published in Angewandte Chemie International Edition. 18 
2.7 Experimental 
General: Reactions were carried out under nitrogen in flame-dried glassware. 
Tris(dibenzylideneacetone)dipalladium and (S)-Siphos-PE were purchased from Strem 
Chemical Co. and used without further purification.  All other reagents including all aryl 
and alkenyl bromides were purchased from commercial sources and used as received 
unless otherwise noted. Xylenes were purified by distillation over CaH2 prior to use in 
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reactions.  Methylene chloride and toluene were purified using a GlassContour solvent 
system. All yields refer to isolated compounds that are estimated to be >95% pure as 
judged by 1H NMR analysis.  The yields reported here refer to a single experiment and 
may differ from those reported in chapter 2 which are an average of 2 or more runs.  
General procedure for the synthesis of N-allylurea substrates.  A flame-dried round 
bottom flask equipped with a stirbar was cooled under a stream of nitrogen. The flask 
was charged with the appropriate isocyanate (1.0 equiv) and methylene chloride (0.60 
M). The resulting solution was cooled to 0 °C and stirred for 5 min, then the allylic amine 
(1.1 equiv) was added dropwise. The solution was warmed to rt and stirred for five h. 
The mixture was then concentrated in vacuo and purified by flash chromatography on 
silica gel.  
 
1-allyl-1,3-bis(4-methoxyphenyl)urea (2-14): The reaction of 0.60 g (3.68 mmol) of N-
allyl-4-methoxyaniline with 0..48 mL (3.35 mmol) of 4-methoxyphenyl isocyanate 
according to the general procedure afforded  750 mg  (71%) of the title compound as a 
white solid, mp 52-55 °C. 1H NMR (400 MHz, CDCl3) δ 7.22-7.14 (m, 4H), 6.94 (d, J = 
8.6 Hz, 2H), 6.75 (d, J= 9.00 Hz, 2H),  6.02 (s, br, 1H), 5.96–5.86 (m, 1H), 5.10 (s, 1H), 
5.06 (d, J = 5.5 Hz, 1H), 4.27 (d, J = 6.4 Hz, 2H), 3.82 (s, 3H), 3.72 (s, 3H). 
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1-allyl-3-(4-methoxyphenyl)-1-phenylurea (2-16): The reaction of 0.50 mL (3.68 
mmol) of N-allylaniline with 0.48 mL (3.35 mmol) of 4-methoxyphenyl isocyanate 
according to the general procedure afforded  662 mg  (70%) of the title compound as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 7.48 (t, J= 7.6 Hz, 2H), 7.38 (t, J= 6.8 Hz, 1H),  
7.33 (d, J = 8.6 Hz, 2H), 7.20 (d, J= 9.1 Hz, 2H),  6.80 (d, J = 9.1 Hz, 2H), 6.06 (s, br, 
1H), 6.01-5.92 (m, 1H), 5.16-5.10 (m, 2H), 4.35 (d, J = 6.2 Hz, 2H), 3.77 (s, 3H). 
 
1-allyl-1-(4-(tert-butyl)phenyl)-3-(4-methoxyphenyl)urea (2-18): The reaction of 607 
mg  (3.21 mmol) of N-allyl-4-tert-butylaniline with 0.40 mL (2.92 mmol) of 4-
methoxyphenyl isocyanate according to the general procedure afforded  900 mg  (90%) 
of the title compound as a clear viscous oil. 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 
8.2 Hz, 2H), 7.23-7.15 (m, 4H),  6.76 (d, J = 8.7 Hz, 2H), 6.08 (s, br, 1H), 5.99-5.88 (m, 
1H), 5.16-5.07 (m, 2H), 4.29 (d, J = 6.2 Hz, 2H), 3.73 (s, 3H), 1.33 (s, 9H). 
 
1,1-diallyl-3-(4-methoxyphenyl)urea (2-21): The reaction of 0.40 mL (3.30 mmol) of 
Diallylamine with 0.539mL (3.00 mmol) of 4-methoxyphenyl isocyanate according to the 
general procedure afforded  695 mg  (93%) of the title compound as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.25 (d, J = 9.2 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 6.35 (s, br, 
1H), 5.94–5.86 (m, 2H), 5.33-5.26 (m, 4H), 3.98 (d, J = 5.6 Hz, 4H), 3.79 (s, 3H). 
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1-Allyl-3-(4-methoxyphenyl)-1-methylurea (2-23): The reaction of 0.47 mL (4.92 
mmol) of N-allylmethylamine with 0.58 mL (4.47 mmol) of 4-methoxyphenyl isocyanate 
according to the general procedure afforded  841 mg  (85%) of the title compound as a 
white solid, mp 52-55 °C. 1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 9.0 Hz, 2H), 6.81 (d, 
J = 9.0 Hz, 2H), 6.61 (s, br, 1H), 5.90–5.78 (m, 1H), 5.25 (d, J = 5.5 Hz, 1H), 5.22 (s, 
1H), 3.94 (d, J = 5.3 Hz, 2H), 3.76 (s, 3H), 2.97 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
155.8, 155.7, 133.5, 132.2, 122.1, 116.8, 114.0, 55.5, 51.5, 34.5; IR (film) 1638 cm-1. 
MS (CI) 221.1280 (221.1285 calcd for C12H16N2O2, M + H
+). 
 
1-Allyl-3-{4-[benzyl(methyl)amino]phenyl}-1-methylurea (2-25):  A flame dried 
schlenk flask equipped with a stirbar was cooled under a stream of nitrogen and 
charged with 1-allyl-3-(4-bromophenyl)-1-methylurea (1.00 g, 3.72 mmol), lithium 
bis(trimethylsilyl)amide (1.37 g, 4.46 mmol), Pd2(dba)3 (34.1 mg, 0.0372 mmol), and 
DavePhos (35.1 mg, 0.0893 mmol). The flask was purged with N2 pressure for 30 s 
then THF (8.2 mL) and N-methyl benzylamine (0.58 mL, 4.46 mmol) were added. The 
resulting mixture was heated to 65 °C with stirring for 15 h, then was cooled to rt. A 
solution of of 1M HCl (8 mL) was added and the resulting mixture was stirred at rt for 
five min. A solution of saturated aqueous NaHCO3 (8 mL) was slowly added and the 
mixture was transferred to a separatory funnel after bubbling ceased. The mixture was 
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extracted with ethyl acetate (3 x 20 mL) then the combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was 
purified by flash chromatography on silica gel to afford 450 mg (40%) of the title 
compound as a light brown solid, mp 93-97 °C. 1H NMR (400 MHz, CDCl3) δ 7.31–7.14 
(m, 7H), 6.68 (d, J = 9.0 Hz, 2H), 6.18 (s, br, 1H), 5.83 (ddt, J = 5.5, 5.2, 12.0 Hz, 1H), 
5.26–5.19 (m, 2H), 4.46 (s, 2H), 3.93 (d, J = 5.5 Hz, 2H), 2.96 (s, 3H), 2.94 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 156.2, 146.5, 138.9, 133.6, 128.8, 128.4, 126.8, 126.7, 
122.5, 116.7, 113.0, 57.0, 51.4, 38.7, 34.4; IR (film) 1637 cm-1. MS (CI) 310.1916 
(310.1914 calcd for C19H23N3O, M + H+). 
 
1-Allyl-1-methyl-3-phenylurea (2-27): The reaction of 0.37 mL (3.85 mmol) of N-
allylmethylamine with 0.42 mL (3.50 mmol) of phenyl isocyanate according to the 
general procedure afforded  644 mg  (88%) of the title compound as a white solid, mp 
71-74 °C. 1H NMR (400 MHz, CDCl3) δ 7.34 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 7.8 Hz, 
2H), 6.98 (t, J = 7.4 Hz, 1H), 6.48 (s, br, 1H), 5.88–5.78 (m, 1H), 5.26–5.19 (m, 2H), 
3.93 (d, J = 5.5 Hz, 2H), 2.96 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 155.6, 139.2, 133.4, 
128.8, 122.9, 119.8, 116.9, 51.5, 38.7, 34.5; IR (film) 1639 cm-1. MS (CI) 191.1180 
(191.1179 calcd for C11H14N2O, M + H
+). 
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1-Allyl-3-(4-bromophenyl)-1-methylurea (2-29): The reaction of 0.80 mL (8.44 mmol) 
of N-allylmethylamine with 1.51 g (7.67 mmol) of 4-bromophenyl isocyanate according 
to the general procedure afforded 1.88 g  (91%) of the title compound as a white solid, 
mp 123-126 °C. 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 8.9 
Hz, 2H), 6.47 (s, br, 1H), 5.81 (ddt, J = 5.5, 5.6, 9.9 Hz, 1H), 5.27–5.19 (m, 2H), 3.92 (d, 
J = 5.3 Hz, 2H), 2.96 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 155.2, 138.3, 133.2, 131.7, 
121.4, 117.0, 115.2, 51.5, 34.6; IR (film) 1634 cm-1. MS (CI) 269.0282 (269.0284 calcd 
for C11H13BrN2O, M + H
+). 
 
1-Allyl-3-(4-cyanophenyl)-1-methylurea (2-31): The reaction of 0.73 mL (7.65 mmol) 
of N-allylmethylamine with 1.00 g (6.96 mmol) of 4-cyanophenyl isocyanate according to 
the general procedure afforded  1.17 g  (78%) of the title compound as a white solid, mp 
119-122 °C.  1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 8.8 Hz, 
2H), 6.69 (s, br, 1H), 5.86 (ddt, J = 5.1, 5.4, 11.9 Hz, 1H), 5.32–5.25 (m, 2H), 3.80 (d, J 
= 5.4 Hz, 2H), 3.03 (s, 3H) ; 13C NMR (100 MHz, CDCl3) δ 154.6, 143.5, 133.1, 132.9, 
119.2, 119.0, 117.4, 105.3, 51.6, 34.8; IR (film) 1664 cm-1. MS (CI) 216.1135 (216.1131 
calcd for C12H13N3O3, M + H
+). 
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1-Allyl-1-methyl-3-(4-nitrophenyl)urea (2-33): The reaction of 0.77 mL (8.09 mmol) of 
N-allylmethylamine with 1.21 g (7.35 mmol) of 4-nitrophenyl isocyanate according to the 
general procedure afforded  1.61 g  (93%) of the title compound as a yellow solid, mp 
78-81 °C. 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 9.2 Hz, 2H), 7.53 (d, J = 9.2 Hz, 
2H), 7.00 (s, br, 1H), 5.84 (ddt, J = 5.3, 5.6, 11.4 Hz, 1H), 5.32–5.22 (m, 2H), 3.98 (d, J 
= 5.3 Hz, 2H), 3.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 154.7, 145.6, 142.2, 132.8, 
125.0, 118.4, 117.4, 51.6, 34.8; IR (film) 1660 cm-1. MS (CI) 236.1037 (236.1030 calcd 
for C11H13N3O3, M + H
+). 
 
1-Methyl-1-(2-methylallyl)-3-(4-nitrophenyl)urea (2-53): A flame dried flask equipped 
with a stirbar was cooled under a stream of nitrogen and charged with 3-bromo-2-
methylpropene (4.60 mL, 45 mmol). The flask was cooled to 0 °C and stirred for five 
min, then methylamine (27.2 mL, 225 mmol, 33% solution in EtOH) was added and the 
resulting mixture was warmed to rt and stirred for 15 h. A solution of 1M NaOH (20 mL) 
was added and the resulting mixture was transferred to a separatory funnel. The 
mixture was extracted with ether (3 x 20 mL) then the combined organic layers were 
washed with 1M NaOH (1x12 mL), dried over anhydrous Na2SO4, filtered, and partially 
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concentrated in vacuo (to remove excess methylamine) to afford N,2-dimethylprop-2-
en-1-ylamine as a solution in ethanol. The solution was transferred to a flask equipped 
with a stirbar and cooled to –10 °C. Neat 4-nitrophenyl isocyanate (1.64 g, 10 mmol) 
was added and the resulting solution and the reaction was slowly warmed to rt over the 
course of five h. The reaction mixture was then concentrated in vacuo and the crude 
product was purified by flash column chromatography to yield 350 mg (14 %) of the title 
compound as a yellow solid, mp 79-82 °C. 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 9.3 
Hz, 2H), 7.52 (d, J = 9.1 Hz, 2H), 6.92 (s, br, 1H), 5.03 (s, 1H) 4.96 (s, 1H), 3.90 (s, 2H), 
3.05 (s, 3H), 1.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 154.7, 145.5, 142.3, 141.0, 
125.0, 118.3, 112.5, 55.2, 35.3, 19.7; IR (film) 1658 cm-1. MS (CI) 250.1191 (250.1186 
calcd for C12H15N3O3, M + H
+). 
 
1-cinnamyl-1-methyl-3-(4-nitrophenyl)urea (2-55): A flame dried flask equipped with 
a stirbar was cooled under a stream of nitrogen and charged with cinnamyl bromide 
(4.33 g, 22 mmol). The flask was cooled to 0 °C and stirred for five min, then 
methylamine (27.2 mL, 225 mmol, 33% solution in EtOH) was added and the resulting 
mixture was warmed to rt and stirred for 15 h. A solution of 1M NaOH (20 mL) was 
added and the resulting mixture was transferred to a separatory funnel. The mixture 
was extracted with ether (3 x 20 mL) then the combined organic layers were washed 
with 1M NaOH (1x12 mL), dried over anhydrous Na2SO4, filtered, and partially 
concentrated in vacuo (to remove excess methylamine) to afford (E)-N-methyl-3-
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phenylprop-2-en-1-amine as a solution in ethanol. The solution was transferred to a 
flask equipped with a stirbar and cooled to –10 °C. Neat 4-nitrophenyl isocyanate 
(1.44g, 8.8 mmol) was added and the resulting solution and the reaction was slowly 
warmed to rt over the course of five h. The reaction mixture was then concentrated in 
vacuo and the crude product was purified by flash column chromatography to yield 430 
mg (16 %) of the title compound as a white solid, mp 120-124 °C. 1H NMR (500 MHz, 
CDCl3) δ 8.14 (d, J = 9.1 Hz, 2H), 7.55 (d, J = 9.3 Hz, 2H), 7.40 (d, J = 7.3 Hz, 2H), 7.34 
(t, J = 7.3 Hz, 2H), 7.28 (t, J = 7.1 Hz, 1H), 6.92 (s, br, 1H), 6.60 (d, J = 16.0 Hz, 1H), 
6.23 (dt, J = 5.9, 15.9 Hz, 1H), 4.17 (d, J= 5.9 Hz, 2H), 3.10 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 154.5, 145.4, 142.4, 135.9, 132.8, 128.7, 128.2, 126.5, 125.1, 123.9, 
118.4, 51.2, 34.8; IR (film) 1659 cm-1. MS (CI) 312.1353 (312.1343 calcd for 
C17H17N3O3, M + H
+). 
General procedure for asymmetric Pd-catalyzed carboamination reactions of N-
allylurea derivatives. A flame-dried Schlenk tube equipped with a stirbar was cooled 
under a stream of nitrogen and then charged with Pd2(dba)3 (2 mol %), (S)-Siphos-PE 
(6 mol %), the urea substrate (1.0 equiv), and NaOtBu (2.0 equiv). The flask was purged 
with N2, then the aryl or alkenyl halide (2.0 equiv), the additive (H2O 2.0 equiv or TFA 40 
mol % if needed) and xylenes (0.20 M, for reactions at 120 °C) or toluene (0.20 M, for 
reactions at 90 °C) were added. The resulting mixture was heated to 90 °C or 120 °C 
with stirring until the starting material had been consumed as judged by TLC analysis. 
The reaction mixture was then cooled to rt, saturated aqueous ammonium chloride 
(6mL/mmol substrate) was added, and the mixture was transferred to a separatory 
funnel. The mixture was extracted with ethyl acetate (3 x 5 mL) then the combined 
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organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. 
The crude product was purified by flash chromatography on silica gel. 
 
(S)-3-benzyl-1-(4-methoxyphenyl)-4-(naphthalen-2-ylmethyl)imidazolidin-2-one (2-
12). The general procedure was employed for the coupling of 1-allyl-3-benzyl-1-(4-
methoxyphenyl)urea (0.15 mmol, 45 mg) and 2-bromonaphthalene (0.30 mmol, 60 mg), 
using a catalyst composed of Pd2(dba)3 (0.003  mmol, 2.8 mg) and (S)-Siphos-PE 
(0.009 mmol, 4.5 mg), a reaction temperature of 90 °C, and a reaction time of 12 h. This 
procedure afforded the title compound (18.8 mg, 30%) as an oil. 1H NMR (500 MHz, 
CDCl3) δ 7.82 (d, J = 8.0 Hz, 1H), 7.79-7.75 (m, 2H), 7.57 (s, 1H), 7.50-7.46 (m, 
2H),7.43- 7.33 (m, 7H), 7.18 (d, J = 8.6 Hz, 1H), 6.86 (d, J = 9.3 Hz, 2H), 5.00 (d, J = 
15.1 Hz, H), 4.24 (d, J = 15.1 Hz, 1H), 3.91-3.84 (m, 1H), 3.79 (s, 3H),  3.62 (app. t, J = 
9.0 Hz, 1H), 3.49 (dd, J = 6.3, 9.0 Hz, 1H), 3.37 (dd, J = 4.3, 13.5 Hz, 1H),  2.79 (dd, J = 
9.6, 13.5 Hz, 1H). The enantiopurity was determined to be 82:18 er by chiral HPLC 
analysis (Chiralcel ADH, 25 cm x 4.6 mm, 20% IPA/Hexanes, 2.0 mL/min, λ 254 nm, 
RT= 9.4 and 11.3 min). 
 
 
3-benzyl-1-(4-methoxyphenyl)-4-methylimidazolidin-2-one (2-13). The general 
procedure was employed for the coupling of 1-allyl-3-benzyl-1-(4-methoxyphenyl)urea 
(0.15 mmol, 45 mg) and 2-bromonaphthalene (0.30 mmol, 60 mg), using a catalyst 
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composed of Pd2(dba)3 (0.003  mmol, 2.8 mg) and 2-L5 (0.009 mmol, 4.5 mg), a 
reaction temperature of 90 °C, and a reaction time of 12 h. This procedure afforded the 
title compound in 7.0 mg (11%). 1H NMR (500 MHz, CDCl3) δ 7.49 (d, J = 9.0 Hz, 2H), 
6.91 (d, J = 9.2 Hz, 2H) 4.85 (d, J = 15.4 Hz, 1H), 4.16 (d, J = 15.1 Hz, 1H), 3.87 (app. t, 
J = 8.7 Hz, 1H), 3.81 (s, 3H), 3.65-3.58 (m, 1H), 3.34 (dd, J = 7.3, 8.5 Hz, 1H), 1.27 (d, 
J = 6.1 Hz, 3H). 
 
(S)-4-(4-(tert-butyl)benzyl)-1,3-bis(4-methoxyphenyl)imidazolidin-2-one (2-15). The 
general procedure was employed for the coupling of 1-allyl-1,3-bis(4-
methoxyphenyl)urea  (0.10 mmol, 31.2 mg) and 1-bromo-4-tert-butylbenzene (0.15 
mmol, 32.0 mg), using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-
Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C, and a reaction time 
of 12 h. This procedure afforded the title compound (42.1 mg, 99%) as a white solid. 1H 
NMR (400 MHz, CDCl3) δ 7.50–7.39 (m, 4H), 7.34 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 8.0 
Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 4.52–4.42 (m, 1H), 3.84 (s, 
3H), 3.79 (s, 3H),  3.61 (dd, J = 5.8, 8.9 Hz, 1H), 3.11 (dd, J = 2.9, 13.7 Hz, 1H), 2.72 
(dd, J = 9.5, 13.6 Hz, 1H), 1.34 (s, 9H).The enantiopurity was determined to be 81:19 er 
by chiral HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 10% IPA/Hexanes, 1.50 
mL/min, λ 254 nm, RT= 21.1 and 23.3 min). 
 
 
42 
 
 
(S)-4-(4-(tert-butyl)benzyl)-1-(4-(tert-butyl)phenyl)-3-(4-
methoxyphenyl)imidazolidin-2-one (2-19). The general procedure was employed for 
the coupling of 1-allyl-1-(4-(tert-butyl)phenyl)-3-(4-methoxyphenyl)urea (0.10 mmol, 33.8 
mg) and 1-bromo-4-tert-butylbenzene (0.20 mmol, 42.6 mg), using a catalyst composed 
of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction 
temperature of 90 °C, and a reaction time of 12 h. This procedure afforded the title 
compound (27.4 mg, 58%) as an oil. 1H NMR (500 MHz, CDCl3) δ 7.48–7.43 (m, 4H), 
7.36–7.31 (m, 4H),  7.09 (d, J = 8.3 Hz, 2H), 6.98 (d, J = 9.0 Hz, 2H), 4.53–4.46 (m, 
1H), 3.87 (app. t, J = 9.4 Hz, 1H), 3.85 (s, 3H), 3.66 (dd, J = 5.3, 9.1 Hz, 1H), 3.11 (dd, J 
= 5.3, 9.1 Hz, 1H),  2.72 (dd, J = 9.5, 14.4 Hz, 1H), 1.32 (s, 9H), 1.30 (s, 9H). The 
enantiopurity was determined to be 84:16 er by chiral HPLC analysis (Chiralcel ADH, 25 
cm x 4.6 mm, 10% IPA/Hexanes, 1.50 mL/min, λ 254 nm, RT= 6.6 and 7.9 min). 
 
(S)-1-allyl-4-(4-(tert-butyl)benzyl)-3-(4-methoxyphenyl)imidazolidin-2-one (2-22). 
The general procedure was employed for the coupling of 1,1-diallyl-3-(4-
methoxyphenyl)urea (0.10 mmol, 24.6 mg) and 4-bromobenzophenone (0.20 mmol, 
52.2 mg), using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-
Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C, and a reaction time 
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of 12 h. This procedure afforded the title compound (40 mg, 93%) as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.78–7.69 (m, 4H), 7.58 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.6 
Hz, 2H),  7.38 (d, J = 9.2 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 6.92 (d, J = 9.0 Hz, 2H), 
5.74–5.63 (m, 1H), 5.18–5.11 (m, 2H), 4.46–4.38 (m, 1H), 3.79 (s, 3H), 3.36 (app. t, J = 
8.9 Hz, 1H), 3.16-3.11 (m, 2H), 2.80 (dd, J = 8.9, 13.6 Hz, 1H).The enantiopurity was 
determined to be 86:14 er by chiral HPLC analysis (Chiralcel ADH, 25 cm x 4.6 mm, 
20% IPA/Hexanes, 2.00mL/min, λ 254 nm, RT= 17.0 and 36.0 min). 
 
(–)-(4S)-3-{4-[Benzyl(methyl)amino]phenyl}-4-[4-(tert-butyl)benzyl]-1-
methylimidazolidin-2-one (2-26). The general procedure was employed for the 
coupling of 1-allyl-3-{4-[benzyl(methyl)amino]phenyl}-1-methylurea (0.10 mmol, 30.9 
mg) and 4-bromo-tert-butylbenze (0.20 mmol, 42.6 mg), using a catalyst composed of 
Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction 
temperature of 90 °C, and a reaction time of 12 h. This procedure afforded the title 
compound (28.7 mg, 65%) as an orange oil: [α]23D –23.2 (c 0.68, CH2Cl2). 
1H NMR (400 
MHz, CDCl3) δ 7.34–7.23 (m, 9H), 7.05 (d, J = 8.2 Hz, 2H), 6.77 (d, J = 9.0 Hz, 2H), 
4.52 (s, 2H), 4.28–4.20 (m, 1H), 3.30 (app. t, J = 8.6 Hz, 1H), 3.12 (dd, J = 6.1, 8.8 Hz, 
1H), 3.06 (dd, J = 3.3, 13.7 Hz, 1H), 3.00 (s, 3H), 2.79 (s, 3H) 2.58 (dd, J = 10.0, 13.5 
Hz, 1H), 1.30 (s, 9H); 13C NMR (125 MHz, CDCl3); 159.5, 149.6, 147.3, 139.0, 133.8, 
128.8, 128.6, 128.2, 126.9, 126.8, 125.5, 124.5, 112.9, 57.0, 55.9, 50.1, 38.7, 38.0, 
34.4, 31.4, 31.3; IR (film) 1704 cm-1; MS (CI) 442.2866 (442.2859 calcd for C29H35N3O, 
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M + H+). The enantiopurity was determined to be 86:14 er by chiral HPLC analysis 
(Chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.50 mL/min, λ 198 nm, RT= 6.1 
and 9.2 min). 
 
(–)-(4S)-4-[4-(tert-Butyl)benzyl]-3-(4-methoxyphenyl)-1-methylimidazolidin-2-one 
(2-24). The general procedure was employed for the coupling of 1-allyl-3-(4-
methoxyphenyl)-1-methylurea (0.10 mmol, 22.1 mg) and 4-bromo-tert-butylbenze (0.20 
mmol, 42.6 mg) using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-
Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C, and a reaction time 
of 12 h. This procedure afforded the title compound (33.0 mg, 93%) as an orange oil: 
[α]23D –10.1 (c 0.76, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 9.0 Hz, 2H), 7.31 
(d, J = 8.3 Hz, 2H), 7.06 (d, J = 8.3 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 4.37–4.29 (m, 1H), 
3.82 (s, 3H), 3.36 (app. t, J = 8.7 Hz, 1H), 3.17 (dd, J = 5.9, 9.2 Hz, 1H), 3.05 (dd, J = 
3.7, 13.7 Hz, 1H), 2.81 (s, 3H), 2.62 (dd, J = 9.8, 13.7 Hz, 1H), 1.31 (s, 9H); 13C NMR 
(100 MHz, CDCl3) 159.0, 156.4, 149.6, 133.5, 131.8, 128.8, 125.5, 123.8, 114.3, 55.5, 
55.4, 49.8, 37.8, 34.4, 31.3, 31.2; IR (film) 1700 cm-1; MS (CI) 353.2232 (353.2224 
calcd for C22H28N2O2, M + H
+). The enantiopurity was determined to be 89:11 er by 
chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.50 mL/min, 
λ 198 nm, RT= 5.3 and 8.1 min). 
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(–)-(4S)-4-[4-(tert-Butyl)benzyl]-1-methyl-3-phenylimidazolidin-2-one (2-28). The 
general procedure was employed for the coupling of 1-allyl-1-methyl-3-phenylurea (0.10 
mmol, 17.6 mg) and 4-bromo-tert-butylbenze (0.20 mmol, 42.6 mg) using a catalyst 
composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), 
a reaction temperature of 90 °C and a reaction time of 12 h. This procedure afforded the 
title compound (29.0 mg, 90%) as white solid, mp 67–70 °C: [α]23D –19.4 (c 0.55, 
CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.6 Hz, 2H), 7.37 (t, J = 7.4 Hz, 2H), 
7.32 (d, J = 8.4 Hz, 2H), 7.12–7.06 (m, 3H), 4.48–4.40 (m, 1H), 3.37 (app. t, J = 8.6 Hz, 
1H), 3.20 (dd, J = 4.9, 8.4 Hz, 1H), 3.11 (dd, J = 3.3, 13.8 Hz, 1H), 2.81 (s, 3H), 2.64 
(dd, J = 9.8, 13.8 Hz, 1H), 1.30 (s, 9H); 13C NMR (100 MHz, CDCl3) 158.3, 149.7, 138.9, 
133.5, 129.0, 128.8, 125.6, 123.4, 120.7, 54.4, 49.4, 37.5, 34.4, 31.3, 31.0; IR (film) 
1707 cm-1; MS (CI) 323.2125 (323.2118 calcd for C21H26N2O, M + H
+). The 
enantiopurity was determined to be 89:11 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 8% IPA/Hexanes, 1.0 mL/min, λ 198 nm, RT= 9.5 and 10.1 min). 
 
(–)-(4S)-3-(4-Bromophenyl)-4-[4-(tert-butyl)benzyl]-1-methylimidazolidin-2-one (2-
30).  The general procedure was employed for the coupling of 1-allyl-3-(4-
bromophenyl)-1-methylurea (0.10 mmol, 26.9 mg) and 4-bromo-tert-butylbenze (0.20 
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mmol, 42.6 mg) using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-
Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 90 °C and a reaction time of 
12 h. This procedure afforded the title compound (18.0 mg, 45%) as an orange oil: [α]23D 
–41.6 (c 0.42, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.49–7.43 (m, 4H), 7.32 (d, J = 8.3 
Hz, 2H), 7.07 (d, J = 8.1 Hz, 2H), 4.44–4.38 (m, 1H), 3.39 (app. t, J = 8.8 Hz, 1H), 3.22 
(dd, J = 4.6, 9.0 Hz, 1H), 3.07 (dd, J = 3.7, 13.8 Hz, 1H), 2.82 (s, 3H), 2.66 (dd, J = 9.5, 
13.8 Hz, 1H), 1.32 (s, 9H); 13C NMR (100 MHz, CDCl3) 157.9, 150.0, 138.1, 133.3, 
131.9, 128.8, 125.6, 121.9, 116.0, 54.2, 49.2, 37.4, 34.3, 31.3, 31.9; IR (film) 1708 cm-1; 
MS (CI) 401.1230 (401.1223 calcd for C21H25BrN2O, M + H
+). The enantiopurity was 
determined to be 91:9 ee by chiral HPLC analysis (chrialcel ADH, 25 cm x 4.6 mm, 15% 
IPA/Hexanes, 1.50 mL/min, λ 198 nm, RT= 4.3 and 6.0 min). 
 
(–)-(5S)-4-{5-[4-(tert-Butyl)benzyl]-3-methyl-2-oxoimidazolidin-1-yl}benzonitrile (2-
32): The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-
1-methylurea (0.10 mmol, 21.5 mg) and 4-bromo-tert-butylbenze (0.20 mmol, 42.6 mg) 
using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 
mmol, 3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This 
procedure afforded the title compound (30.2 mg, 87%) as a light orange solid, mp 108–
113 °C: [α]23D –73.6 (c 0.91, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 9.0 Hz, 
2H), 7.63 (d, J = 9.0 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 4.50 (m, 
1H), 3.46 (app. t, J = 8.8 Hz, 1H), 3.28 (dd, J = 3.5, 9.2 Hz, 1H), 3.10 (dd, J = 3.5, 14.1 
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Hz, 1H), 2.83 (s, 3H) 2.73 (dd, J = 9.2, 14.0 Hz, 1H), 1.32 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 156.9, 150.2, 143.2, 133.1, 132.6, 128.8, 125.7, 119.2, 118.5, 105.0, 53.6, 
48.7, 37.3, 34.5, 31.3, 30.8; IR (film) 1712 cm-1; MS (CI) 348.2082 (348.2070 calcd for 
C22H25N3O, M + H
+). The enantiopurity was determined to be 93:7 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, 
RT= 5.4 and 8.6 min). 
 
(–)-(4S)-4-[4-(tert-Butyl)benzyl]-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2-
34). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromo-tert-butylbenzene (0.40 mmol, 85.2 
mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE 
(0.012 mmol 6.1 mg), a reaction temperature of 115 °C and a reaction time of 18 h. This 
procedure afforded the title compound (59.6 mg, 81%) as a bright yellow solid, mp 115–
118 °C: [α]23D –102.3 (c 1.49, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 9.2 Hz, 
2H), 7.78 (d, J = 9.4 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.9 (d, J = 8.2 Hz, 2H), 4.56–4.49 
(m, 1H), 3.48 (app. t, J = 9.0 Hz, 1H), 3.29 (dd, J = 3.0, 9.3 Hz, 1H), 3.11 (dd, J = 3.5, 
13.8 Hz, 1H), 2.83 (s, 3H), 2.75 (dd, J = 9.0, 13.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
δ 156.7, 150.3, 145.2, 141.9, 132.5, 128.8, 125.8, 125.0, 117.7, 53.7, 48.6, 37.3, 34.5, 
31.3, 30.8; IR (film) 1717 cm-1. MS (CI) 368.1968 (368.1969 calcd for C21H25N3O3, M + 
H+). The enantiopurity was determined to be 96:4 er by chiral HPLC analysis (chiralcel 
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ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.50 mL/min, λ 198 nm, RT= 6.1 and 9.4 
min). 
 
(–)-(5S)-4-[3-Methyl-5-(4-methylbenzyl)-2-oxoimidazolidin-1-yl]benzonitrile (2-36). 
The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-
methylurea (0.10 mmol, 21.5 mg) and 4-bromotoluene (0.20 mmol, 34.2 mg) using a 
catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 
3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This procedure 
afforded the title compound (26.3 mg, 86%) as a light orange solid, mp 123–126 °C: 
[α]23D –55.7 (c 0.90, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 9.0 Hz, 2H), 7.65 
(d, J = 9.0 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 4.51–4.45 (m, 1H), 
3.44 (app. t, J = 9.0 Hz, 1H), 3.26 (dd, J = 3.7, 9.2 Hz, 1H), 3.09 (dd, J = 3.4, 13.9 Hz, 
1H), 2.82 (s, 3H) 2.72 (dd, J = 9.3, 13.9 Hz, 1H), 2.35 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 156.9, 143.2, 136.9, 133.1, 132.5, 129.5, 129.0, 119.2, 118.5, 105.0, 53.5, 
48.5, 37.2, 30.8, 21.0; IR (film) 1712 cm-1; MS (CI) 306.1608 (306.1601 calcd for 
C19H19N3O, M + H
+). The enantiopurity was determined to be 90:10 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, 
RT= 5.4 and 8.6 min). 
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(S)-4-(5-benzyl-3-methyl-2-oxoimidazolidin-1-yl)benzonitrile (2-37). The general 
procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-1-methylurea 
(0.10 mmol, 21.5 mg) and bromobenzene (0.20 mmol, 31.4 mg) using a catalyst 
composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 3.0 mg), 
a reaction temperature of 120 °C and a reaction time of 14 h. This procedure afforded 
the title compound (21.8 mg, 70%) as a light orange solid. 1H NMR (400 MHz, CDCl3) δ 
7.74 (d, J = 9.0 Hz, 2H), 7.62 (d, J = 9.0 Hz, 2H), 7.39-7.25 (m, 3H), 7.14 (d, J = 6.8 Hz, 
2H), 4.52–4.45 (m, 1H), 3.42 (app. t, J = 9.0 Hz, 1H), 3.24 (dd, J = 3.5, 9.1 Hz, 1H), 
3.10 (dd, J = 3.3, 13.8 Hz, 1H), 2.79 (s, 3H) 2.74 (dd, J = 9.1, 13.9 Hz, 1H). The 
enantiopurity was determined to be 90:10 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 254 nm, RT= 10.4 and 17.5 min). 
 
(–)-(5S)-4-{3-Methyl-2-oxo-5-[4-(trifluoromethyl)benzyl]imidazolidin-1-
yl}benzonitrile (2-38). The general procedure was employed for the coupling of 1-allyl-
3-(4-cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 4-bromobenzotrifluoride 
(0.20 mmol, 45.0 mg), using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) 
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and (S)-Siphos-PE (0.006 mmol, 3.0 mg), a reaction temperature of 120 °C and a 
reaction time of 14 h. This procedure afforded the title compound (20.7 mg, 62%) as a 
light orange solid, mp 120–124 °C: [α]23D –29.5 (c 1.12, CH2Cl2); 
1H NMR (700 MHz, 
CDCl3) δ 7.72 (d, J= 8.9 Hz, 2H), 7.64 (d, J= 8.9 Hz, 2H), 7.57 (d, J= 8.0 Hz, 2H), 7.27 
(d, J= 8.2 Hz, 2H), 4.56-4.52 (m, 1H), 3.46 (app. t, J= 9.0 Hz, 1H), 3.20 (dd, J= 3.4, 9.0 
Hz, 1H), 3.13 (dd, J= 3.3, 14.1 Hz, 1H), 2.97 (dd, J= 8.7, 14.0 Hz, 1H), 2.78 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 156.7, 142.9, 139.7, 133.2, 129.7 (q, 32.4 Hz), 129.6, 
125.8(q, 3.8 Hz), 124.0 (q, 272.0 Hz), 119.1, 118.7, 105.5, 53.0, 48.4, 37.5, 30.7 ; IR 
(film) 1717 cm-1; MS (CI) 360.1322 (360.1318 calcd for C19H16F3N3O, M + H
+). The 
enantiopurity was determined to be 86:14 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 200nm, RT= 8.9 and 16.6 min). 
 
(–)-(5S)-4-[5-(4-Methoxybenzyl)-3-methyl-2-oxoimidazolidin-1-yl]benzonitrile (2-
39). The general procedure was employed for the coupling of 1-allyl-3-(4-cyanophenyl)-
1-methylurea (0.10 mmol, 21.5 mg) and 4-bromoanisole (0.20 mmol, 37.4 mg) using a 
catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol, 
3.0 mg), a reaction temperature of 120 °C and a reaction time of 14 h. This procedure 
afforded the title compound in (23.5 mg, 73%) as a light orange solid, mp 87–91 °C: 
[α]23D –52.9 (c 0.37, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 9.0 Hz, 2H), 7.63 
(d, J = 8.8 Hz, 2H), 7.06 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 4.46 (m, 1H), 3.79 
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(s, 3H), 3.43 (app. t, J = 9.0 Hz, 1H), 3.24 (dd, J = 3.3, 9.2 Hz, 1H), 3.04 (dd, J = 3.3, 
14.0 Hz, 1H), 2.80 (s, 3H) 2.71 (dd, J = 9.0, 14.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
158.4, 156.9, 143.2, 133.1, 130.2, 127.5, 118.5, 114.2, 105.0, 55.3, 53.5, 48.5, 36.7, 
30.8; IR (film) 1711 cm-1; MS (CI) 322.1548 (322.1550 calcd for C19H19N3O2, M + H
+). 
The enantiopurity was determined to be 92:8 er by chiral HPLC analysis (chiralcel ADH, 
25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 12.3 and 23.3 min.) 
 
(+)-(E,5S)-4-(3-Methyl-2-oxo-5-(3-(trimethylsilyl)allyl)imidazolidin-1-yl)benzonitrile 
(2-40). The general procedure was employed for the coupling of 1-allyl-3-(4-
cyanophenyl)-1-methylurea (0.10 mmol, 21.5 mg) and 2-bromovinyltrimethylsilane (0.20 
mmol, 35.8 mg) using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and (S)-
Siphos-PE (0.006 mmol, 3.0mg), a reaction temperature of 120 °C and a reaction time 
of 14 h. This procedure afforded the title compound (20.0 mg, 64%) as a light orange 
solid, mp 130–133 °C: [α]23D +6.4 (c 0.50, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.66 
(d, J = 9.0 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 5.87 (dt, J = 6.2, 18.5 Hz, 1H), 5.76 (d, J = 
18.7 Hz, 1H), 4.35 (m, 1H), 3.56 (app. t, J = 9.0 Hz, 1H), 3.23 (dd, J = 3.4, 9.1 Hz, 1H), 
2.88 (s, 3H) 2.53 (m, 1H), 2.38 (m, 1H) 0.04 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
156.6, 143.1, 138.8, 136.5, 133.0, 127.5, 119.1, 118.6, 105.0, 51.6, 48.8, 38.9, 30.8, –
1.4; IR (film) 1702 cm-1; MS (CI) 314.1685 (314.1683 calcd for C17H23N3OSi, M + H
+). 
The enantiopurity was determined to be 93:7er by chiral HPLC analysis (chiralcel ADH, 
25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 200 nm, RT= 3.9 and 5.1 min). 
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(–)-(4S)-1-Methyl-3-(4-nitrophenyl)-4-[4-(trifluoromethyl)benzyl]imidazolidin-2-one 
(2-41). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromobenzotrifluoride (0.40 mmol, 90.0 
mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE 
(0.012 mmol 6.1 mg), H2O (0.40 mmol, 7 µL) as an additive, a reaction temperature of 
115 °C and a reaction time of 18 h. This procedure afforded the title compound (54.6 
mg, 72%) as a bright yellow solid, mp 161–164 °C: [α]23D –75.1 (c 11.5, CH2Cl2); 
1H 
NMR (400 MHz, CDCl3) δ 8.23 (d, J = 9.2 Hz, 2H), 7.78 (d, J = 9.3 Hz, 2H), 7.58 (d, J = 
8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 4.64–4.58 (m, 1H), 3.51 (app. t, J = 9.0 Hz, 1H), 
3.24 (dd, J = 3.1, 9.3 Hz, 1H), 3.17 (dd, J = 3.1, 9.3 Hz, 1H), 3.01 (dd, J = 8.6, 14.0 Hz, 
1H), 2.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 156.5, 144.8, 142.1, 139.6, 129.6 (q, 
65.2 Hz), 129.5, 125.8 (q, 3.81), 125.1, 123.9 (q, 272.0 Hz), 117.8, 53.2, 48.3, 37.5, 
30.7; IR (film) 1708 cm-1. MS (CI) 380.1211 (380.1217 calcd for C18H16F3N3O3, M + H
+). 
The enantiopurity was determined to be 97:3 er by chiral HPLC analysis (chiralcel ADH, 
25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 9.3 and 16.8 min). 
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(–)-(4S)-1-Methyl-3-(4-nitrophenyl)-4-[3-(trifluoromethyl)benzyl]imidazolidin-2-one 
(2-42). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 3-bromobenzotrifluoride (0.40 mmol, 90.0 
mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE 
(0.012 mmol 6.1 mg), H2O (0.40 mmol, 7 µL) as an additive, a reaction temperature of 
115 °C and a reaction time of 18 h. This procedure afforded the title compound (53.1 
mg, 70%) as a bright yellow solid, mp 145–148 °C: [α]23D –64.1 (c 1.16, CH2Cl2); 
1H 
NMR (400 MHz, CDCl3) δ 8.22 (d, J = 9.0 Hz, 2H), 7.77 (d, J = 9.0 Hz, 2H), 7.53 (d, J = 
7.8 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.38 (s, 1H), 7.32 (d, J = 7.6 Hz, 1H), 4.65–4.58 
(m, 1H), 3.53 (app. t, J = 9.0 Hz, 1H), 3.24 (dd, J = 2.7, 9.2 Hz, 1H), 3.15 (dd, J = 3.5, 
14.1 Hz, 1H), 2.93 (dd, J = 8.4, 14.0 Hz, 1H), 2.79 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 156.5, 144.9, 142.1, 136.1, 132.7, 131.2 (q, J = 32.4 Hz), 129.4, 125.8 (q, J = 3.8 Hz), 
125.1, 124.2 (q, J = 3.8 Hz), 123.9 (q, J = 271.8 Hz), 117.8, 53.1, 48.4, 37.6, 30.7; IR 
(film) 1714 cm-1. MS (CI) 380.1224 (380.1217 calcd for C18H16F3N3O3, M + H
+). The 
enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 7.7 and 13.0 min). 
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(–)-(4S)-1-Methyl-3-(4-nitrophenyl)-4-[2-(trifluoromethyl)benzyl]imidazolidin-2-one 
(2-43). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 2-bromobenzotrifluoride (0.40 mmol, 90.0 
mg), using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE 
(0.012 mmol 6.1 mg), H2O (0.40 mmol, 7 µL) as an additive, a reaction temperature of 
115 °C and a reaction time of 18 h. This procedure afforded the title compound (42.5 
mg, 56%) as a bright yellow solid, mp 70–73 °C: [α]23D –98.7 (c 0.72, CH2Cl2); 
1H NMR 
(400 MHz, CDCl3) δ 8.14 (d, J = 9.0 Hz, 2H), 7.72–7.64 (m, 3H), 7.44 (t, J = 7.4 Hz, 1H), 
7.34 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 4.72–4.64 (m, 1H), 3.43 (app. t, J = 9.0 
Hz, 1H), 3.36 (dd, J = 5.1, 14.4 Hz, 1H), 3.20 (dd, J = 2.0, 9.3 Hz, 1H), 2.96 (dd, J = 9.0, 
14.3 Hz, 1H), 2.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 156.7, 145.1, 142.0, 134.4, 
132.1, 129.2 (q, J = 30.0 Hz), 127.5, 126.6 (q, J = 5.7 Hz), 124.8, 124.4 (q, J = 272.3 
Hz), 118.0, 53.1, 48.3, 35.0, 30.9 (one peak is missing due to incidental equivalence); 
IR (film) 1722 cm-1. MS (CI) 380.1226 (380.1217 calcd for C18H16F3N3O3, M + H
+). The 
enantiopurity was determined to be 91:9 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 7.9 and 12.5 min). 
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(–)-(4S)-4-(4-Benzoylbenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2-44). 
The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromobenzophenone (0.40 mmol, 104.4 
mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE 
(0.012 mmol 6.1 mg), H2O (0.40 mmol,  7 µL) as an additive, a reaction temperature of 
115 °C and a reaction time of 18 h. This procedure afforded the title compound (68.1 
mg, 82%) as a bright yellow solid, mp 115–118 °C: [α]23D –53.7 (c 0.97, CH2Cl2); 
1H 
NMR (400 MHz, CDCl3) δ 8.21 (d, J = 9.3 Hz, 2H), 7.80–7.72 (m, 6H), 7.57 (t, J = 7.4 
Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 4.65–4.58 (m, 1H), 3.50 (app. 
t, J = 9.0 Hz, 1H), 3.26 (dd, J = 3.1, 9.2 Hz, 1H), 3.18 (dd, J = 3.5, 14.0 Hz, 1H), 2.91 
(dd, J = 8.8, 13.9 Hz, 1H), 2.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 196.1, 156.6, 
145.0, 142.1, 140.3, 137.3, 136.6, 132.6, 130.6, 130.0, 129.2, 128.4, 125.1, 117.8, 53.2, 
48.4, 37.8, 34.4, 30.8; IR (film) 1715, 1657 cm-1. MS (CI) 416.1620 (416.1605 calcd for 
C24H21N3O4, M + H
+). The enantiopurity was determined to be 93:7 er by chiral HPLC 
analysis (ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 39.0 
and 54.9 min.) 
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(–)-(4S)-4-(4-Fluorobenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2-45). 
The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromofluorobenzene (0.40 mmol, 70.0 
mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE 
(0.012 mmol 6.1 mg), H2O (0.40 mmol,  7 µL) as an additive, a reaction temperature of 
115 °C and a reaction time of 18 h. This procedure afforded the title compound (43.0 
mg, 65%) as a bright yellow solid, mp 153–157 °C: [α]23D –75.4 (c 1.10, CH2Cl2); 
1H 
NMR (400 MHz, CDCl3) δ 8.22 (d, J = 9.3 Hz, 2H), 7.88 (d, J = 9.3 Hz, 2H), 7.14–7.08 
(m, 2H), 7.01 (app. t, J = 8.6 Hz, 2H), 4.58–4.51 (m, 1H), 3.49 (app. t, J = 9.0 Hz, 1H), 
3.24 (dd, J = 3.1, 9.2 Hz, 1H), 3.06 (dd, J = 3.3, 14.0 Hz, 1H), 2.86–2.75 (m, 1H), 2.77 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 162.1 (d, J = 245.0 Hz), 156.6 145.0, 142.0, 
131.1 (d, J= 3.5 Hz), 130.7 (d, J = 8.0 Hz), 125.1, 117.7, 115.8 (d, J = 21.3 Hz), 53.4, 
48.2, 36.8, 30.7; IR (film) 1717 cm-1. MS (CI) 330.1258 (330.1248 calcd for 
C17H16FN3O3, M + H
+). The enantiopurity was determined to be 97:3 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, 
RT= 12.0 and 22.7 min). 
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(–)-(4S)-4-(4-Chlorobenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2-46). 
The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromochlorobenzene (0.40 mmol, 76.6 
mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE 
(0.012 mmol 6.1 mg), H2O (0.40 mmol, 7 µL) as an additive, a reaction temperature of 
115 °C and a reaction time of 18 h. This procedure afforded the title compound (51.2 
mg, 74%) as a bright yellow solid, mp 144–147 °C: [α]23D –72.9 (c 0.81, CH2Cl2); 
1H 
NMR (400 MHz, CDCl3) δ 8.24 (d, J = 9.3 Hz, 2H), 7.78 (d, J = 9.3 Hz, 2H), 7.30 (d, J = 
8.3 Hz, 2H), 7.08 (d, J = 8.2 Hz, 2H), 4.57–4.50 (m, 1H), 3.48 (app. t, J = 9.0 Hz, 1H), 
3.23 (dd, J = 3.1, 9.1 Hz, 1H), 3.08 (dd, J = 3.3, 14.0 Hz, 1H), 2.85–2.78 (m, 1H), 2.80 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 156.6, 144.9, 142.1, 133.8, 133.3, 130.5, 129.0, 
125.1, 117.7, 53.3, 48.2, 37.0, 34.4; IR (film) 1716 cm-1. MS (CI) 346.0956 (346.0953 
calcd for C17H16ClN3O3, M + H
+). The enantiopurity was determined to be 96:4 er by 
chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 
195 nm, RT= 12.5 and 22.7 min). 
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(–)-(4S)-4-(4-Methoxybenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2-49). 
The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-bromoanisole (0.40 mmol, 74.8 mg) using 
a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE (0.012 
mmol 6.1 mg), TFA (0.08 mmol, 6 µL) as an additive, a reaction temperature of 115 °C 
and a reaction time of 18 h. This procedure afforded the title compound (55.3 mg, 81%) 
as a bright yellow solid, mp 110–113 °C: [α]23D –71.3 (c 0.98, CH2Cl2); 
1H NMR (400 
MHz, CDCl3) δ 8.22 (d, J = 9.2 Hz, 2H), 7.79 (d, J = 9.4 Hz, 2H), 7.06 (d, J = 8.5 Hz, 
2H), 6.85 (d, J = 8.5 Hz, 2H), 4.52–4.48 (m, 1H), 3.77 (s, 3H), 3.46 (app. t, J = 8.9 Hz, 
1H), 3.26 (dd, J = 3.2, 9.0 Hz, 1H), 3.04 (dd, J = 3.4, 14.1 Hz, 1H), 2.79 (s, 3H), 2.74 
(dd, J = 8.9, 14.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 158.8, 156.7, 145.2, 141.9, 
130.2, 127.3, 125.0, 117.7, 114.3, 55.3, 53.7, 48.3, 36.8, 30.8; IR (film) 1717 cm-1. MS 
(CI) 342.1457 (342.1448 calcd for C18H19N3O4, M + H
+). The enantiopurity was 
determined to be 95:5 er by chiral HPLC analysis (chrialcel ADH, 25 cm x 4.6 mm, 15% 
IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 14.1 and 25.9 min.) 
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(–)-(4S)-4-(3-Methoxybenzyl)-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2-50). 
The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 3-bromoanisole (0.40 mmol, 74.8 mg) using 
a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE (0.012 
mmol 6.1 mg), a reaction temperature of 115 °C and a reaction time of 18 h. This 
procedure afforded the title compound (51.2 mg, 75%) as a bright yellow solid, mp 110–
114 °C: [α]23D –94.2 (c 0.73, CH2Cl2);  
1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 9.1 Hz, 
2H), 7.77 (d, J = 9.3 Hz, 2H), 7.23 (t, J = 8.0 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.73 (d, J 
= 7.6 Hz, 1H), 6.65 (s, 1H), 4.56–4.48 (m, 1H), 3.76 (s, 1H), 3.44 (app. t, J = 9.0 Hz, 
1H), 3.26 (dd, J = 2.9, 9.2 Hz, 1H), 3.08 (dd, J = 3.3, 13.9 Hz, 1H), 2.79 (s, 3H), 2.73 
(dd, J = 9.0, 13.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 159.9, 156.7, 145.1, 141.9, 
137.1, 129.9, 125.0, 121.4, 117.6, 115.4, 112.0, 55.2, 53.5, 48.4, 37.7, 30.8; IR (film) 
1716 cm-1. MS (CI) 342.1461 (342.1448 calcd for C18H19N3O4, M + H
+). The 
enantiopurity was determined to be 92:8 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 12.6 and 19.6 min). 
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(–)-(4S)-1-Methyl-4-(naphthalen-2-ylmethyl)-3-(4-nitrophenyl)imidazolidin-2-one (2-
51). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 2-bromonaphthalene (0.40 mmol, 82.8 mg) 
using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-PE (0.012 
mmol 6.1 mg), a reaction temperature of 115 °C and a reaction time of 18 h. This 
procedure afforded the title compound (51.3 mg, 71%) as a bright yellow solid, mp 152–
155 °C: [α]23D –116.7 (c 0.74, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 9.1 Hz, 
2H), 7.86–7.78 (m, 5H), 7.62 (s, 1H), 7.54–7.46 (m, 2H), 7.28 (d, J = 8.4 Hz, 1H), 4.68–
4.61 (m, 1H), 3.46 (app. t, J = 9.2 Hz, 1H), 3.36–3.28 (m, 2H), 2.93 (dd, J = 9.3, 13.9 
Hz, 1H), 2.81 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 156.7, 145.1, 142.0, 133.4, 133.0, 
132.4, 128.7, 128.0, 127.7, 127.4, 126.9, 126.5, 126.0, 125.0, 117.8, 53.6, 48.5, 37.9, 
30.8; IR (film) 1715 cm-1. MS (CI) 362.1507 (362.1499 calcd for C21H19N3O3, M + H
+). 
The enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 
25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 9.4 and 17.4 min). 
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(–)-(4S)-1-Methyl-4-(4-morpholinobenzyl)-3-(4-nitrophenyl)imidazolidin-2-one (2-
52). The general procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-
nitrophenyl)urea (0.20 mmol, 47.0 mg) and 4-(4-bromophenyl)morpholine (0.40 mmol, 
96.8 mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and (S)-Siphos-
PE (0.012 mmol 6.1 mg), H2O (0.40 mmol, 7 µL) as an additive, a reaction temperature 
of 115 °C and a reaction time of 18 h. This procedure afforded the title compound (63.4 
mg, 80%) as a bright yellow solid, mp 125–129 °C: [α]23D –91.0 (c 0.97, CH2Cl2); 
1H 
NMR (400 MHz, CDCl3) δ 8.22 (d, J = 9.2 Hz, 2H), 7.78 (d, J = 9.2 Hz, 2H), 7.05 (d, J = 
8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 4.53–4.45 (m, 1H), 3.90–3.81 (m, 4H), 3.46 (app. 
t, J = 8.9 Hz, 1H), 3.27 (dd, J = 2.9, 9.2 Hz, 1H), 3.18–3.08 (m, 4H), 3.04 (dd, J = 3.2, 
14.1 Hz, 1H), 2.81 (s, 3H), 2.72 (dd, J = 8.8, 14.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) 
δ 156.7, 150.4, 145.2, 141.9, 130.0, 126.6, 125.0, 117.7, 115.9, 67.1, 53.8, 49.3, 48.4, 
36.8, 30.8; IR (film) 1717 cm-1. MS (CI) 397.1872 (397.1870 calcd for C21H24N4O4 
M+H+). The enantiopurity was determined to be 93:7 er by chiral HPLC analysis 
(chiralcel ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 195 nm, RT= 25.7 
and 33.0 min). 
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(+)-(4S)-4-[4-(tert-Butyl)benzyl]-1,4-dimethyl-3-(4-nitrophenyl)imidazolidin-2-one 
(2-54): The general procedure was employed for the coupling of 1-methyl-1-(2-
methylallyl)-3-(4-nitrophenyl)urea (0.10 mmol, 24.9 mg) and 4-bromo-tert-butylbenzene 
(0.20 mmol, 42.6 mg) using a catalyst composed of Pd2(dba)3 (0.002 mmol, 1.8 mg) and 
(S)-Siphos-PE (0.006 mmol, 3.0mg), a reaction temperature of 135 °C and a reaction 
time of 18 h. This procedure afforded the title compound (27.5 mg, 72%) as a yellow oil: 
[α]23D +70.2 (c 0.90, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 9.1 Hz, 2H), 7.54 
(d, J = 9.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 8.1 Hz, 2H), 3.49 (d, J = 9.1 
Hz, 1H), 3.11 (d, J = 13.5 Hz, 1H), 3.23 (d, J = 8.8 Hz, 1H), 2.81 (d, J = 14.4 Hz, 1H), 
2.74 (s, 3H), 1.47, (s, 3H), 1.29 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 158.0, 150.2, 
144.5, 144.3, 132.3, 129.7, 125.6, 125.4, 124.4, 61.5, 56.3, 44.2, 34.5, 313, 30.6, 25.1; 
IR (film) 1716 cm-1; MS (CI) 382.2133 (382.2125 calcd for C22H27N3O3, M + H
+). The 
enantiopurity was determined to be 88:12 er by chiral HPLC analysis (ADH, 25 cm x 4.6 
mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 7.5 and 7.9 min.) 
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Deuterium Labeling Studies: 
 
(Z)-1-(3-d-Allyl)-1-methyl-3-(4-nitrophenyl)urea (2-56):19 A flame dried round bottom 
flask equipped with a stir bar was cooled to rt under a stream of N2 and charged with N-
methylallylamine ( 5.0 mmol, 0.47 mL) and Et2O (10 mL). The resulting solution was 
cooled to –42 °C using a CO2/CH3CN bath and stirred for 5 min. A solution of n-BuLi in 
hexanes (3.12 mL, 1.6 M, 5 mmol) was added slowly and the resulting mixture was 
stirred at –42 °C for 20 min. A solution of t-BuLi in pentane (3.50 mL, 1.4 M, 5 mmol) 
was added slowly and the resulting solution was stirred at –42 °C for 30 min. The 
CO2/CH3CN bath was replaced with a brine/ice bath and the reaction mixture was 
allowed to slowly warm to room temperature as the ice melted. The bath was removed 
and the mixture was stirred at rt for 1 h. The reaction mixture was then cooled to –78 °C 
and D2O (1.8 mL, 100 mmol) from freshly cracked ampules was slowly added. The 
resulting mixture was warmed to rt and stirred overnight. The reaction mixture was 
cooled to 0 °C, quenched with H2O (2 mL) and transferred to a separatory funnel. The 
mixture was extracted with Et2O (2 x 5 mL) and the combined organic layers were dried 
over anhydrous Na2SO4 and filtered to afford a solution of (Z)-N-methyl-3-
deuterioallylamine. The solution was transferred to a round bottom flask and cooled to 0 
°C. A solution of 4-nitrophenylisocyanate (3.63 mmol, 596 mg) in CH2Cl2 (4 mL) was 
slowly added and the resulting mixture was warmed to rt and stirred for 5 h. The 
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reaction mixture was then concentrated in vacuo and the crude product was purified by 
flash chromatography on silica gel to afford the title compound as (315 mg, 37% yield, 
>95% deuterium incorporation) a yellow solid, mp 80–83 °C. 1H NMR (700 MHz, CDCl3) 
δ 8.12 (d, J = 9.2 Hz, 2H), 7.51 (d, J = 9.2 Hz, 2H), 6.88 (s, br, 1H), 5.87–5.82 (m, 1H), 
5.27 (d, J = 10.4 Hz, 1H), 3.98 (d, J = 5.3 Hz, 2H), 3.03 (s, 3H); 13C NMR (175 MHz, 
CDCl3) δ 154.5, 145.5, 142.3, 132.7, 125.0, 118.4, 117.2 (t, J = 23.8 Hz), 51.6, 34.8; IR 
(film) 1652 cm-1. MS (CI) 237.1099 (237.1092 calcd for C11H12DN3O3, M + H
+).  
 
(–)-(1’R,4S)-1’-Deuterio-4-[4-(tert-butyl)benzyl]-1-methyl-3-(4-
nitrophenyl)imidazolidin-2-one (2-57). The general procedure was employed for the 
coupling of (Z)-1-(3-d-allyl)-1-methyl-3-(4-nitrophenyl)urea (0.10 mmol, 23.6 mg) and 4-
bromo-tert-butylbenzene (0.20 mmol, 42.6 mg) using a catalyst composed of Pd2(dba)3 
(0.002 mmol, 1.8 mg) and (S)-Siphos-PE (0.006 mmol 3.0 mg), a reaction temperature 
of 115 °C, and a reaction time of 18 h. This procedure afforded the title compound (32.1 
mg, 85%) as a bright yellow solid, mp 110–113 °C, [α]23D –104 (c 1.00, CH2Cl2). This 
material was judged to be a 7:1 mixture of diastereomers by 1H NMR analysis. Data are 
for the major isomer:  1H NMR (700 MHz, CDCl3) δ 8.22 (d, J = 8.9 Hz, 2H), 7.78 (d, J = 
8.9 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 8.2 Hz, 2H), 4.54–4.50 (m, 1H), 3.48 
(app. t, J = 8.7 Hz, 1H), 3.29 (dd, J = 2.6, 9.0 Hz, 1H), 3.09 (d, J = 3.2 Hz, 0.12 H), 2.74 
(d, J = 9.0 Hz, 0.88 H), 2.83 (s, 3H), 1.30 (s, 9H); 13C NMR (175 MHz, CDCl3) δ 156.7, 
150.3, 145.2, 141.9, 132.4, 128.8, 125.8, 125.0, 117.7, 53.7, 48.6, 37.0 (t, J = 17.7 Hz), 
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34.5, 31.3, 30.8; IR (film) 1717 cm-1. MS (CI) 369.2034 (369.2031 calcd for 
C21H24DN3O3, M + H
+). The enantiopurity was determined to be 95:5 er by chiral HPLC 
analysis (ADH, 25 cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 6.3 and 
9.5 min). The 1’R,4S relative stereochemistry was assigned on the basis of comparison 
of NMR data to those obtained for a sample of the title compound prepared using a 
catalyst composed of Pd2(dba)3 and DPE-Phos, which has previously been shown to 
effect the syn-carboamination of N-allylurea derivatives.4 
Deprotection of 2m and Assignment of Absolute Sterochemistry: 
The absolute stereochemistry of the urea products was assigned by deprotection of 2-
48 (prepared via Pd-catalyzed carboamination of 2-33) to urea 2-58. The optical rotation 
of 2-58 was of the same sign (–) as that of a separate sample of 2-58 prepared from L-
phenylalanine as described below. 
 
(–)-(4S)-4-Benzyl-1-methyl-3-(4-nitrophenyl)imidazolidin-2-one (2-48): The general 
procedure was employed for the coupling of 1-allyl-1-methyl-3-(4-nitrophenyl)urea (1.0 
mmol, 235.2 mg) and bromobenzene (1.2 mmol, 188.4 mg) using a catalyst composed 
of Pd2(dba)3 (0.02 mmol, 18.0 mg) and (S)-Siphos-PE (0.06 mmol, 30.0 mg), a reaction 
temperature of 115 °C, and a reaction time of 18 h. This procedure afforded the title 
compound (256.9 mg, 83%) as a bright yellow solid, mp 125–128 °C: [α]23D –108.9 (c 
1.22, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 9.3 Hz, 2H), 7.80 (d, J = 9.3 Hz, 
2H), 7.33 (t, J = 6.9 Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.06 (d, J = 7.1 Hz, 2H), 4.58–4.52 
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(m, 1H), 3.47 (app. t, J = 8.8 Hz, 1H), 3.28 (dd, J = 2.9, 9.2 Hz, 1H), 3.14 (dd, J = 3.2, 
13.9 Hz, 1H), 2.83–2.77 (m, 1H), 2.81 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 156.7, 
145.1, 142.0, 135.5, 129.2, 128.9, 127.3, 125.0, 117.7, 53.7, 48.4, 37.7, 30.8; IR (film) 
1717 cm-1; MS (CI) 312.1347 (312.1343 calcd for C17H17N3O3, M + H
+). The 
enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 15% IPA/Hexanes, 1.5 mL/min, λ 198 nm, RT= 10.5 and 17.1 min). 
 
(–)-(4S)-4-Benzyl-1-methylimidazolidin-2-one (2-58). A glass microwave tube 
equipped with a stirbar was charged with 4-Benzyl-1-methyl-3-(4-
nitrophenyl)imidazolidin-2-one (77.8 mg, 0.25 mmol,), 10% Pd/C (38.9 mg, 5% w/w Pd), 
ethyl acetate (2 mL) and methanol (1 mL). The tube was placed into a stainless steel 
bomb that was pressurized with H2 to 50 psi and the reaction mixture was then stirred at 
rt for 12 h. The reaction vessel was then depressurized and the mixture was filtered 
through a pad of celite. The celite was washed with methanol (25 mL) and the combined 
organic solutions were concentrated in vacuo. The crude product from this reaction was 
dissolved in CH2Cl2 (0.7 mL) and transferred to a flame dried Schlenk tube equipped 
with a stir bar that had been cooled under a stream of nitrogen. Acetic anhydride (28 µL, 
0.30 mmol) was added to the flask and the resulting solution was stirred at rt for 5 h. A 
solution of saturated aqueous Na2CO3 (5 mL) was added to the reaction vessel and  the 
resulting mixture was transferred to a separatory funnel. The mixture was extracted with 
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CH2Cl2 (3 x 10 mL) and the combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product from this reaction was 
placed into a round bottom flask equipped with a stir bar and dissolved in CH3CN (3.5 
mL) and H2O (0.70 mL). The mixture was cooled to 0 °C, stirred for 5 min, then ceric 
ammonium nitrate (1.13 mmol, 618.0 mg) was added in one portion. The resulting 
mixture was stirred at 0 °C for 25 min then saturated aqueous sodium sulfite (6 mL) was 
added. The mixture was transferred to a separatory funnel and extracted with ethyl 
acetate (3 x 10 mL). The combined organic layers were washed with saturated aqueous 
NaHCO3 (5 mL) and brine (5 mL) then dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The crude product was purified by flash chromatography on 
silica gel to afford the title compound (41.6 mg, 88% overall yield) as a brown oil, [α]23D 
–27.0 (c 1.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.1 Hz, 2H), 7.24 (t, J = 
7.6 Hz, 1H), 7.17 (d, J = 7.1 Hz, 2H), 4.82–4.52 (s, br, 1H), 3.85 (m, 1H), 3.47 (app. t, J 
= 8.6 Hz, 1H), 3.13 (dd, J = 6.1, 8.8 Hz, 1H), 2.81 (app. d, J = 7.1 Hz, 2H), 2.76 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 161.9, 137.1, 129.0, 128.8, 126.9, 52.7, 51.1, 42.0, 30.5; 
IR (film) 1699 cm-1; MS (CI) 191.1181 (191.1179 calcd for C11H14N2O, M + H
+). The 
enantiopurity was determined to be 93:7 er by chiral HPLC analysis (Lux Amylose-2, 25 
cm x 4.6 mm, 10% IPA/Hexanes, 1.0 mL/min, λ 210 nm, RT= 21.3 and 22.7 min). 
 
(–)-(4S)-4-Benzyl-1-methylimidazolidin-2-one (2-60) A flame-dried round bottomed 
flask equipped with a stirbar was cooled under a stream of nitrogen and charged with 
(S)-N1-methyl-3-phenylpropane-1,2-diamine11 (100.0 mg, 0.60 mmol) and THF (1 mL). 
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Solid CDI (90.0 mg, 0.56 mmol) was added and the resulting mixture was heated to 60 
°C with stirring for 12 h. The reaction mixture was then cooled to rt and the solvent was 
removed in vacuo. The product was purified by flash chromatography on silica gel to 
afford the title compound (32.0 mg, 30% yield); [α]23D –37.2 (c 0.90, CH2Cl2). The 
spectroscopic properties of this compound were identical to that of compound 6. The 
enantiopurity was determined to be 98:2 er by chiral HPLC analysis (Lux Amylose-2, 25 
cm x 4.6 mm, 10% IPA/Hexanes, 1.0 mL/min, λ 210 nm, RT= 21.3 and 22.7 min). 
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Chapter 3 
Enantioselective Synthesis of Tetrahydroquinolines, 
Tetrahydroquinoxalines, and 
Tetrahydroisoquinolines via Pd-Catalyzed Alkene Carboamination 
Reactions 
3.1 Introduction 
Benzo-fused heterocycles are prominent in a variety of natural products and 
biologically active compounds.1 As such, many groups have attempted to construct 
molecules of this nature in an enantioselective fashion. Typically, enantioenriched 
benzo-fused heterocycles are synthesized via the asymmetric hydrogenation of an 
aromatic heterocycle (Figure 3.1).2,3 However, a major drawback to this methodology is 
that no new carbon-heteroatom or carbon-carbon bonds are formed in the reaction, 
which inhibits the facile access to a library of compounds. Also, these hydrogenations 
require high pressure,4 which is not suitable for simple reaction set up in a typical 
laboratory environment. Other methods to access these benzo-fused heterocycles 
include asymmetric hydroamination reactions,4 asymmetric imine addition reactions,5 
C–H functionalizations,6 asymmetric alkylations,7 asymmetric N-allylations,8 and 
asymmetric N-arylations.9 However, these transformations in most cases are limited to 
the formation of tertiary carbon stereocenters. The use of asymmetric catalysis to 
generate heterocycles bearing quaternary stereocenters is very rare.5b,
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Figure 3.1 Typical synthesis of benzo-fused heterocycles 
 
We envisioned forming a variety of benzo-fused heterocycles through our 
recently developed asymmetric Pd-catalyzed carboamination reactions. 10 Moreover, we 
wanted to demonstrate the utility of this methodology to form quaternary stereocenters 
through the use of substrates bearing 1,1-disubstituted alkenes (Scheme 3.1).11 This 
chapter describes the enantioselective synthesis of tetrahydroquinolines, 
tetrahydroquinoxalines, and tetrahydroisoquinolines with a single catalyst system. The 
reactions reported herein are the first examples of highly enantioselective (>95:5 e.r.) 
transition metal catalyzed C-N bond formation involving addition to 1,1-disubstituted 
alkenes.12 
Scheme 3.1 Envisioned route to access enantioenriched benzo-fused heterocycles 
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3.2 Initial Optimization of Reaction Conditions and Substrates 
To initiate our studies we examined the feasibility of the reaction of substrate 3-1 
and a catalyst composed of Pd2(dba)3 and (S)-Siphos-PE (3-L1). Previous attempts by 
our group to cyclize onto 1,1-disubstituted alkenes led to diminished 
enantioselectivity.10b Gratifyingly, the reaction of 3-1 under these conditions led to the 
formation of product 3-2 in 86% yield and 92:8 er (Table 3.1). The use of a variety of 
other ligands, palladium sources, bases, or solvents did not improve the outcome of the 
reaction. 
Table 3.1 Initial ligand screen with substrate 3-1a 
 
a
 Conditions: Reactions were conducted on a 0.10  mmol scale using 1.0 equiv substrate, 2.0 equiv Ar-Br, 
2.0 equiv NaO
t
Bu, toluene (0.2 M),105 °C, 12-14 h. Yields and enantiomeric ratios refer to isolated 
compound 3-2. 
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 In our aforementioned carboamination methodology to afford imidazolidin-2-
ones,10b we noted that the use of a more electron poor N-allyl urea substrate afforded 
products in better enantioselectivities than the analogous electron rich N-allyl urea 
substrates. Thus, in order to determine the correlation between nitrogen nucleophilicity 
and asymmetric induction in this system, substrates 3-1 to 3-7 were synthesized and 
subjected to the reaction conditions. Interestingly, enhancing the nitrogen nucleophilicity 
was beneficial to the enantioselectivity of the tetrahydroquinoline products. As such it 
was shown that the highest enantioinduction was observed from the reaction of 3-7 
bearing a p-NMe2 group. Heating the reaction of substrate 3-7 up to 125 °C afforded the 
product in 95% yield and with no change in enantioselectivity (entry 5). 
Table 3.2 Electronic effectsa 
 
a
 Conditions: Reactions were conducted on a 0.10  mmol scale using 1.0 equiv substrate, 2.0 equiv Ar-Br, 
2.0 equiv NaO
t
Bu, toluene (0.2 M),110 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated 
compounds. 
C
 Reaction was heated to 125 °C. 
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3.3 Electrophile and Substrate Scope for the Synthesis of Tetrahydroquinolines, 
Tetrahydroquinoxalines, and Tetrahydroisoquinolines 
 In order to test the versatility of this transformation, a series of aryl and alkenyl 
halides were subjected to the reaction conditions with substrate 3-7 (Table 3.3). 
Electron rich aryl halides (entries 1-3), electron poor aryl halides (entries 4-6), and a 
variety of alkenyl bromides (entries 7-9) all afforded products in good yield and er. 
Table 3.3 Enantioselective synthesis of tetrahydroquinolines with 3-7a 
 
a
 Conditions: Reactions were conducted on a 0.20  mmol scale using 1.0 equiv substrate, 2.0 equiv Ar-Br, 
2.0 equiv NaO
t
Bu, xylenes (0.2 M),125 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated 
compounds.  
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 We also subjected substrate 3-1 to a variety of aryl and alkenyl halides as well. 
This reaction worked well for electron poor and electron rich aryl halides, as well as for 
alkenyl bromides (entries 1-8). Conducting the reaction on a larger scale using half of 
the standard catalyst loading afforded product 3-22 in a comparable yield and er to the 
small scale reaction (entry 6). The presence of substituents larger than a methyl group 
on the alkene had an adverse effect on the reaction outcome (entries 9-10). 
Table 3.4 Enantioselective synthesis of tetrahydroquinolinesa 
 
a
 Conditions: Reactions were conducted on a 0.20  mmol scale using 1.0 equiv substrate, 2.0 equiv Ar-Br, 
2.0 equiv NaO
t
Bu, toluene (0.2 M), 90 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated 
compounds. 
C
 Reaction was ran on 1.0 mmol scale with half of the catalyst loading. 
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To further demonstrate the robust nature of these reactions, we wanted to form 
these carboamination products from compounds bearing differently substituted 
backbones. As such, the naphthyl ring fused substrate 3-25 and the methoxy 
substituted substrate 3-27 were subjected to the reaction conditions noted in Scheme 
3.2. These reactions afforded their respective products in 63% yield and 93:7 er (3-26) 
and 83% yield and 96:4 er (3-28). 
Scheme 3.2 Different substrate backbones 
 
 To further investigate the utility of this reaction, we wanted to synthesize a 
product containing multiple heteroatoms. As such we synthesized substrate 3-29 (Table 
3.5) and subjected it to the same catalyst system and conditions that were used for the 
tetrahydroquinoline products. This reaction worked well with a variety of aryl halides 
(entries 1-5) affording an array of tetrahydroquinoxaline products in good yields and 
enantioselectivities. The reaction also worked well with an alkenyl bromide (entry 6) 
affording 3-37 in 74% and 98:2 er. Substrate 3-30, bearing an –CH2OBn substituted 
alkene, afforded product 3-38 in similar yield and enantioselectivity as compared to 3-
29. However, the phenyl substitutued alkene substrate 3-31 proved to be unreactive. A 
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variety of protecting groups were tested on the non-cyclizing nitrogen including Boc, Bn, 
Et, and PMP, all of which led to lower yields and enantioselectivities in the observed 
reaction products. 
Table 3.5 Enantioselective synthesis of tetrahydroquinoxalinesa 
 
a
 Conditions: Reactions were conducted on a 0.20  mmol scale using 1.0 equiv substrate, 2.0 equiv Ar-Br, 
2.0 equiv NaO
t
Bu, toluene (0.2 M), 110 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated 
compounds. 
C
 Reaction was conducted at 120 °C in xylenes. 
 
 We wanted to further demonstrate the utility of these reactions by forming 
tetrahydroisoquinoline products. However, initial attempts to access these products by 
cyclizing onto 1,1-disubstituted alkenes proved unfruitful. However, with the use of a 
methyl carbamate protecting group13 we were able to afford tetrahydroisoquinoline 
products with tertiary stereocenters in moderate yields and good enantioselectivities 
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(Table 3.6). The use of other groups on the cyclizing nitrogen such as PMP, Ac, Boc, 
Cbz, and a variety of other carbamates afforded either no product or lower yields and 
enantioselectivities for the corresponding products. 
Table 3.6 Enantioselective synthesis of tetrahydroisoquinolinesa 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 1.2 equiv Ar-Br, 1.2 equiv NaO
t
Bu, 
toluene (0.125 M), 90 °C, 2 h. 
b
Yields and enantiomeric ratios refer to isolated compounds. 
C
 Reactions 
was conducted at  70 °C for 12 h. 
 
3.4 Assignment of Absolute Configuration 
 The absolute stereochemistry of product 3-16 was established by single crystal 
x-ray analysis as shown below. The stereochemistry of all other products was assigned 
based on analogy to 3-16. 
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Figure 3.2 X-ray crystal structure of 3-16 
  
 
3.5 Conclusions 
 In conclusion, we developed an enantioselective synthesis of three separate 
classes of molecules: tetrahydroquinolines, tetrahydroquinoxalines, and 
tetrahydroisoquinolines. This methodology was carried out using a single catalyst 
system composed of Pd2(dba)3/(S)-Siphos-PE, which afforded good enantioselectivities 
for all three of the benzo-fused heterocycles that were synthesized. The work in this 
chapter not only shows the utility of enantioselective carboamination reactions, but it 
also offers a good alternative to the synthesis of benzo-fused heterocycles compared to 
more conventional means such as hydrogenation. Lastly, the reactions displayed here 
in chapter 3 are rare examples of highly enantioselective addition reactions between 
1,1-disubstituted alkenes and amine nucleophiles. 
 
The work in this chapter was published in Chemical Science.14  
3.6 Experimental 
General: Reactions were carried out under nitrogen in flame-dried glassware. 
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Tris(dibenzylideneacetone)dipalladium and (S)-Siphos-PE were purchased from Strem 
Chemical Co. and used without further purification. 2-Allylbenzonitrile was prepared 
according to a slight modification of a literature procedure (BuMgCl was used in place of 
BuMgBr).15 (Z)-1-bromobut-1-ene was synthesized according to a published 
procedure.16 All other reagents including all aryl and alkenyl bromides were purchased 
from commercial sources and used as received unless otherwise noted. Xylenes were 
purified by distillation over CaH2 prior to use in reactions.  Methylene chloride and 
toluene were purified using a GlassContour solvent system. All yields refer to isolated 
compounds that are estimated to be >95% pure as judged by 1H NMR or GC analysis. 
The yields reported herein describe the result of a single experiment, whereas yields 
reported chapter 3 describe the average of two or more runs, and the two may differ. 
 
1-Bromo-2-(3-methylbut-3-en-1-yl)benzene (3-S1a): A flame-dried round bottom flask 
equipped with a stir bar was cooled under a stream of nitrogen. 2-bromobenzyl bromide 
(1.25 g, 5.0 mmol), and THF (5 mL) were added to the flask and the resulting solution 
was cooled to 0 °C. 2-methylallylmagnesium chloride (20 mL, 10 mmol, 0.5 M solution 
in THF) was slowly added and the resulting mixture was moved into an oil bath and 
heated to 40 °C for 1.5 h. The mixture was then cooled to rt and quenched with 4 mL of 
2M H2SO4. Water (5 mL) and ether (15 mL) were added and the mixture was 
transferred to a separatory funnel. The layers were separated, the aqueous layer was 
extracted with diethyl ether (3x15 mL), and the organic layers were then combined, 
dried over anhydrous sodium sulfate, and concentrated in vacuo. The product was 
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purified via flash chromatography on silica gel using hexanes as the eluent to afford 
1.06 g (95%) of the title compound as a clear oil. 1H NMR (700 MHz, CDCl3) δ 7.54 (d, J 
= 7.8 Hz, 1 H), 7.25–7.21 (m, 1 H), 7.08–7.02 (m, 1 H), 4.79 (s, 1 H), 4.76 (s, 1 H), 
2.91–2.86 (m, 2 H), 2.32 (t, J = 8.6 Hz, 2 H), 2.81 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 
145.1; 141.5; 132.9; 130.36; 127.7; 127.5; 124.6; 110.7; 38.1; 34.9; 22.7; IR (film) 2933, 
1648, 1439 cm-1.  
 
1-Bromo-4-methoxy-2-(3-methylbut-3-en-1-yl)benzene (3-S1b): The conversion of 2-
bromo-5-methoxybenzyl bromide (1.40 g, 5.0 mmol) was accomplished using a 
procedure analogous to that described above for the preparation of S1b except using 
2.5 equiv of 2-methylallylmagnesium chloride. This procedure afforded 1.15 g (90%) of 
the title compound as a clear oil. 1H NMR (700 MHz, CDCl3) δ 7.40 (d, J = 8.7 Hz, 1H), 
6.77 (d, J = 3.1 Hz, 1 H), 6.62 (dd, J = 3.1, 8.7 Hz, 1 H), 4.77 (s, 1 H), 4.75 (s, 1 H), 3.78 
(s, 3 H), 2.83–2.78 (m, 2 H), 2.29 (t, J = 8.5 Hz, 2 H), 1.79 (s, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 159.1, 145.3, 142.6, 133.4, 116.1, 115.0, 113.2, 110.6, 55.6, 38.0, 35.1, 22.7; 
IR (film) 2933, 1571, 1471 cm-1.  
 
1-Bromo-2-(3-methylbut-3-en-1-yl)naphthalene (3-S1c): The conversion of 1-bromo-
2-(bromomethyl)naphthalene (0.60 g, 2.0 mmol) was accomplished using a procedure 
82 
 
analogous to that described above for the preparation of S1a except using 2.5 equiv of 
2-methylallylmagnesium chloride and a reaction temperature of 45 °C instead of 40 °C 
for the heated segment of the reaction. This procedure afforded 1.15 g (80%) of the title 
compound as a clear oil. 1H NMR (700 MHz, CDCl3) δ 8.32 (d, J = 8.5 Hz, 1 H), 7.80 (d, 
J = 8.0 Hz, 1 H), 7.74 (d, J = 8.3 Hz, 1 H), 7.58 (t, J = 7.0 Hz, 1 H), 7.48 (t, J = 8.0 Hz, 1 
H), 7.36 (d, J = 8.3 Hz, 1 H), 4.78 (d, J = 5.1 Hz, 2 H), 3.12 (t, J = 8.8 Hz, 2 H), 2.39 (t, J 
= 8.9 Hz, 2 H), 1.85 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 145.4, 139.8, 133.4, 132.8, 
128.19, 128.18, 127.7, 127.5, 127.4, 126.0, 123.8, 110.7, 38.3, 36.2, 22.8; IR (film) 
2916, 1603, 1494 cm-1. 
 
3-(2-bromophenyl)-N-methoxy-N-methylpropanamide: According to a literature 
prodecure,17 a round bottom flask was equipped with a stirbar and charged with 3-(2-
bromophenyl)propionic acid (4.00 g, 17.5 mmol), N,O-dimethylhydroxylamine 
hydrochloride (2.90 g, 29.7 mmol), THF (35 mL, 0.5 M), water (35 mL, 0.5 M), and 
aqueous 1 M NaOH (3 mL). ). A solution of EDCI (8.39 g, 43.8 mmol) and 1 M NaOH (7 
mL) in water (117 mL) was then added dropwise over 20 min. After the addition was 
complete, 1 M NaOH (5.5 mL) was added to raise the pH of the solution to 4.5 and the 
mixture was then stirred at rt for 8 h. The reaction mixture was then saturated with solid 
sodium chloride, transferred to a separatory funnel, and extracted with ethyl acetate (5 x 
100 mL). The combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude product was purified by flash 
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chromatography on silica gel to afford the title compound as a clear oil (4.49 g, 94%).1H 
NMR (500 MHz, CDCl3) δ 7.53 (d, J = 8.1 Hz, 1 H), 7.29 (d, J = 7.3 Hz, 1 H), 7.23 (t, J = 
7.3 Hz, 1 H), 7.07 (t, J = 7.3 Hz, 1 H), 3.63 (s, 3 H), 3.18 (s, 3 H), 3.07 (t, J = 7.6 Hz, 2 
H), 2.76 (t, J = 7.3 Hz, 2 H); 13C NMR (125 MHz, CDCl3) δ173.4, 140.6, 132.9, 130.9, 
128.0, 127.6, 124.4, 61.3, 32.1, 32.0, 31.3; This compounds properties were identical to 
that as stated in the literature.17 
General procedure A: addition of grignard to 3-(2-bromophenyl)-N-methoxy-N-
methylpropanamide. A flame dried round bottom flask equipped with a stirbar was 
cooled under a stream of nitrogen and charged with 3-(2-bromophenyl)-N-methoxy-N-
methylpropanamide (1.0 equiv.). Then diethyl ether (0.40 M) was added to the flask and 
it was cooled to 0 °C. The grignard reagent (1.50 equiv.) was added dropwise and the 
reaction was allowed to slowly warm to room temperature and stir for 5 hours. The 
reaction mixture was then cooled back to 0 °C and it was quenched with saturated 
ammonium chloride (1mL/mmol substrate) and then water (5mL/mmol substrate) was 
added. This mixture was transferred to a separatory funnel and extracted with EtOAc. 
The combined organic layers were dried with sodium sulfate and concentrated in vacuo. 
The crude products were purified by flash chromatography on silica gel. 
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3-(2-bromophenyl)-1-phenylpropan-1-one (3-S2a): General procedure A was used 
for the reaction of 3-(2-bromophenyl)-N-methoxy-N-methylpropanamide (2.72 g, 10 
mmol), and phenylmagnesium bromide (1 M THF, 15 mL). This procedure afforded 1.92 
grams (66%) of the title product as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 
8.1 Hz, 2 H), 7.57-7.52 (m, 2H), 7.45 (t, J = 7.8 Hz, 2 H), 7.31 (d, J = 6.9 Hz, 1 H), 7.24 
(t, J = 8.1 Hz, 1 H), 7.07 (t, J = 7.3 Hz, 1 H), 2.82 (t, J = 7.3 Hz, 2 H), 2.45 (t, J = 7.8 Hz, 
2 H); 13C NMR (125 MHz, CDCl3) δ 199.0, 140.6, 136.8, 133.2, 132.9, 130.9, 128.7, 
128.1, 128.0, 127.7, 124.4, 38.7, 30.1. This compounds properties were identical to that 
as stated in the literature.18 
 
1-(2-bromophenyl)pentan-3-one (3-S2b): General procedure A was used for the 
reaction of 3-(2-bromophenyl)-N-methoxy-N-methylpropanamide (1.10 g, 4.04mmol), 
and ethylmagnesium bromide (3 M THF, 2.02 mL). This procedure afforded 775 mgs 
(80%) of the title product as a clear oil. 1H NMR (700 MHz, CDCl3) δ 7.47 (d, J = 7.8 Hz, 
1 H), 7.21-7.16 (m, 2 H), 7.01 (t, J = 8.0 Hz, 1 H), 2.97 (t, J = 7.7 Hz, 2 H), 2.70 (t, J = 
7.8 Hz, 2 H), 2.48 (q, J = 7.3 Hz, 2 H), 1.01 (t, J = 7.2 Hz, 3 H); 13C NMR (175 MHz, 
CDCl3) δ210.0, 140.3, 132.7, 130.5, 127.8, 127.5, 124.1, 41.9, 35.9, 30.3, 7.7; IR (film) 
2973, 2936, 1711 cm-1. 
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1-(2-bromophenyl)-4-methylpentan-3-one (3-S2c): General procedure A was used for 
the reaction of 3-(2-bromophenyl)-N-methoxy-N-methylpropanamide (2.72 g, 10mmol), 
and isopropylmagnesium chloride (2 M THF, 7.50 mL). This procedure afforded 625 
mgs (25%) of the title product as a clear oil. 1H NMR (700 MHz, CDCl3) δ 7.50 (d, J = 
8.0 Hz, 1 H), 7.24-7.19 (m, 2 H), 7.05 (t, J = 8.2 Hz, 1 H), 3.00 (t, J = 7.5 Hz, 2 H), 2.77 
(t, J = 7.7 Hz, 2 H), 2.57 (sep., J = 7.0 Hz, 1 H), 1.06 (d, J = 7.0 Hz, 6 H); 13C NMR (175 
MHz, CDCl3) δ213.4, 140.6, 132.8, 130.7, 127.9, 127.5, 124.2, 41.0, 40.0, 30.5, 18.1; IR 
(film) 2967, 2932, 1708 cm-1. 
General procedure B: wittig reaction of ketones. A flame dried round bottom flask 
equipped with a stirbar was cooled under a stream of nitrogen and charged with 
methyltriphenylphosphonium bromide (1.4 equiv.). Then THF (0.15 M) was added to the 
flask and it was cooled to 0 °C. Potassium tert-butoxide (1.4 equiv.) was then added all 
at once and the mixture was allowed to stir at 0 °C for 45 minutes. To this mixture was 
added the appropriate ketone from above (1.0 equiv.) slowly in a solution of THF (0.65 
M). The reaction mixture was then allowed to slowly warm to room temperature and stir 
for 16 hours. After 16 hours the reaction was concentrated in vacuo and then filtered 
through celite with hexanes. The filtrate was then concentrated in vacuo and the crude 
product was purified by flash chromatography on silica gel. 
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1-bromo-2-(3-phenylbut-3-en-1-yl)benzene (3-S1d): General procedure A was used 
for the reaction of methyltriphenylphosphonium bromide (3.31 g, 9.28mmol), KOtBu 
(1.04 g, 9.28mmol), and 3-(2-bromophenyl)-1-phenylpropan-1-one (1.92 g, 6.63mmol). 
This procedure afforded 1.06 grams (56%) of the title compound as a clear oil. 1H NMR 
(400 MHz, CDCl3) δ 7.53 (d, J = 8.0 Hz, 1 H), 7.46 (d, J = 8.2 Hz, 2 H), 7.34 (t, J = 6.3 
Hz, 2 H), 7.30–7.13 (m, 3H), 7.04 (t, J = 8.0 Hz, 1 H), 5.31 (s, 1 H), 5.08 (s, 1 H), 2.91-
2.83 (m, 2 H), 2.82-2.76 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ147.6, 141.2, 140.9, 
132.8, 130.6, 128.4, 127.7, 127.5, 127.4, 126.2, 124.4, 112.9, 35.5, 35.4. This 
compounds properties were identical to that as stated in the literature.18 
 
1-bromo-2-(3-methylenepentyl)benzene (3-S1e): General procedure A was used for 
the reaction of methyltriphenylphosphonium bromide (620 mgs, 1.73mmol), KOtBu (194 
mgs, 1.73mmol), and 1-(2-bromophenyl)pentan-3-one (300 mgs, 1.24mmol). This 
procedure afforded 163 mgs (55%) of the title compound as a clear oil. 1H NMR (400 
MHz, CDCl3) δ 7.54 (d, J = 7.8 Hz, 1 H), 7.23 (d, J =  4.7 Hz, 2 H), 7.08-7.04 (m, 1 H), 
4.80 (s, 2 H), 2.89 (t, J = 8.2 Hz, 2 H), 2.35 (t, J = 8.6 Hz, 2 H), 2.13 (q, J = 7.4 Hz, 2 H), 
1.08 (t, J = 7.4 Hz, 3 H); 13C NMR (175 MHz, CDCl3) δ150.7, 141.6, 132.8, 130.3, 
127.6, 127.4, 124.4, 108.3, 36.4, 35.1, 29.0, 12.4; IR (film) 3024, 2920, 1494 cm-1. 
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1-bromo-2-(4-methyl-3-methylenepentyl)benzene (3-S1e): General procedure A was 
used for the reaction of methyltriphenylphosphonium bromide (1.19 g, 3.34mmol), 
KOtBu (774 mgs, 3.34mmol), and 1-(2-bromophenyl)-4-methylpentan-3-one (610 mgs, 
2.40mmol). This procedure afforded 230 mgs (38%) of the title compound as a clear oil. 
1H NMR (700 MHz, CDCl3) δ 7.55 (d, J = 7.8 Hz, 1 H), 7.25 (d, J = 4.4 Hz, 2 H), 7.09-
7.05 (m, 1 H), 4.86 (s, 1 H), 4.81 (s, 1 H), 2.89 (t, J = 8.2 Hz, 2 H), 2.37-2.31 (m, 3 H), 
1.10 (d, J = 7.0 Hz, 6 H); 13C NMR (175 MHz, CDCl3) δ 155.2, 141.7, 132.8, 130.3, 
127.6, 127.4, 124.4, 107.0, 35.4, 34.5, 34.0, 21.9; IR (film)  2959, 2927, 1470 cm-1. 
General procedure C: synthesis of 2-(3-methylbut-3-en-1-yl)aniline substrates. A 
flame dried Schlenk flask equipped with a stir bar was cooled under a stream of 
nitrogen and charged with Pd2(dba)3 (0.75 mol %), XPhos (2.25 mol %), 1-bromo-2-(3-
methylbut-3-en-1-yl)benzene (1.0 equiv), the appropriate aniline derivative (1.2 equiv), 
and NaOtBu (1.5 equiv). The flask was then purged with nitrogen, and toluene (0.5 M) 
was added. The resulting mixture was heated to 105 °C with stirring until the starting 
material had been consumed as judged by TLC, GC, or 1H NMR analysis of an aliquot 
removed from the reaction mixture (ca. 12 h). The reaction mixture was then cooled to 
rt, saturated aqueous ammonium chloride (6 mL/mmol substrate) was added, and the 
mixture was transferred to a separatory funnel. The mixture was extracted with ethyl 
acetate (3 x 20 mL) then the organic layers were combined, dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude product was then purified 
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by flash chromatography on silica gel using a hexanes/Et2O mixture as the eluent. 
 
N-(4-Methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (3-1). General Procedure C 
was employed for the coupling of 1-bromo-2-(3-methylbut-3-en-1-yl)benzene (1.125 g, 
5.0 mmol) and p-anisidine (738 mg, 6.0 mmol). This procedure afforded 1.09 g (82%) of 
the title compound as a yellow oil. 1H NMR (700 MHz, CDCl3) δ 7.28 (d, J = 7.7 Hz, 1 
H), 7.18 (t, J = 8.7 Hz, 1 H), 7.14 (d, J = 8.4 Hz, 1 H), 7.06 (d, J = 8.4 Hz, 2 H), 6.98–
6.92 (m, 3H), 5.40 (s, br, 1 H), 4.88 (s, 1 H), 4.86 (s, 1 H), 3.86 (s, 3 H), 2.82 (t, J = 8.4 
Hz, 2 H), 2.45 (t, J = 8.4 Hz, 2 H), 1.88 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 155.0, 
145.6, 142.8, 137.0, 130.2, 129.7, 127.0, 121.5, 120.7, 117.0, 114.8, 110.5, 55.6, 37.4, 
29.9, 22.8; IR (film) 3398, 2933, 1507 cm-1; MS (ESI+) 268.1704 (268.1696 calcd for 
C18H21NO, M + H
+). 
 
4-{[2-(3-Methylbut-3-en-1-yl)phenyl]amino}benzonitrile (3-3). General Procedure C 
was employed for the coupling of 1-bromo-2-(3-methylbut-3-en-1-yl)benzene (225 mg, 
1.0 mmol) and p-cyanoaniline (142 mg, 1.20 mmol) except using a catalyst loading of 1 
mol % Pd2(dba)3. This procedure afforded 223 mg (28%) of the title compound as a 
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yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 11.9 Hz, 2 H), 7.30 (d, J = 11.2 Hz, 
1 H), 7.28–7.16 (m, 3 H), 6.75 (d, J = 12.6 Hz, 2 H), 5.89 (s, br, 1 H), 4.74 (s, 1 H), 4.65 
(s, 1 H), 2.73 (t, J = 10.5 Hz, 2 H), 2.26 (t, J = 11.9 Hz, 2 H), 1.72 (s, 3 H); 13C NMR 
(175 MHz, CDCl3) δ 149.9, 145.2, 137.8, 137.4, 133.8, 130.5, 127.3, 126.1, 125.3, 
120.3, 114.2, 110.9, 100.5, 38.4, 30.1, 22.7; IR (film) 3338, 2927, 2213, 1513 cm-1; MS 
(ESI+) 263.1546 (263.1543 calcd for C18H18N2, M + H
+). 
 
N-[4-(tert-Butyl)phenyl]-2-(3-methylbut-3-en-1-yl)aniline (3-5). General Procedure C 
was employed for the coupling of 1-bromo-2-(3-methylbut-3-en-1-yl)benzene (225 mg, 
1.0 mmol) and p-tert-butylaniline (0.19 mL, 1.2 mmol). This procedure afforded 210 mg 
(72%) of the title compound as a yellow oil. 1H NMR (700 MHz, CDCl3) δ 7.41 (d, J = 
9.1 Hz, 2 H), 7.37 (d, J = 7.7 Hz, 1 H), 7.32 (d, J = 7.7 Hz, 1 H), 7.25 (t, J = 7.7 Hz, 1 H), 
7.09–7.03 (m, 3 H), 5.52 (s, br, 1 H), 4.91 (s, 1 H), 4.88 (s, 1 H), 2.87 (t, J = 8.4 Hz, 2 
H), 2.46 (t, J = 9.1 Hz, 2 H), 1.90 (s, 3 H), 1.45 (s, 9 H); 13C NMR (175 MHz, CDCl3) δ 
145.6, 143.5, 141.7, 141.5, 132.1, 129.9, 127.0, 126.2, 121.9, 119.2, 117.6, 110.7, 37.8, 
34.2, 31.7, 30.1, 22.8; IR (film) 3398, 2961, 1514 cm-1; MS (ESI+) 294.2228 (294.2216 
calcd for C21H27N, M + H
+). 
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N1,N1-Dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (3-7). 
General Procedure C was employed for the coupling of 1-bromo-2-(3-methylbut-3-en-1-
yl)benzene (1.10 g, 4.88 mmol) and 4-(dimethylamino)aniline (798 mg, 5.86 mmol). This 
procedure afforded 1.16 g (85%) of the title compound as a yellow oil. 1H NMR (700 
MHz, C6D6) δ 7.15–7.13 (m, 1 H), 7.10 (d, J = 9.7 Hz, 1 H), 7.07 (t, J = 7.8 Hz, 1 H), 
6.98 (d, J = 8.9 Hz, 2 H), 6.86 (t, J = 7.3 Hz, 1 H), 6.61 (d, J = 8.9 Hz, 2 H), 5.06 (s, 1 
H), 4.78 (s, 2 H), 2.61 (t, J = 7.8 Hz, 2 H), 2.56 (s, 6 H), 2.29 (t, J = 8.5 Hz, 2 H), 1.62 (s, 
3 H); 13C NMR (175 MHz, C6D6) δ 147.5, 145.6, 144.5, 134.0, 129.8, 129.4, 127.3, 
123.4, 120.2, 116.4, 114.5, 110.8, 41.0, 37.5, 30.2, 22.7; IR (film) 3410, 2934, 1516 cm-
1; MS (ESI+) 281.2018 (281.2012 calcd for C19H24N2, M + H
+). 
 
4-Methoxy-N-(4-methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (3-27). General 
Procedure C was employed for the coupling of 1-bromo-4-methoxy-2-(3-methylbut-3-en-
1-yl)benzene (420 mg, 1.65 mmol) and p-anisidine (243 mg, 1.98 mmol) and a reaction 
time of 3 h. This procedure afforded 421 mg (86%) of the title compound as an orange 
oil. 1H NMR (700 MHz, C6D6) δ 7.05 (d, J = 8.7 Hz, 1 H), 6.88 (d, J = 2.7 Hz, 1 H), 6.77 
(d, J = 8.9 Hz, 2 H), 6.68–6.62 (m, 3 H), 4.77–4.74 (m, 2 H), 4.66 (s, br, 1 H), 3.40 (s, 3 
91 
 
H), 3.36 (s, 3 H), 2.64 (t, J = 8.9 Hz, 2 H), 2.24 (t, J = 8.3 Hz, 2 H), 1.59 (s, 3 H); 13C 
NMR (175 MHz, C6D6) δ 156.3, 153.7, 145.1, 140.3, 137.0, 135.0, 124.4, 117.3, 115.6, 
114.8, 111.9, 110.4, 54.8, 54.7, 38.0, 30.2, 22.2; IR (film) 3379, 2933, 1509 cm-1; MS 
(ESI+) 297.1726 (297.1723 calcd for C19H23NO2, M + H
+). 
 
N-(4-Methoxyphenyl)-2-(3-methylbut-3-en-1-yl)naphthalen-1-amine (3-25). General 
Procedure C was employed for the coupling of 1-bromo-2-(3-methylbut-3-en-1-
yl)naphthalene (380 mg, 1.38 mmol) and p-anisidine (204 mg, 1.65 mmol) except using 
a catalyst composed of Pd2(dba)3 (25 mg, 0.0276 mmol, 2.0 mol %) and JohnPhos 
(16.5 mg, 0.0552 mmol, 4.0 mol %). This procedure afforded 308 mg (70%) of the title 
compound as a yellow solid, mp 80–84 °C. 1H NMR (700 MHz, C6D6) δ 8.06 (d, J = 8.2 
Hz, 1 H), 7.71 (d, J = 7.2 Hz, 1 H), 7.59 (d, J = 8.3 Hz, 1 H), 7.28–7.23 (m, 3 H), 6.66 (d, 
J = 8.9 Hz, 2 H), 6.36 (d, J = 8.9 Hz, 2 H), 4.93 (s, 1H), 4.73 (d, J = 15.2 Hz, 2 H), 3.30 
(s, 3 H), 2.80 (t, J = 8.8 Hz, 2 H), 2.24 (t, J = 8.2 Hz, 2 H), 1.60 (s, 3 H); 13C NMR (175 
MHz, C6D6) δ 153.4, 145.2, 142.1, 136.7, 135.9, 134.2, 132.5, 128.6, 128.5, 128.4, 
126.4, 125.7, 124.6, 115.4, 115.2, 111.0, 55.2, 39.1, 31.1, 22.5; IR (film) 3382, 2959, 
1505 cm-1; MS (ESI+) 317.1771 (317.1771 calcd for C22H23NO, M + H
+). 
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N-(4-methoxyphenyl)-2-(3-phenylbut-3-en-1-yl)aniline (3-10). General Procedure C 
was employed for the coupling of 1-bromo-2-(3-phenylbut-3-en-1-yl)benzene (1.06 g, 
3.70 mmol) and p-anisidine (547 mg, 4.44 mmol) using a catalyst composed of 
Pd2(dba)3 (25 mg, 0.0277 mmol, 0.75 mol %) and XPhos (40 mg, 0.083 mmol, 2.25 mol 
%). This procedure afforded 1.18 (95%) of the title compound as a pale yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.6 Hz, 2 H), 7.42-7.32 (m, 3 H), 7.24-7.08 (m, 3 
H), 6.98-6.85 (m, 5 H), 5.38 (s, 1 H), 5.20 (br s, 1 H), 5.14 (s, 1H), 3.83 (s, 3 H), 2.92 (t, 
J = 8.8 Hz, 2 H), 2.80 (t, J = 9.0 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ154.8, 147.7, 
147.6, 142.6, 140.7, 136.9, 130.1, 129.8, 128.5, 127.6, 127.0, 126.1, 121.1, 120.7, 
117.2, 114.7, 113.0, 55.6, 35.3, 30.5; IR (film) 3406, 2938, 1508 cm-1; MS (ESI+) 
330.1852 (330.1852 calcd for C23H23NO, M + H
+). 
 
N-(4-methoxyphenyl)-2-(3-methylenepentyl)aniline (3-9). General Procedure C was 
employed for the coupling of 1-bromo-2-(3-methylenepentyl)benzene (160 mg, 0.67 
mmol) and p-anisidine (99 mg, 0.80 mmol) except using a catalyst composed of 
Pd2(dba)3 (9.2 mg, 0.010 mmol, 1.5 mol %) and XPhos (12.7 mg, 0.0268 mmol, 4.0 mol 
%). This procedure afforded 170 mg (90%) of the title compound as a pale yellow oil. 1H 
NMR (500 MHz, CDCl3) δ 7.17 (d, J = 7.3 Hz, 1 H), 7.09 (t, J = 7.8 Hz, 1 H), 7.04 (d, J = 
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7.8 Hz, 1 H), 6.98 (d, J = 9.2 Hz, 2 H), 6.90-6.83 (m, 3H), 5.30 (br s, 1 H), 4.8  (s, 2 H),  
3.80 (s, 3 H), 2.73 (t, J = 7.8 Hz, 2 H), 2.39 (t, J = 8.3 Hz, 2 H), 2.10 (q, J = 7.3 Hz, 2 H), 
1.06 (t, J = 7.3 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ155.0, 151.2, 142.8, 136.9, 
130.2, 129.6, 126.9, 121.3, 120.6, 116.7, 114.8, 108.2, 55.7, 35.9, 30.2, 29.1, 12.4; IR 
(film) 3392, 2960, 1508 cm-1; MS (ESI+) 282.1849 (282.1852 calcd for C19H23NO, M + 
H+). 
 
N-(4-methoxyphenyl)-2-(4-methyl-3-methylenepentyl)aniline (3-11). General 
Procedure C was employed for the coupling of 1-bromo-2-(4-methyl-3-
methylenepentyl)benzene (150 mg, 0.59 mmol) and p-anisidine (88 mg, 0.71 mmol) 
except using a catalyst composed of Pd2(dba)3 (11 mg, 0.0118 mmol, 2.0 mol %) and 
XPhos (11 mg, 0.0236 mmol, 4.0 mol %). This procedure afforded 170 mg (97%) of the 
title compound as a pale yellow oil. 1H NMR (700 MHz, CDCl3) δ 7.16 (d, J = 7.3 Hz, 1 
H), 7.08 (t, J = 8.0 Hz, 1 H), 7.03 (d, J = 7.8 Hz, 1 H), 6.98 (d, J = 8.7 Hz, 2 H), 6.87-
6.83 (m, 3H), 5.29 (br s, 1 H), 4.82  (s, 1 H), 4.77 (s, 1 H), 3.79 (s, 3 H), 2.72 (t, J = 8.0 
Hz, 2 H), 2.36 (t, J = 8.5 Hz, 2 H), 2.28 (sep. J = 7.0 Hz, 1 H), 1.04 (d, J = 6.8 Hz, 6 H); 
13C NMR (175 MHz, CDCl3) δ155.7, 155.0, 142.8, 136.8, 130.2, 129.7, 126.9, 121.7, 
120.5, 116.6, 114.7, 106.9, 55.7, 34.1, 33.9, 30.4, 21.9 ; IR (film) 3389, 2958, 1508 cm-
1; MS (ESI+) 296.2007 (296.2009 calcd for C20H25NO, M + H
+). 
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N-Methyl-N-(2-methylallyl)-2-nitroaniline (3-S3a). A flame dried flask equipped with a 
stir bar was cooled under nitrogen and charged with 1-Fluoro-2-nitrobenzene (2.10 mL, 
20 mmol) and anhydrous DMF (20 mL). Methylamine (20 mL, 40 mmol, 2.0 M in THF) 
was added and the resulting mixture was heated to 50 °C for 12 hours. The reaction 
mixture was then cooled to rt, and excess methylamine and THF were evaporated in 
vacuo to afford crude N-methyl-2-nitroaniline, which was dissolved in DMF (15 mL) and 
added slowly to a flame dried flask containing a suspension of NaH (880 mg, 22 mmol, 
60% in mineral oil) in DMF (10 mL) that had been cooled to 0 °C. The resulting mixture 
was stirred for 30 minutes at 0 °C then 3-bromo-2-methylpropene (3.05 mL, 30 mmol), 
was added slowly. The ice bath was removed, the reaction flask was placed in an oil 
bath (rt) and then was heated to 100 °C for 6 h. The mixture was then allowed to cool to 
room temperature and saturated aqueous NH4Cl (40 mL) and EtOAc (80 mL) were 
added. The mixture was transferred to a separatory funnel, the layers were separated, 
and the organic layer was separated and washed with brine (2 x 10 mL). The organic 
layer was then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. 
The crude product was purified by flash chromatography on silica gel using 
hexanes/Et2O as the eluant to afford 2.25 g (51%) of the title compound as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.2 Hz, 1 H), 7.34 (t, J = 7.8 Hz, 1 H), 7.01 (d, 
J = 8.4 Hz, 1 H), 6.81 (t, J = 7.6 Hz, 1 H), 4.91 (s, 1 H), 4.84 (s, 1 H), 3.71 (s, 2 H), 2.76 
(s, 3 H), 1.69 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 145.8, 140.6, 140.1, 133.1, 126.6, 
119.8, 118.5, 113.1, 60.6, 40.2, 20.2; IR (film) 2914, 1604, 1512 cm-1. 
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N-methyl-2-nitro-N-(2-phenylallyl)aniline (3-S3b): Following the above procedure, 1-
Fluoro-2-nitrobenzene (0.97 mL, 9.25 mmol) and methylamine (9.25 mL, 18.5 mmol, 2.0 
M in THF) were reacted to form the crude N-methyl-2-nitroaniline. This crude product 
was added dropwise to a flame dried round bottom flask containing a suspension of 
NaH (60% in mineral oil 406 mg, 10.15 mmol) in DMF at 0 °C. Again, following the 
above procedure, (3-bromoprop-1-en-2-yl)benzene5 (2.73 g, 13.85 mmol) was added to 
this mixture. The above procedure afforded the title compound in 1.64 g (66%) as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.4 Hz, 1 H), 7.38-7.26 (m, 6  H), 
6.95 (d, J = 8.6 Hz, 1 H), 6.82 (t, J = 7.4 Hz, 1 H), 5.51 (s, 1 H), 5.22 (s, 1 H), 4.22 (s, 2 
H), 2.84 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 145.4, 142.5, 139.6, 138.9, 132.9, 
128.3, 127.9, 126.3, 126.0, 119.5, 118.2, 114.3, 58.0, 39.9; IR (film) 2931, 1604, 1511 
cm-1. 
 
N-(2-((benzyloxy)methyl)allyl)-N-methyl-2-nitroaniline (3-S3c): Following the above 
procedure, 1-Fluoro-2-nitrobenzene (0.84 mL, 8.00 mmol) and methylamine (8 mL, 16 
mmol, 2.0 M in THF) were reacted to form the crude N-methyl-2-nitroaniline. This crude 
product was added dropwise to a flame dried round bottom flask containing a 
suspension of NaH (60% in mineral oil, 352 mg, 8.80 mmol) in DMF at 0 °C. Again, 
following the above procedure, (((2-(chloromethyl)allyl)oxy)methyl)benzene6 (2.35 g, 
96 
 
12.00 mmol) was added to this mixture. The above procedure afforded the title 
compound in 810 mg (33%) as a yellow oil containing a slight unknown impurity which 
was carried on to the next step. 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.6 Hz, 1 H), 
7.40-7.23 (m, 6 H), 7.05 (d, J = 8.4 Hz, 1 H), 6.82 (t, J = 7.2 Hz, 1 H), 5.24 (s, 1 H), 5.12 
(s, 1 H), 4.46 (s, 2 H), 3.98 (s, 2 H), 3.89 (s, 2 H), 2,76 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ160.6, 145.6, 141.1, 138.1, 133.0, 128.4, 127.7, 127.6, 126.4, 119.8, 118.5, 
115.1, 72.4, 71.3, 56.7, 40.4; IR (film) 2916, 2848, 1511 cm-1. 
 
N1-Methyl-N1-(2-methylallyl)benzene-1,2-diamine (3-S3d). A flame dried flask 
equipped with a stir bar was cooled under nitrogen and charged with Zinc dust (8.56 g, 
130.9 mmol) and anhydrous ethanol (75 mL). The resulting suspension was vigorously 
stirred, glacial acetic acid (7.50 mL, 131 mmol) was added, and the mixture was cooled 
to 0 °C. A solution of N-methyl-N-(2-methylallyl)-2-nitroaniline (1.80 g, 8.7 mmol) in 
anhydrous ethanol (15 mL) was added, the ice bath was removed, and the mixture was 
stirred vigorously at room temperature for 2 h. The mixture was then filtered through 
celite and the filtrate was evaporated in vacuo. The resulting material was dissolved in 
EtOAc (50 mL), transferred to a separatory funnel, and washed with saturated aqueous 
NaHCO3 (100 mL). The layers were separated and the aqueous layer was washed with 
EtOAc (2 x 50 mL). The combined organic layers were then washed with brine (30 mL), 
dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product 
was purified by flash chromatography on silica gel using hexanes/Et2O as the eluant  to 
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afford 1.12 g (73%) of the title compound as a red oil. 1H NMR (700 MHz, CDCl3) δ 7.02 
(d, J = 7.8 Hz, 1 H), 6.91 (t, J = 7.8 Hz, 1 H), 6.76–6.71 (m, 2 H), 5.03 (s, 1 H), 4.90 (s, 
1 H), 4.00 (s, br, 2 H), 3.35 (s, 2 H), 2.58 (s, 3 H), 1.78 (s, 3 H); 13C NMR (175 MHz, 
CDCl3) δ 143.2, 141.8, 140.4, 124.4, 120.5, 118.6, 115.3, 112.5, 62.6, 40.5, 20.6; IR 
(film) 3441, 2970, 1607, 1499 cm-1. 
 
N1-methyl-N1-(2-phenylallyl)benzene-1,2-diamine (3-S3e): Following the above 
procedure, Zinc dust (5.99 g, 91.7 mmol), Acetic Acid (5.30 mL, 91.7 mmol), and N-
methyl-2-nitro-N-(2-phenylallyl)aniline (1.64 g, 6.11 mmol) were reacted to afford the 
title compound in 802 mg (55%) as a red oil. 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 
7.6 Hz, 2 H), 7.35–7.25 (m, 3 H), 7.08 (d, J = 7.83 Hz, 1 H), 6.93 (t, J = 7.6 Hz, 1 H), 
6.75 (t, J = 7.8 Hz, 1 H), 6.70 (d, J = 7.8 Hz, 1 H), 5.46 (s, 1 H), 5.39 (s, 1 H), 3.88 (s, 2 
H), 3.78 (s, br, 2 H), 2.60 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 145.6, 142.1, 140.1, 
139.9, 128.2, 127.6, 126.5, 124.6, 120.9, 118.3, 115.1, 114.6, 60.4, 40.6; IR (film) 3439, 
3347, 1606, 1499 cm-1. 
 
N1-(2-((benzyloxy)methyl)allyl)-N1-methylbenzene-1,2-diamine (3-S3f): Following 
the above procedure, Zinc dust (2.55 g, 39 mmol), Acetic Acid (2.25 mL, 39 mmol), and 
N-(2-((benzyloxy)methyl)allyl)-N-methyl-2-nitroaniline (810 mg, 2.60 mmol) were 
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reacted to afford the title compound in 372 mg (50%) as a red oil. 1H NMR (700 MHz, 
CDCl3) δ 7.36-7.32 (m, 4 H), 7.30-7.27 (m, 1 H), 7.01 (d, J = 7.7 Hz, 1 H), 6.89 (t, J = 
7.5 Hz, 1 H), 6.70 (t, J = 7.7 Hz, 1 H),  6.67 (d, J = 7.8 Hz, 1 H),  5.26 (s, 1 H), 5.22 (s, 1 
H), 4.50 (s, 2 H), 4.09 (s, 2 H), 4.03 (br s, 2 H), 3.49 (s, 2 H), 2.59 (s, 3H); 13C NMR 
(175 MHz, CDCl3) δ143.4, 141.8, 139.6, 138.2, 128.4, 127.8, 127.7, 124.4, 120.3, 
118.1, 115.2, 115.1, 72.0, 71.5, 58.8, 40.4; IR (film) 2920,1604, 1494 cm-1. 
 
N1-(4-Methoxyphenyl)-N2-methyl-N2-(2-methylallyl)benzene-1,2-diamine (3-29). 
General Procedure C was employed for the coupling of 4-bromoanisole (0.80 mL, 6.35 
mmol) and N1-methyl-N1-(2-methylallyl)benzene-1,2-diamine (1.12 g, 6.35 mmol), 
except using a catalyst composed of Pd2(dba)3 (116 mg, 0.127 mmol, 2.0 mol %) and 
JohnPhos (75 mg, 0.250 mmol, 4.0 mol %) and a reaction temperature of 85 °C. This 
procedure afforded 1.49 g (79%) of the title compound as a red oil. 1H NMR (700 MHz, 
CDCl3) δ 7.16–7.10 (m, 4 H), 6.98 (t, J = 7.3 Hz, 1 H), 6.89 (d, J = 7.5 Hz, 2 H), 6.81 (t, 
J = 7.3 Hz, 1 H), 6.57 (s, br, 1 H), 5.07 (s, 1 H), 4.95 (s, 1 H), 3.83 (s, 3 H), 3.39 (s, 2 H), 
2.65 (s, 3 H), 1.81 (s, 3 H); 13C NMR (175 MHz CDCl3) δ 155.1, 143.1, 141.2, 140.2, 
136.2, 124.5, 122.0, 120.7, 118.9, 114.8, 113.0, 112.7, 63.2, 55.7, 40.8, 20.7; IR (film) 
3355, 2933, 1510 cm-1; MS (ESI+) 283.1807 (283.1805 calcd for C18H22N2O, M + H
+) 
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N1-(4-methoxyphenyl)-N2-methyl-N2-(2-phenylallyl)benzene-1,2-diamine (3-31): 
General Procedure C was employed for the coupling of 4-bromoanisole (0.41 mL, 3.3 
mmol) and N1-methyl-N1-(2-phenylallyl)benzene-1,2-diamine (790 mg, 3.3 mmol), 
except using a catalyst composed of Pd2(dba)3 (60 mg, 0.066 mmol, 2.0 mol %) and 
JohnPhos (40 mg, 0.132 mmol, 4.0 mol %) and a reaction temperature of 85 °C. This 
procedure afforded 750 mg (66%) of the title compound as a red oil. 1H NMR (400 MHz, 
CDCl3) δ .757-7.52 (m, 2 H), 7.46-7.40 (m, 3H), 7.30 (d, J = 7.8 Hz, 1 H), 7.24 (d, J = 
8.0 Hz, 1 H), 7.12 (t, J = 7.4 Hz, 1 H), 7.03 (d, J = 8.8 Hz, 2 H), 6.98-6.89 (m, 3 H), 6.41 
(s, br, 1 H) 5.56 (s, 1 H), 5.48 (s, 1 H), 4.03 (s, 2 H), 3.89 (s, 3 H), 2.73 (s, 3 H); 13C 
NMR (100 MHz CDCl3) δ 154.8, 145.8, 140.5, 140.4, 139.9, 135.6, 128.3, 127.5, 126.5, 
124.8, 121.8, 121.3, 118.4, 115.2, 114.4, 112.2, 61.0, 55.4, 41.0; IR (film) 3347, 2947, 
1510 cm-1; MS (ESI+) 239.1537 (239.1543 calcd for C23H24N2O, M + H
+) 
 
N1-(2-((benzyloxy)methyl)allyl)-N2-(4-methoxyphenyl)-N1-methylbenzene-1,2-
diamine (3-30): General Procedure C was employed for the coupling of 4-bromoanisole 
(0.165 mL, 1.32 mmol) and N1-(2-((benzyloxy)methyl)allyl)-N1-methylbenzene-1,2-
diamine (372 mg, 1.32 mmol), except using a catalyst composed of Pd2(dba)3 (26 mg, 
0..0264 mmol, 2.0 mol %) and JohnPhos (16 mg, 0.528 mmol, 4.0 mol %) and a 
reaction temperature of 85 °C. This procedure afforded 380 mg (75%) of the title 
compound as a red oil. 1H NMR (700 MHz, CDCl3) δ 7.32–7.26 (m, 4 H), 7.13 (d, J = 
7.7 Hz, 1 H), 7.09 (d, J = 8.0 Hz, 1 H), 7.06 (d, J = 8.7 Hz, 2 H), 6.96 (t, J = 7.8 Hz, 1 H), 
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6.84 (d, J = 8.9 Hz, 2 H), 6.78 (t, J = 7.7 Hz, 1 H), 6.73 (s, br, 1 H), 5.29 (s, 1 H), 4.44 
(s, 2 H), 4.09 (s, 2 H), 3.80 (s, 3 H), 3.53 (s, 2 H), 2.65 (s, 3 H); 13C NMR (175 MHz 
CDCl3) δ 155.0, 143.2, 140.4, 140.2, 138.1, 135.9, 129.4, 127.8, 127.6, 124.4, 122.5, 
120.5, 118.4, 115.5, 114.5, 112.7, 71.7, 71.4, 59.4, 55.6, 40.7; IR (film) 3338, 2946, 
1509 cm-1; MS (ESI+) 389.2226 (389.2224 calcd for C25H28N2O2, M + H
+) 
 
Methyl (2-allylbenzyl)carbamate (3-39). A flame dried round bottom flask equipped 
with a stir bar was cooled under a stream of nitrogen and charged with ether (20 mL) 
and LiAlH4 (39 mL, 39 mmol, 1.0 M in ether). The mixture was cooled to 0 °C, stirred for 
five min, then a solution of 2-allylbenzonitrile15 (2.80 g, 19.5 mmol) in ether (15 mL) was 
added slowly dropwise. The reaction mixture was stirred for 1.5 h at 0 °C and then was 
slowly quenched with 1.5 mL H2O, 1.5 mL 15% NaOH and 3.0 mL H2O. The resulting 
mixture was stirred at rt for 20 min, then the salts were filtered off through a fritted 
funnel. The filtrate was dried over anhydrous MgSO4 and concentrated in vacuo to 
afford 2-allylbenzylamine, which was used without further purification.  
The crude 2-allylbenzylamine product from above was dissolved in dichloromethane (60 
mL) and added to a flame dried round bottom flask equipped with a stir bar. Solid K2CO3 
(2.95 g, 21.3 mmol) was added to the flask and the resulting mixture was cooled to 0 
°C. Methyl chloroformate (1.0 equiv., 1.5 mL) was then slowly added, and the resulting 
mixture was warmed to room temperature and stirred for 16 h. The reaction mixture was 
filtered, and the filtrate was concentrated in vacuo. The crude product was purified by 
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flash chromatography on silica gel using hexanes/Et2O as the eluent to afford 3.18 g 
(79%) as a clear oil. 1H NMR (500 MHz, d8-toluene, 90 °C) δ 7.07 (d, J = 6.6 Hz, 1 H), 
7.02–6.93 (m, 3 H), 5.82–7.72 (m, 1 H), 4.91 (d, J = 10.0 Hz, 1 H); 4.85 (d, J = 16.9 Hz, 
1 H), 4.58 (s, br, 1 H), 4.16 (d, J = 5.9 Hz, 2 H), 3.42 (s, 3 H), 3.18 (d, J = 6.1 Hz, 2 H); 
13C NMR (125 MHz, d8-toluene, 90 °C) δ 157.7, 139.2, 138.5, 138.2, 131.2, 130.0, 
128.8, 127.9, 116.7, 52.6, 44.1, 38.0; IR (film) 3326, 2949, 1702, 1527 cm-1; MS (CI+) 
206.1175 (206.1176 calcd for C12H15NO2, M + H
+) 
General Procedure D: Asymmetric Pd-catalyzed carboamination reactions. A 
flame dried Schlenk flask equipped with a stir bar was cooled under a stream of 
nitrogen and charged with Pd2(dba)3 (2 mol %), (S)-Siphos-PE (6 mol %), the aryl or 
alkenyl halide (1.0–2.0 equiv.), NaOtBu (1.3–2.0 equiv.), and the amino alkene 
substrate. The flask was purged with nitrogen, and toluene (0.1 M) was added (xylenes 
was used as solvent in cases where reactions were heated over 110 °C). The resulting 
mixture was heated to 80–125 °C with stirring for 2–15 hrs. The reaction mixture was 
then cooled to rt, saturated aqueous ammonium chloride (6 mL/mmol) was added, and 
the mixture was transferred to a separatory funnel. The mixture was extracted with ethyl 
acetate and the combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel using hexanes/Et2O as the eluant. 
 
102 
 
(R)-(+)-2-[4-(tert-Butyl)benzyl]-1-(4-methoxyphenyl)-2-methyl-1,2,3,4 
tetrahydroquinoline (3-2). General Procedure D was employed for the coupling of N-
(4-methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (27 mg, 0.10 mmol) and 1-bromo-4-
tert-butylbenzene (43 mg, 0.20 mmol) using NaOtBu (19 mg, 0.20 mmol) as the base 
and a reaction temperature of 110 °C for 14 h. This procedure afforded 35 mg (86%) of 
the title compound as a white solid, mp 47–50 °C. This material was judged to be 92:8 
er by chiral HPLC analysis (Chiracel ADH, 25 cm x 4.6 mm, 0.5% IPA/Hexanes, 1 
mL/min, λ 254 nm, RT= 6.1 and 7.3 min). [α]23D +50.6 (c 3.33, CH2Cl2); 
1H NMR (500 
MHz, CDCl3) δ 7.29 (d, J = 7.8 Hz, 2 H), 7.13–7.05 (m, 4 H), 7.04–6.91 (m, 3 H), 6.87 (t, 
J = 7.6 Hz, 1 H), 6.62 (t, J = 7.1 Hz, 1 H), 6.04 (d, J = 8.3 Hz, 1 H), 3.87 (s, 3 H), 3.11 
(ddd, J = 5.6, 9.6, 15.9 Hz, 1 H), 2.95–2.82 (m, 3 H), 1.96 (dt, J = 5.9, 12.3 Hz, 1 H), 
1.82–1.76 (m, 1 H), 1.33 (s, 9 H), 1.11 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 158.2, 
149.0, 146.4, 136.2, 135.2, 133.4, 130.5, 129.1, 126.5, 124.8, 120.9, 116.0, 115.1, 
114.8, 114.4, 57.4, 55.4, 44.6, 34.4, 32.3, 31.4, 25.9, 24.5 (an extra peak at 114.4 is 
present due to apparent slow bond rotation); IR (film) 2961, 1603, 1507 cm-1; MS (ESI+) 
400.2632 (400.2635 calcd for C28H33NO, M + H
+).  
 
(R)-(+)-4-{2-[4-(tert-Butyl)benzyl]-2-methyl-3,4-dihydroquinolin-1(2H)-
yl}benzonitrile (3-4).  General Procedure D was employed for the coupling of 4-{[2-(3-
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methylbut-3-en-1-yl)phenyl]amino}benzonitrile (26 mg, 0.10 mmol,) and 1-bromo-4-tert-
butylbenzene (43 mg, 0.20 mmol) using NaOtBu (19 mg, 0.20 mmol) as the base and a 
reaction temperature 110 °C for 14 h. This procedure afforded 20 mg (51%) of the title 
compound as an orange oil. This material was judged to be 62:38 er by chiral HPLC 
analysis (Chiracel ODH, 15 cm x 4.6 mm, 1% IPA/Hexanes, 1 mL/min, λ 254 nm, RT= 
5.6 and 8.0 min). [α]23D +50.3 (c 0.68, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.52 (d, J = 
8.7 Hz, 2 H), 7.28 (d, J = 8.2 Hz, 2 H), 7.11 (d, J = 7.5 Hz, 1 H), 7.02 (d, J = 8.2 Hz, 2 
H), 6.91 (t, J = 8.0 Hz, 1 H), 6.88–6.78 (m, 2 H), 6.73 (t, J = 7.3 Hz, 1 H), 6.15 (d, J = 
8.2 Hz, 1 H), 3.09 (ddd, J = 6.3, 11.2, 17.3 Hz, 1 H), 2.93–2.86 (m, 2 H), 2.66 (d, J = 
13.1 Hz, 1 H), 1.95 (ddd, J = 4.2, 6.3, 13.3 Hz, 1 H), 1.84 (ddd, J = 6.0, 11.2, 13.2 Hz, 1 
H), 1.31 (s, 9 H), 1.05 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 150.0, 149.7, 145.0, 
134.8, 133.1, 132.3, 130.7, 129.7, 126.8, 125.1,123.1, 119.1, 118.6, 118.5, 109.0, 58.2, 
43.4, 34.6, 33.7, 31.6, 26.7, 24.2; IR (film) 2962, 1596, 1500 cm-1; MS (ESI+) 395.2472 
(395.2482 calcd for C28H30N2, M + H
+).  
 
(R)-(+)-2-[4-(tert-Butyl)benzyl]-1-[4-(tert-butyl)phenyl]-2-methyl-1,2,3,4-
tetrahydroquinoline (3-6). General Procedure D was employed for the coupling of N-
[4-(tert-butyl)phenyl]-2-(3-methylbut-3-en-1-yl)aniline (29 mg, 0.10 mmol) and 1-bromo-
4-tert-butylbenzene (43 mg, 0.20 mmol) using NaOtBu (19 mg, 0.20 mmol) as the base 
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and a reaction temperature of 110 °C for 14 h. This procedure afforded 40 mg (93%) of 
the title compound as a pale yellow solid, mp 59–63 °C. This material was judged to be 
87:13 er by chiral HPLC analysis (LuxAmylose, 25 cm x 4.6 mm, 1% IPA/Hexanes, 0.3 
mL/min, λ 254nm, RT= 12.0 and 12.5 min). [α]23D  +40.3 (c 2.30, CH2Cl2); 
1H NMR (500 
MHz, CDCl3) δ 7.40 (d, J = 8.1 Hz, 2 H), 7.29 (d, J = 8.3 Hz, 2 H), 7.12–6.98 (m, 5 H), 
6.87 (t, J = 7.3 Hz, 1 H), 6.62 (t, J = 7.1 Hz, 1 H), 6.04 (d, J = 8.3 Hz, 1 H), 3.12 (ddt, J = 
5.6, 11.1, 15.5 Hz, 1 H), 2.94–2.81 (m, 3 H), 1.99–1.92 (m, 1 H), 1.80 (ddd, J = 5.7, 9.6, 
13.2 Hz, 1 H), 1.39 (s, 9 H), 1.33 (s, 9 H), 1.11 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 
149.7, 149.1, 146.4, 140.9, 135.4, 132.0, 130.7, 129.3, 126.6, 126.4, 124.9, 121.0, 
116.2, 115.5, 57.5, 44.8, 34.8, 34.6, 32.5, 31.7, 31.6, 26.1, 24.7; IR (film) 2962, 1600, 
and 1507 cm-1; MS (ESI+) 426.3174 (426.3155 calcd for C31H39N, M + H
+).  
 
(R)-(+)-4-{2-[4-(tert-Butyl)benzyl]-2-methyl-3,4-dihydroquinolin-1(2H)-yl)-N,N-
dimethylaniline (3-8). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and 1-bromo-4-tert-butylbenzene (85 mg, 0.40 mmol), using NaOtBu (38 mg, 0.40 
mmol,) as the base and a reaction temperature of 125 °C (xylenes) for 14 h. This 
procedure afforded 80 mg (95%) of the title compound as a white solid, mp 144–147 °C. 
This material was judged to be 95:5 er by chiral HPLC analysis (Chiracel ADH, 25 cm x 
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4.6 mm, 1.2% IPA/Hexanes, 2 mL/min, λ 254 nm, RT = 3.6 and 5.0 min). [α]23D  +31.8 (c 
1.75, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 8.1 Hz, 2 H), 7.15–7.01 (m, 5 
H), 6.90 (t, J = 7.1 Hz, 1 H), 6.85–6.78 (m, 2 H), 6.63 (t, J = 7.1 Hz, 1 H), 6.12 (d, J = 
8.3 Hz, 1 H), 3.20–3.09 (m, 1 H), 3.08–2.94 (m, 7 H), 2.92–2.83 (m, 2 H), 1.98 (m, 1 H), 
1.82 (ddd, J = 5.3, 9.6, 13.0 Hz, 1 H), 1.36 (s, 9 H), 1.15 (s, 3 H); 13C NMR (125 MHz 
CDCl3) δ 149.3, 149.0, 147.0, 135.5, 133.2, 132.3, 130.6, 129.1, 126.6, 124.9, 120.8, 
115.7, 115.0, 113.4, 113.1, 57.6, 44.9, 40.8, 34.5, 32.4, 31.6, 26.0, 24.7 (an extra peak 
at 113.1 is present due to apparent slow bond rotation); IR (film) 2961, 1609, 1516 cm-1; 
MS (ESI+) 413.2955 (413.2951 calcd for C29H36N2, M + H
+).  
 
(R)-(+)-N,N-Dimethyl-4-[2-methyl-2-(4-morpholinobenzyl)-3,4-dihydroquinolin-
1(2H)-yl]aniline (3-12). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and 4-(4-bromophenyl)morpholine (97 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 
mmol) as the base and a reaction temperature of 125 °C (xylenes) for 14 h. This 
procedure afforded 77 mg (87%) of the title compound as a yellow solid, mp 158–161 
°C. This material was judged to be 95:5 er by chiral HPLC analysis (Chiracel ADH, 25 
cm x 4.6 mm, 1% IPA/Hexanes, 2 mL/min, λ 254 nm, RT = 14.6 and 20.1 min). [α]23D 
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+24.7 (c 1.10, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.13–7.03 (m, 5 H), 6.92–6.77 (m, 
5 H), 6.61 (t, J = 7.2 Hz, 1 H), 6.10 (d, J = 8.3 Hz, 1 H), 3.92–3.86 (m, 4 H), 3.20–3.14 
(m, 4 H), 3.10–3.04 (m, 1 H), 3.02 (s, 6 H), 2.92–2.79 (m, 3 H), 1.95 (m, 1 H), 1.78 (ddd, 
J = 5.5, 9.5, 13.2 Hz, 1 H), 1.12 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 149.7, 149.1, 
147.0, 133.2, 133.1, 132.2, 131.6, 130.1, 129.1, 126.6, 120.8, 115.7, 115.3, 115.0, 
113.3, 113.0, 67.1, 57.6, 49.6, 44.5, 40.8, 32.3, 25.9, 24.7 (extra peaks at 133.1 and 
113.0 are present due to apparent slow bond rotation); IR (film) 2963, 1609, 1514 cm-1; 
MS (ESI+) 442.285 (442.28 calcd for C29H35N3O, M + H
+).  
 
(R)-(+)-4-[2-(4-Methoxybenzyl)-2-methyl-3,4-dihydroquinolin-1(2H)-yl]-N,N-
dimethylaniline (3-13). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and 4-bromoanisole (75 mg, 0.40 mmol), using NaOtBu (38 mg, 0.40 mmol) as the base 
and a reaction temperature of 125 °C (xylenes) for 14 h. This procedure afforded 68 mg 
(88%) of the title compound as a yellow solid, mp 101–105 °C. This material was judged 
to be 95:5 er by chiral HPLC analysis (Chiracel ADH, 25 cm x 4.6 mm, 1% 
IPA/Hexanes, 1 mL/min, λ 254 nm, RT= 10.2 and 15.1 min). [α]23D  +30.6 (c 2.10, 
CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.13–7.01 (m, 5 H), 6.90 (t, J = 7.3 Hz, 1 H), 
6.85–6.77 (m, 4 H), 6.62 (t, J = 7.4 Hz, 1 H), 6.10 (d, J = 8.1 Hz, 1 H), 3.82 (s, 3 H), 
107 
 
3.14–3.05 (m, 1 H), 3.02 (s, 6 H), 2.92–2.80 (m, 3 H), 1.94 (dt, J = 6.0, 12.5 Hz, 1 H), 
1.79 (ddd, J = 5.5, 9.4, 13.3 Hz, 1 H), 1.11 (s, 3 H); 13C NMR (125 MHz CDCl3) δ 158.1, 
149.2, 146.9, 133.2, 133.0, 132.3, 131.8, 130.7, 129.1, 126.6, 120.8, 115.8, 115.1, 
113.4, 113.3, 113.0, 57.5, 55.3, 44.5, 40.8, 32.3, 25.8, 24.6 (extra peaks at 133.0 and 
113.0 are present due to apparent slow bond rotation); IR (film) 2962, 1609, 1512 cm-1; 
MS (ESI+) 387.2432 (387.2431 calcd for C26H30N2O, M + H
+).  
 
(R)-(+)-N,N-Dimethyl-4-{2-methyl-2-[4-(trifluoromethyl)benzyl]-3,4-dihydroquinolin-
1(2H)-yl}aniline (3-14). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and 4-bromobenzotrifluoride (90.0 mg, 0.40 mmol), using NaOtBu (38 mg, 0.40 mmol) 
as the base and a reaction temperature of 125 °C (xylenes) for 14 h. This procedure 
afforded 75.6 mg (89%) of the title compound as a white solid, mp 127-130 °C. This 
material was judged to be 94:6 er by chiral HPLC analysis (Chiracel ADH, 25 cm x 4.6 
mm, 1% IPA/Hexanes, 1 mL/min, λ 254 nm, RT= 6.1 and 8.9 min). [α]23D  +31.5 (c 1.43, 
CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 8.0 Hz, 2 H), 7.30 (d, J = 8.0 Hz, 2 
H), 7.14–6.97 (m, 3 H), 6.91 (t, J = 7.7 Hz, 1 H), 6.86–6.76 (m, 2 H), 6.65 (t, J = 7.1 Hz, 
1 H), 6.14 (d, J = 8.2 Hz, 1 H), 3.15–2.85 (m, 10 H), 1.95 (dt, J = 6.0, 12.4 Hz, 1 H), 
1.79 (ddd, J = 5.6, 9.5, 13.1, Hz, 1 H), 1.13 (s, 3 H); 13C NMR (125 MHz CDCl3) δ 149.4, 
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146.8, 143.0, 133.0, 132.2, 131.2, 129.2, 128.6 (q, J = 32 Hz), 126.8, 124.6 (q, J = 270 
Hz), 124.9 (q, J = 3 Hz), 120.8, 116.2, 115.6, 113.4, 113.0, 57.3, 45.2, 40.6, 32.4, 25.7, 
24.4 (an extra peak at 113.0 is present due to apparent slow bond rotation); IR (film) 
2971, 1610, 1517 cm-1; MS (ESI+) 425.2202 (425.2199 calcd for C26H27F3N2, M + H
+).  
 
 
(R)-(+)-N,N-Dimethyl-4-{2-methyl-2-[3-(trifluoromethyl)benzyl]-3,4-dihydroquinolin-
1(2H)-yl}aniline (3-15). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and 3-bromobenzotrifluoride (90 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as 
the base and a reaction temperature of 125 °C (xylenes) for 14 h. This procedure 
afforded 80 mg (94%) of the title compound as a brown solid, mp 91–94 °C. This 
material was judged to be 92:8 er by chiral HPLC analysis (Chiracel ADH, 25 cm x 4.6 
mm, 1 % IPA/Hexanes, 1 mL/min, λ 254 nm, RT= 4.2 and 5.4 min). [α]23D  +22.5 (c 1.35, 
CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.3 Hz, 1 H), 7.46–7.35 (m, 3 H), 
7.12–6.93 (m, 3 H), 6.91 (t, J = 7.5 Hz, 1 H), 6.85–6.75 (m, 2 H), 6.65 (t, J = 7.3 Hz, 1 
H), 6.15 (d, J = 8.3 Hz, 1 H), 3.15–3.02 (m, 7 H), 3.00–2.97 (m, 2 H), 3.93–3.85 (m, 1 
H), 1.95 (dt, J = 5.9, 13.9 Hz, 1 H), 1.82 (ddd, J = 5.50, 9.40, 13.30 Hz, 1 H), 1.12 (s, 3 
H); 13C NMR (125 MHz, CDCl3) δ 149.4, 146.8, 139.7, 134.3, 133.0, 132.9, 132.3, 130.4 
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(q, J = 31 Hz), 129.2, 128.5, 127.5 (q, J = 4 Hz), 126.8, 124.4 (q, J = 270 Hz), 123.2 (q, 
J= 4 Hz), 120.8, 116.3, 115.7, 113.4, 112.9, 57.3, 45.3, 40.8, 32.6, 25.8, 24.6 (extra 
peaks at 132.9 and 112.9 are present due to apparent slow bond rotation); IR (film) 
2971, 1609, 1518 cm-1; MS (ESI+) 425.22 (425.2199 calcd for C26H27F3N2, M + H
+).  
 
(R)-(+)-[4-({1-[4-(Dimethylamino)phenyl]-2-methyl-1,2,3,4-tetrahydroquinolin-2-
yl}methyl)phenyl](phenyl)methanone (3-16). General Procedure D was employed for 
the coupling of N1,N1-dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-
diamine (56 mg, 0.20 mmol) and 4-bromobenzophenone (104 mg, 0.40 mmol) using 
NaOtBu (38 mg, 0.40 mmol) as the base and a reaction temperature of 125 °C (xylenes) 
for 14 h. This procedure afforded 76 mg (82%, 93% pure) of the title compound as a 
yellow solid, mp 156–159 °C. This material was judged to be 96:4 er by chiral HPLC 
analysis (Chiracel ADH, 25 cm x 4.6 mm, 5 % IPA/Hexanes, 1 mL/min, λ 254 nm, RT= 
11.6 and 25.8 min). [α]23D  +32.7 (c 1.10, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.83 (d, 
J = 7.5 Hz, 2 H), 7.76 (d, J = 8.0 Hz, 2 H), 7.61 (t, J = 7.4 Hz, 1 H), 7.51 (t, J = 7.6 Hz, 2 
H), 7.30 (d, J = 8.0 Hz, 2 H), 7.10–6.98 (m, 3 H), 6.91 (t, J = 7.7 Hz, 1 H),  6.79 (dd, J = 
8.5, 19.0 Hz, 2 H), 6.63 (t, J = 7.1 Hz, 1 H), 6.13 (d, J = 8.3 Hz, 1 H), 3.15–3.08 (m, 1 
H), 3.06–3.00 (m, 7 H), 2.99 (d, J = 12.8 Hz, 1 H), 2.89 (dt, J = 5.9, 16.6 Hz, 1 H),  1.98 
(dt, J = 5.9, 12.4 Hz, 1 H), 1.83 (ddd, J = 5.5, 9.6, 13.2 Hz, 1 H), 1.15 (s, 3 H); 13C NMR 
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(175 MHz, CDCl3) δ 196.4, 149.2, 146.6, 143.8, 137.8, 135.4, 132.8, 132.2, 132.0, 
130.7, 130.0, 129.8, 129.0, 128.2, 126.6, 120.6, 116.0, 115.3, 113.2, 112.8, 57.4, 45.3, 
40.6, 32.5, 25.9, 24.4 (2 extra peaks in the arene region are present due to apparent 
slow bond rotation); IR (film) 2927, 1656, 1517 cm-1; MS (ESI+) 461.2583 (461.2587 
calcd for C32H32N2O, M + H
+).  
 
(R)-(+)-N,N-dimethyl-4-[2-methyl-2-(2-methylallyl)-3,4-dihydroquinolin-1(2H)-
yl]aniline (3-17). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and 2-bromopropene (48 mg 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as the base 
and a reaction temperature of 125 °C (xylenes) for 14 h. This procedure afforded 55 mg 
(86%) of the title compound as an off-white solid, mp 76–79 °C. This material was 
judged to be 95:5 er by chiral HPLC analysis (Chiracel ODH, 25 cm x 4.6 mm, 1% 
IPA/Hexanes, 0.2 mL/min, λ 254nm, RT = 13.4 and 15.2 min). [α]23D  +37.7 (c 1.81, 
CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.12–7.00 (m, 3 H), 6.85 (t, J = 7.1 Hz, 1 H), 6.79 
(d, J = 8.8 Hz, 2 H), 6.58 (t, J = 7.3 Hz, 1 H), 6.04 (d, J = 8.3 Hz, 1 H), 4.92 (s, 1 H), 
4.78 (s, 1 H), 3.06–2.98 (m, 7H), 2.85 (dt, J = 5.9, 16.5 Hz, 1 H), 2.50 (d, J = 13.1 Hz, 1 
H), 2.29 (d, J = 13.0 Hz, 1 H), 2.07 (dt, J = 5.9, 13.1 Hz, 1 H), 1.93 (ddd, J= 5.5, 9.6, 
13.2 Hz, 1 H), 1.80 (s, 3 H), 1.21 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 149.3, 146.8, 
142.7, 133.1, 132.3, 129.1, 126.6, 120.8, 115.7, 115.5, 114.9, 113.3, 113.0, 57.2, 46.9, 
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40.8, 33.0, 27.1, 25.5, 24.7 (an extra peak at 113.0 is present due to apparent slow 
bond rotation); IR (film) 2969, 1609, 1517 cm-1; MS (ESI+) 321.2329 (321.2325 calcd for 
C22H28N2, M + H
+).  
 
(R)-(+)-N,N-Dimethyl-4-[2-methyl-2-(3-methylbut-2-en-1-yl)-3,4-dihydroquinolin-
1(2H)-yl]aniline (3-18). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and 1-bromo-2-methyl-1-propene (54 mg 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) 
as the base and a reaction temperature of 125 °C (xylenes) for 14 h. This procedure 
afforded 66 mg (98%) of the title compound as an orange oil. This material was judged 
to be 95:5 er by chiral HPLC analysis (Chiracel ODH, 15 cm x 4.6 mm, 0.9% 
IPA/Hexanes, 0.1 mL/min, λ 254 nm, RT = 26.1 and 28.2 min). [α]23D  +53.4 (c 2.35 
CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.12–6.96 (m, 3 H), 6.83 (t, J = 7.1 Hz, 1 H), 6.77 
(d, J = 8.3Hz, 2 H), 6.55 (t, J = 7.1 Hz, 1 H), 6.02 (d, J = 8.3 Hz, 1 H), 5.19 (t, J = 7.3 
Hz, 1 H), 3.01 (s, 3 H), 2.88–2.82 (m, 1 H), 2.32 (dd, J= 7.2, 14.4 Hz, 1 H), 2.20 (dd, J = 
7.5, 14.4 Hz, 1 H), 2.00 (dt, J = 6.2, 12.9 Hz, 1 H), 1.79 (ddd, J= 5.9, 8.1, 13.5 Hz, 1 H), 
1.72 (s, 3 H), 1.56 (s, 3 H), 1.22 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 149.3, 147.2, 
133.6, 133.0, 132.3, 129.1, 126.6, 121.0, 120.3, 115.5, 114.8, 113.3, 57.6, 40.8, 37.9, 
32.8, 26.3, 25.9, 24.7, 18.3; IR (film) 2967, 1608, 1516 cm-1; MS (ESI+) 335.2136 
(335.2482 calcd for C23H30N2, M + H
+).  
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(Z,R)-(+)-N,N-Dimethyl-4-[2-methyl-2-(pent-2-en-1-yl)-3,4-dihydroquinolin-1(2H)-
yl]aniline (3-19). General Procedure D was employed for the coupling of N1,N1-
dimethyl-N4-[2-(3-methylbut-3-en-1-yl)phenyl]benzene-1,4-diamine (56 mg, 0.20 mmol) 
and (Z)-1-bromo-1-butene (54 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as the 
base and a reaction temperature of 125 °C (xylenes) for 14 h. This procedure afforded 
61 mg (91%) of the title compound as an off-white solid, mp 122–125 °C. This material 
was judged to be 95:5 er by chiral HPLC analysis (Chiracel ODH, 15 cm x 4.6 mm, 
0.8% IPA/Hexanes, 0.1 mL/min, λ 254 nm, RT = 30.0 and 33.3 min). [α]23D  +59.3 (c 
1.50, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.16–6.93 (m, 3 H), 6.88 (t, J = 7.3 Hz, 1 
H), 6.81 (d, J = 8.8 Hz, 2 H), 6.59 (t, J = 7.1 Hz, 1 H), 6.09 (d, J = 8.3 Hz, 1 H),  5.55–
5.38 (m, 2 H), 3.04 (s, 6 H), 2.95–2.85 (m, 2 H), 2.45 (dd, J = 7.3, 14.4 Hz, 1 H), 2.30 
(dd, J = 7.2, 14.4 Hz, 1 H), 2.12–1.92 (m, 3 H), 1.86 (ddd, J = 5.7, 8.4, 13.6 Hz, 1 H), 
1.18 (s, 3 H), 0.98 (t, J = 7.6 Hz, 3 H); 13C NMR (125 MHz, CDCl3) δ 149.3, 147.1, 
134.0, 133.0, 132.2, 129.1, 126.6, 124.5, 120.9, 115.6, 114.8, 113.2, 57.2, 40.8, 36.9, 
32.8, 26.0, 24.6, 21.0, 14.3; IR (film) 2964, 1609, 1517 cm-1; MS (ESI+) 335.2495 
(335.2482 calcd for C23H30N2, M + H
+).  
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(R)-(+)-4-(4-{[1-(4-Methoxyphenyl)-2-methyl-1,2,3,4-tetrahydroquinolin-2-
yl]methyl}phenyl)morpholine (3-20). General Procedure D was employed for the 
coupling of N-(4-methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (54 mg, 0.20 mmol) 
and 4-(4-bromophenyl)morpholine (97 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 
mmol) as the base and a reaction temperature of 90 °C for 14 h. This procedure 
afforded 70 mg (82%) of the title compound as a white solid, mp 62–65 °C. This 
material was judged to be 94:6 er by chiral HPLC analysis (Chiracel ADH, 15 cm x 4.6 
mm, 5% IPA/Hexanes, 1 mL/min, λ 254 nm, RT = 8.8 and 11.1 min). [α]23D  +56.1 (c 
1.11, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.14–7.05 (m, 5 H), 7.02–6.95 (m, 2 H), 
6.88 (t, J = 7.2 Hz, 1 H), 6.84 (d, J = 8.3 Hz, 2 H), 6.63 (t, J = 7.2 Hz, 1 H), 6.05 (d, J = 
8.4 Hz, 1 H), 3.92–3.84 (m, 7 H), 3.18–3.12 (m, 4H), 3.09 (ddd, J = 5.7, 9.6, 15.9 Hz, 1 
H), 2.89–2.81 (m, 2 H), 2.78 (d, J = 13.2 Hz, 1 H), 1.94 (dt, J = 6.0, 12.5 Hz, 1 H), 1.78 
(ddd, J = 5.5, 9.6, 13.2 Hz, 1 H), 1.09 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 158.2, 
149.7, 146.6, 136.2, 133.6, 133.5, 131.6, 129.8, 129.2, 126.6, 121.0, 116.1, 115.3, 
115.2, 114.9, 114.5, 67.1, 57.5, 55.5, 49.5, 44.4, 32.3, 25.8, 24.6 (extra peaks at 133.5 
and 114.5 are present due to apparent slow bond rotation); IR (film) 2928, 1606, 1505 
cm-1; MS (ESI+) 429.2521 (429.2537 calcd for C28H32N2O2, M + H
+).  
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(R)-(+)-2-(4-Chlorobenzyl)-1-(4-methoxyphenyl)-2-methyl-1,2,3,4-
tetrahydroquinoline (3-21). General Procedure D was employed for the coupling of N-
(4-methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (54 mg, 0.20 mmol) and 4-
bromochlorobenzene (77 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as the 
base and a reaction temperature of 90 °C for 14 h. This procedure afforded 62 mg 
(82%) of the title compound as a viscous oil. This material was judged to be 89:11 er by 
chiral HPLC analysis (Chiracel ADH, 15 cm x 4.6 mm, 0.4% IPA/Hexanes, 1.1 mL/min, 
λ 254 nm, RT = 8.9 and 10.5 min). [α]23D  +56.2 (c 0.97, CH2Cl2); 
1H NMR (500 MHz, 
CDCl3) δ 7.25 (d, J = 8.6 Hz, 2 H), 7.15–6.91 (m, 7 H), 6.89 (t, J = 7.3 Hz, 1 H), 6.65 (t, 
J = 7.3 Hz, 1 H), 6.08 (d, J = 8.3 Hz, 1 H), 3.87 (s, 3 H), 3.04 (ddd, J = 5.8, 9.6, 15.9 Hz, 
1 H), 2.87–2.79 (m, 3 H), 1.90 (dt, J = 5.9, 13.4 Hz, 1 H), 1.77 (ddd, J = 5.6, 9.6, 13.3 
Hz, 1 H), 1.08 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 158.3, 146.4, 136.9, 136.3, 133.4, 
132.3, 132.2, 129.3, 128.2, 126.7, 121.0, 116.5, 115.7, 115.1, 114.5,  57.3, 55.6, 44.6, 
32.5, 25.8, 24.5 (an extra peak at 114.5 is present due to apparent slow bond rotation); 
IR (film) 2928, 1604, 1505 cm-1; MS (ESI+) 378.1620 (378.1619 calcd for C24H24ClNO, 
M + H+).  
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(R)-(+)-(4-{[1-(4-Methoxyphenyl)-2-methyl-1,2,3,4-tetrahydroquinolin-2-
yl]methyl}phenyl)(phenyl)methanone (3-22). General Procedure D was employed for 
the coupling of N-(4-methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (54 mg, 0.20 
mmol) and 4-bromobenzophenone (104 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 
mmol) as the base and a reaction temperature of 90 °C for 14 h. This procedure 
afforded 74 mg (83%) of the title compound as a white solid, mp 58–61 °C. This 
material was judged to be 95:5 er by chiral HPLC analysis (Chiracel ADH, 15 cm x 4.6 
mm, 8% IPA/Hexanes, 1 mL/min, λ 254 nm, RT = 10.4 and 16.5 min). [α]23D  +44.7 (c 
0.90, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 7.1 Hz, 2 H), 7.76 (d, J = 8.3 
Hz, 2 H), 7.60 (t, J = 7.3 Hz, 1 H), 7.49 (t, J = 7.8 Hz, 2 H), 7.28 (d, J = 8.1 Hz, 2 H), 
7.15–6.91 (m, 5 H), 6.89 (t, J = 7.1 Hz, 1 H), 6.65 (t, J = 6.4 Hz, 1 H), 6.08 (d, J = 8.1 
Hz, 1 H), 3.87 (s, 3 H), 3.10 (ddd, J= 5.8, 9.7, 16.1 Hz, 1 H), 3.02–2.93 (m, 2 H), 2.87 
(dt, J = 5.8, 16.7 Hz, 1 H),  1.95 (dt, J = 5.9, 13.2 Hz, 1 H), 1.82 (ddd, J = 5.6, 9.7, 13.2 
Hz, 1 H), 1.13 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 196.5, 158.3, 146.4, 143.7, 137.9, 
136.3, 135.7, 133.4, 132.4, 130.8, 130.1, 130.0, 129.3, 128.4, 126.8, 121.0, 116.6, 
115.8, 115.1, 114.5, 57.5, 55.5, 45.3, 32.6, 26.1, 24.5 (an extra peak at 114.5 is present 
due to apparent slow bond rotation); IR (film) 2928, 1656, 1603, 1505 cm-1; MS (ESI+) 
448.2269 (448.2271 calcd for C31H29NO2, M + H
+).  
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(R)-(+)-1-(4-Methoxyphenyl)-2-methyl-2-(3-methylbut-2-en-1-yl)-1,2,3,4-
tetrahydroquinoline (3-23). General Procedure D was employed for the coupling of N-
(4-methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (54 mg, 0.20 mmol) and 1-Bromo-2-
methyl-1-propene (41 µL, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as the base 
and a reaction temperature of 90 °C for 14 h. This procedure afforded 63 mg (98%) of 
the title compound as an orange oil. This material was judged to be 95:5 er by chiral 
HPLC analysis (Chiracel ADH, 15 cm x 4.6 mm, 0.8% IPA/Hexanes, 0.2 mL/min, λ 254 
nm, RT = 22.3 and 24.4 min). [α]23D  +58.0 (c 1.11, CH2Cl2); 
1H NMR (500 MHz, CDCl3) 
δ 7.23–7.08 (m, 2 H), 7.07 (d, J = 7.3 Hz, 1 H), 6.99 (d, J = 9.1 Hz, 2 H), 6.87 (t, J = 7.3 
Hz, 1 H), 6.61 (t, J = 7.4 Hz, 1 H), 6.02 (d, J = 8.3 Hz, 1 H), 5.23 (app. t, J = 7.1 Hz, 1 
H), 3.88 (s, 3 H), 2.95–2.85 (m, 2 H), 2.34 (dd, J = 7.2, 14.3 Hz, 1 H), 2.22 (dd, J = 7.5, 
14.3 Hz, 1 H), 2.05 (dt, J = 6.4, 13.0 Hz, 1 H), 1.89–1.81 (m, 1 H), 1.77 (s, 3 H), 1.60 (s, 
3H), 1.13 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 158.3, 146.8, 136.2, 133.8, 133.4, 
129.2, 126.6, 121.1, 120.0, 115.9, 114.9, 114.7, 57.5, 55.5, 37.9, 32.8, 26.3, 25.9, 24.6, 
18.3; IR (film) 2926, 1599, 1507 cm-1; MS (ESI+) 322.2170 (322.2165 calcd for 
C22H27NO, M+H
+).  
 
(R)-(+)-1-(4-Methoxyphenyl)-2-methyl-2-(2-methylallyl)-1,2,3,4-tetrahydroquinoline 
(3-24). General Procedure D was employed for the coupling of N-(4-methoxyphenyl)-2-
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(3-methylbut-3-en-1-yl)aniline (54 mg, 0.20 mmol) and 2-Bromopropene (35 µL, 0.40 
mmol) using NaOtBu (38 mg, 0.40 mmol) as the base and a reaction temperature of 90 
°C for 14 h. This procedure afforded 52 mg (85%) of the title compound as an orange 
oil. This material was judged to be 96:4 er by chiral HPLC analysis (Chiracel ADH, 15 
cm x 4.6 mm, 0.8% IPA/Hexanes, 0.2 mL/min, λ 254 nm, RT = 22.9 and 23.9 min). 
[α]23D  +49.8 (c 1.04, CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 7.22–7.00 (m, 3 H), 6.98 (d, 
J = 8.2 Hz, 2 H), 6.85 (t, J = 7.4 Hz, 1 H), 6.61 (t, J = 7.0 Hz, 1 H), 6.00 (d, J = 8.2 Hz, 1 
H), 4.95 (s, 1 H), 4.77 (s, 1 H), 3.87 (s, 3 H), 3.02 (ddd, J = 5.5, 9.2, 15.7 Hz, 1 H), 2.85 
(dt, J = 6.0, 16.8 Hz, 1 H), 2.48 (d, J = 13.1 Hz, 1 H), 2.27 (d, J = 13.2 Hz, 1 H), 2.07 (dt, 
J = 5.8, 12.3, Hz, 1 H), 1.93 (ddd, J= 5.7, 9.6, 14.0 Hz, 1 H), 1.81 (s, 3 H), 1.19 (s, 3 H); 
13C NMR (100 MHz, CDCl3) δ 158.3, 146.4, 142.4, 136.2, 133.5, 129.2, 126.6, 121.0, 
116.1, 115.7, 115.1, 114.8, 57.1, 55.5, 46.8, 32.9, 27.0, 25.4, 24.6; IR (film) 2928, 1599, 
and 1506 cm-1; MS (ESI+) 308.2008 (308.2009 calcd for C21H25NO, M + H
+).  
 
(R)-2-benzyl-2-ethyl-1-(4-methoxyphenyl)-1,2,3,4-tetrahydroquinoline (3-25): 
General Procedure D was employed for the coupling of N-(4-methoxyphenyl)-2-(3-
methylenepentyl)aniline (28 mg, 0.10 mmol) and Bromobenzene (21 µL, 0.20 mmol) 
using NaOtBu (19 mg, 0.20 mmol) as the base and a reaction temperature of 110 °C for 
12 h. This procedure afforded 31 mg (86%) of the title compound as an viscous white 
oil. This material was judged to be 75:25 er by chiral HPLC analysis (Chiracel ADH, 15 
cm x 4.6 mm, 1.00% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT = 6.1 and 7.5 min). 
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[α]23D  +13.03 (c 1.35, CH2Cl2); 
1H NMR (700 MHz, C6D6) δ 7.26 (t, J= 7.2 Hz, 2 H), 7.22 
(t, J = 7.2 Hz, 1 H), 7.18-7.09 (m, 3 H), 7.06 (d, J = 7.3 Hz, 1 H), 6.93-6.71 (m, 4 H), 
6.62 (t, J = 7.3 Hz, 1 H), 6.11 (d, J = 8.3 Hz, 1 H), 3.82 (s, 3 H),  3.16 (ddd, J = 17.0, 
11.5, 5.9 Hz, 1 H), 2.95 (d, J = 13.5 Hz, 1 H), 2.90–2.81 (m, 2 H), 1.95–1.83 (m, 2H), 
1.54-1.47 (m, 1 H), 1.37 dq, J= 14.5, 7.2 Hz, 1H) 0.88 (t, J = 7.3 Hz, 3 H); 13C NMR (175 
MHz, CDCl3) δ 157.8, 147.3, 138.5, 136.9, 133.1, 130.9, 128.9, 127.9, 126.4, 126.1, 
122.1, 117.0, 116.4, 114.4, 60.7, 55.4, 42.2, 29.2, 27.8, 24.2, 8.5; IR (film) 2927, 1599, 
and 1507 cm-1; MS (ESI+) 358.2163 (358.2165 calcd for C25H27NO, M + H
+). 
 
(R)-(+)-6-Methoxy-1-(4-methoxyphenyl)-2-methyl-2-(2-methylallyl)-1,2,3,4-
tetrahydroquinoline (3-28). General Procedure D was employed for the coupling of 4-
methoxy-N-(4-methoxyphenyl)-2-(3-methylbut-3-en-1-yl)aniline (60 mg, 0.20 mmol) and 
2-bromopropene (35 µL, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as the base and 
a reaction temperature of 90 °C for 14 h. This procedure afforded 55 mg (82%) of the 
title compound as an orange oil. This material was judged to be 96:4 er by chiral HPLC 
analysis (lux-amylose, 15 cm x 4.6 mm, 2.5% IPA/Hexanes, 0.2 mL/min, λ 254 nm, RT 
= 29.7 and 32.9). [α]23D  +68.3 (c 1.13, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.16–7.03 
(m, 2 H), 6.93 (d, J = 7.7 Hz, 2 H), 6.65 (d, J = 2.9 Hz, 1 H), 6.47 (dd, J = 3.0, 8.9 Hz, 1 
H), 5.98 (d, J = 9.1 Hz, 1 H), 4.92 (s, 1 H), 4.76 (s, 1 H), 3.84 (s, 3 H), 3.72 (s, 3 H), 2.98 
(ddd, J = 5.8, 9.6, 16.0 Hz, 1 H), 2.83 (dt, J = 5.9,16.8 Hz, 1 H), 2.40 (d, J = 13.1 Hz, 1 
H), 2.25 (d, J = 13.1 Hz, 1 H), 2.01 (dt, J = 6.0, 13.2 Hz, 1 H), 1.90 (ddd, J = 5.6, 9.6, 
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13.1 Hz, 1 H), 1.80 (s, 3 H), 1.14 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 157.9, 150.9, 
142.5, 140.8, 137.2, 133.3, 122.2, 116.7, 115.3, 114.4, 114.2, 112.5, 56.7, 55.7, 55.4, 
46.4, 32.9, 26.6, 25.3, 24.7; IR (film) 2933, 1493 cm-1; MS (ESI+) 337.2032 (337.2036 
calcd for C22H27NO2, M
+).  
 
(R)-(+)-1-(4-Methoxyphenyl)-2-methyl-2-(3-methylbut-2-en-1-yl)-1,2,3,4-
tetrahydrobenzo[h]quinoline (3-26). General Procedure D was employed for the 
coupling of N-(4-Methoxyphenyl)-2-(3-methylbut-3-en-1-yl)naphthalen-1-amine (63 mg, 
0.20 mmol) and 1-Bromo-2-methyl-1-propene (41 µL, 0.40 mmol) using NaOtBu (38 mg, 
0.40 mmol) as the base and a reaction temperature of 95 °C for 18 h. This procedure 
afforded 47 mg (63%) of the title compound as a clear oil. This material was judged to 
be 93:7 er by chiral HPLC analysis (Chiracel ADH, 15 cm x 4.6 mm, 0.8% IPA/Hexanes, 
0.150 mL/min, λ 254 nm, RT = 38.1 and 40.9 min). [α]23D  +281.2 (c 1.67, CH2Cl2); 
1H 
NMR (500 MHz, C6D6) δ 8.34 (d, J = 8.5 Hz, 1 H), 7.56 (d, J = 8.0 Hz, 1 H), 7.41 (d, J = 
8.3 Hz, 1 H), 7.18-7.00 (m, 3 H), 6.95 (d, J = 8.2 Hz, 2 H), 6.51 (d, J = 8.3 Hz, 2 H),  
5.48-5.43 (m, 1 H), 3.14 (s, 3 H), 2.85-2.76 (m, 2H), 2.44 (dd, J = 7.0, 14.6 Hz, 1 H), 
2.12 (dd, J = 7.6, 14.6 Hz, 1 H), 1.78 (dt, J = 9.0, 13.5 Hz, 1 H), 1.66 (s, 3 H), 1.52-1.44 
(m, 1H), 1.35 (s, 3 H), 1.07 (s, 3 H); 13C NMR (125 MHz, C6D6
134.9, 133.3, 131.6, 131.3, 128.0, 126.4, 125.8, 125.7, 125.4, 123.8, 121.9, 114.1, 58.9, 
55.0, 37.7, 28.7, 27.4, 26.6, 25.9, 18.4 (one peak missing from arene region due to 
apparent overlap); IR (film) 2926, 1502, and 1390 cm-1; MS (ESI+) 372.2326 (372.2322 
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calcd for C26H29NO, M + H
+).  
 
(S)-(–)-2-Benzyl-1-(4-methoxyphenyl)-2,4-dimethyl-1,2,3,4-tetrahydroquinoxaline 
(3-32). General Procedure D was employed for the coupling of N1-(4-methoxyphenyl)-
N2-methyl-N2-(2-methylallyl)benzene-1,2-diamine (59 mg, 0.20 mmol) and 
bromobenzene (42 µL, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as the base and a 
reaction temperature of 110 °C for 14 h. This procedure afforded 57 mg (79%) of the 
title compound as an orange oil. This material was judged to be 97:3 er by chiral HPLC 
analysis (Chiracel ADH, 15 cm x 4.6 mm, 1% IPA/Hexanes, 1mL/min, λ 254 nm, RT = 
5.1 and 7.9 min). [α]23D  –28.9 (c 1.19, CH2Cl2); 
1H NMR (700 MHz, C6D6)  δ 7.15 (d, J = 
7.5 Hz, 2 H), 7.11 (d, J = 6.6 Hz, 1 H), 7.08 (d, J = 7.5 Hz, 2 H), 6.96 (d, J = 8.5 Hz, 2 
H), 6.86 (t, J = 7.5 Hz, 1 H), 6.81–6.75 (m, 2 H), 6.74 (t, J = 7.8 Hz, 1 H), 6.70 (d, J = 
8.0 Hz, 1 H), 6.40 (d, J = 8.0 Hz, 1 H), 3.32 (s, 3 H), 3.22 (d, J = 12.6 Hz, 1 H), 2.83 (d, 
J = 12.6 Hz, 1 H), 2.70 (d, J = 10.9 Hz, 1 H), 2.65 (d, J = 10.9 Hz, 1 H), 2.62 (s, 3 H), 
0.90 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 158.7, 139.1, 137.0, 136.5, 136.5, 133.5, 
131.2, 128.4, 128.3, 126.5, 119.2, 118.4, 115.5, 115.0, 111.9, 58.0, 57.5, 54.9, 44.1, 
38.9, 23.8 (an extra peak at 136.5 is present due to apparent slow bond rotation); IR 
(film) 2928, 1503 cm-1; MS (ESI+) 359.2118 (359.2118 calcd for C24H26N2O, M + H
+).  
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(S)-(+)-(4-{[1-(4-Methoxyphenyl)-2,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-2-
yl]methyl}phenyl)(phenyl)methanone (3-33). General Procedure D was employed for 
the coupling of N1-(4-methoxyphenyl)-N2-methyl-N2-(2-methylallyl)benzene-1,2-diamine 
(59 mg, 0.2 mmol) and 4-bromobenzophenone (104 mg, 0.40 mmol) using NaOtBu (38 
mg, 0.40 mmol) as the base and a reaction temperature of 110 °C for 14 h. This 
procedure afforded 72 mg (78%) of the title compound as a light yellow solid, mp 63–66 
°C. This material was judged to be 96:4 er by chiral HPLC analysis (Chiracel ADH, 15 
cm x 4.6 mm, 3% IPA/Hexanes, 1 mL/min, λ 254 nm, RT = 18.2 and 25.9 min), [α]23D  
+18.7 (c 0.90, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.79 (d, J = 7.0 Hz, 2 H), 7.75 (d, J 
= 8.0 Hz, 2 H), 7.15 (d, J = 8.5 Hz, 1 H), 7.08 (t, J = 7.6 Hz, 2 H), 7.02 (d, J = 8.0 Hz, 2 
H), 6.96 (d, J = 8.9 Hz, 2 H), 6.87(t, J = 7.5 Hz, 1 H), 6.80 (d, J = 8.2 Hz, 2 H), 6.75 (t, J 
= 8.0 Hz, 1 H), 6.71 (d, J = 8.0 Hz, 1 H), 6.40 (d, J = 8.0 Hz, 1 H), 3.34 (s, 3 H), 3.22 (d, 
J = 12.4 Hz, 1 H), 2.81 (d, J = 12.3 Hz, 1 H), 2.65 (d, J = 11.1 Hz, 1 H), 2.61–2.56 (m, 4 
H), 0.85 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 195.5, 158.8, 138.6, 136.8, 136.4, 
136.3, 136.2, 133.4, 132.0, 131.0, 130.2, 130.2, 128.4, 119.3, 118.6, 115.6, 115.0, 
112.0, 57.9, 57.6, 55.0, 43.9, 38.9, 23.8 (one aromatic carbon signal is missing due to 
incidental equivalence); IR (film) 2972, 1656 1504 cm-1; MS (ESI+) 463.2371 (463.2380 
calcd for C31H30N2O2, M + H
+).  
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(S)-(+)-1-(4-Methoxyphenyl)-2,4-dimethyl-2-(naphthalen-2-ylmethyl)-1,2,3,4-
tetrahydroquinoxaline (3-36). General Procedure D was employed for the coupling of 
N1-(4-methoxyphenyl)-N2-methyl-N2-(2-methylallyl)benzene-1,2-diamine (59 mg, 0.2 
mmol) and 2-bromonaphthalene (83 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) 
as the base and a reaction temperature of 110 °C for 14 h. This procedure afforded 67 
mg (82%) of the title compound as a light yellow solid, mp 62–65 °C. This material was 
judged to be 93:7 er by chiral HPLC analysis (lux-amylose, 15 cm x 4.6 mm, 3% 
IPA/Hexanes, 0.25 mL/min, λ 254 nm, RT = 27.9 and 30.2 min), [α]23D  +8.56 (c 1.39, 
CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.70–7.64 (m, 2 H), 7.59 (t, J = 8.2 Hz, 1 H), 7.52 
(s, 1 H), 7.33–7.26 (m, 2 H), 7.22 (t, J = 8.4 Hz, 1 H), 7.08–6.98 (m, 2 H), 6.90 (t, J = 7.7 
Hz, 1 H), 6.84–6.74 (m, 4 H), 6.44 (d, J = 8.0 Hz, 1 H), 3.40 (d, J = 12.8 Hz, 1 H), 3.35 
(s, 3 H), 2.96 (d, J = 12.8 Hz, 1 H), 2.71–2.62 (m, 5 H), 0.93 (s, 3 H); 13C NMR (175 
MHz, CDCl3) δ 158.7, 137.0, 136.6, 136.5, 136.4, 134.1, 133.7, 133.5, 132.8, 129.8, 
129.7, 128.0, 127.7, 126.2, 125.7, 119.3, 118.4, 115.4, 115.0, 112.0, 57.9, 57.8, 55.0, 
44.1, 38.9, 23.9; IR (film) 2969, 1504 cm-1; MS (ESI+) 409.2268 (409.2274 calcd for 
C28H28N2O, M + H
+).  
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(S)-(+)-4-(4-{[1-(4-Methoxyphenyl)-2,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-2-
yl]methyl}phenyl)morpholine (3-34). General Procedure D was employed for the 
coupling of N1-(4-methoxyphenyl)-N2-methyl-N2-(2-methylallyl)benzene-1,2-diamine (59 
mg, 0.2 mmol) and 4-(4-bromophenyl)morpholine (97 mg, 0.40 mmol) using NaOtBu (38 
mg, 0.40 mmol) as the base and a reaction temperature of 110 °C for 14 h.  This 
procedure afforded 73 mg (82%) of the title compound as a white solid, mp 72–75 °C. 
This material was judged to be 96:4 er by chiral HPLC analysis (Chiracel ADH, 15 cm x 
4.6 mm, 2% IPA/Hexanes, 1 mL/min, λ 254 nm, RT = 16.3 and 17.8 min), [α]23D  +21.6 
(c 0.99, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.08 (d, J = 8.4 Hz, 2 H), 7.02 (d, J = 7.8 
Hz, 2 H), 6.88 (t, J =7.2 Hz, 1 H), 6.83–6.72 (m, 4 H), 6.67 (d, J = 8.3 Hz, 2 H), 6.43 (d, 
J = 7.0 Hz, 1 H), 3.58 (t, J = 4.6 Hz, 4 H), 3.33 (s, 3 H), 3.25 (d, J = 12.9 Hz, 1 H), 2.87 
(d, J = 12.9 Hz, 1 H), 2.83 (d, J = 10.8 Hz, 1 H), 2.79 (d, J = 4.7 Hz, 4 H), 2.72 (d, J = 
10.9 Hz, 1 H), 2.70 (s, 3 H), 0.99 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 158.7, 150.3, 
137.1, 136.6, 136.5, 133.5, 131.8, 130.0, 128.2, 119.2, 118.3, 115.7, 115.4, 114.9, 
111.9, 67.0, 58.1, 57.7, 54.9, 49.6, 43.3, 39.0, 23.8 (an extra peak appears at 136.5 is 
present due to apparent slow bond rotation); IR (film) 2957, 1504 cm-1; MS (ESI+) 
444.2645 (444.2646 calcd for C28H33N3O2, M + H
+).  
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(S)-(+)-2-[4-(1H-pyrrol-1-yl)benzyl]-1-(4-methoxyphenyl)-2,4-dimethyl-1,2,3,4-
tetrahydroquinoxaline (3-35). General Procedure D was employed for the coupling of 
N1-(4-methoxyphenyl)-N2-methyl-N2-(2-methylallyl)benzene-1,2-diamine (59 mg, 0.2 
mmol) and 1-(4-iodophenyl)pyrrole (108 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 
mmol) as the base and a reaction temperature of 120 °C in xylenes for 14 h. This 
procedure afforded 60 mg (70%) of the title compound as an white solid, mp 65–68 °C. 
This material was judged to be 93:7 er by chiral HPLC analysis (Chiracel ADH, 15 cm x 
4.6 mm, 1% IPA/Hexanes, 1 mL/min, λ 254 nm, RT = 16.2 and 22.5 min), [α]23D  +22.7 
(c 0.88, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.03–6.94 (m, 8 H), 6.89 (t, J = 7.3 Hz, 1 
H), 6.81 (d, J = 8.4 Hz, 2 H), 6.76 (d, J = 7.7 Hz, 1 H), 6.74 (d, J = 7.8 Hz, 1 H), 6.45 (t, 
J = 1.9 Hz, 2 H), 6.42 (d, J = 7.8 Hz, 1 H), 3.34 (s, 3 H), 3.18 (d, J = 12.8 Hz, 1 H), 2.79 
(d, J = 12.8 Hz, 1 H), 2.69–2.63 (m, 5 H), 0.89 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 
158.7, 139.5, 136.9, 136.5, 136.1, 136.0, 135.6, 133.0, 131.6, 119.6, 118.94, 118.93, 
118.1, 115.2, 114.6, 111.6, 110.7, 57.9, 57.5, 55.0, 43.3, 39.0, 23.8 (an extra peak at 
136.0 is present due to apparent slow bond rotation); IR (film) 2970, 2360, 2339.4, 
1519, 1504 cm-1; MS (ESI+) 424.2380 (424.2383 calcd for C28H29N3O, M + H
+).  
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(S,Z)-1-(4-methoxyphenyl)-2,4-dimethyl-2-(pent-2-en-1-yl)-1,2,3,4-
tetrahydroquinoxaline (3-37). General Procedure D was employed for the coupling of 
N1-(4-methoxyphenyl)-N2-methyl-N2-(2-methylallyl)benzene-1,2-diamine (59 mg, 0.2 
mmol) and Z-1-bromobutene (54 mg, 0.40 mmol) using NaOtBu (38 mg, 0.40 mmol) as 
the base and a reaction temperature of 110 °C for 14 h. This procedure afforded 50 mg 
(75%) of the title compound as a clear oil. This material was judged to be 98:2 er by 
chiral HPLC analysis (Chriacel ADH, 15 cm x 4.6 mm, 0.50% IPA/Hexanes, 1 mL/min, λ 
254 nm, RT = 6.6 and 9.3 min), [α]23D  +21.7 (c 2.4, CH2Cl2); 
1H NMR (500 MHz, C6D6) 
δ 7.04 (d, J= 7.3 Hz, 2 H), 6.84 (t, J = 7.3 Hz, 1 H), 6.78 (d, J = 8.6 Hz, 2 H), 6.72 (t, J = 
7.7 Hz, 1 H), 6.65 (d, J = 7.8 Hz, 1 H), 6.35 (d, J = 8.0 Hz, 2 H), 5.50–5.41 (m, 1 H), 
5.40–5.32 (m, 1 H),  3.32 (s, 3 H), 2.95 (d, J = 10.8 Hz, 1 H), 2.79 (d, J = 10.8 Hz, 1 H), 
2.70–2.61 (m, 4 H), 2.48 (dd, J= 13.7, 7.1 Hz, 1H), 2.05–1.90 (m, 2H), 1.04 (s, 3 H), 
0.89 (t, J= 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 158.7, 137.4, 136.4, 136.3, 134.5, 
133.6, 124.8, 119.2, 118.2, 115.0, 114.9 111.8, 59.2, 57.0, 54.9, 39.4, 36.0, 23.9, 21.0, 
14.5; IR (film) 2957, 1671, 1504 cm-1; MS (ESI+) 337.2276 (337.2274 calcd for 
C22H28N2O, M + H
+).   
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(S)-2-benzyl-2-((benzyloxy)methyl)-1-(4-methoxyphenyl)-4-methyl-1,2,3,4-
tetrahydroquinoxaline (3-38):  General Procedure D was employed for the coupling of 
N1-(2-((benzyloxy)methyl)allyl)-N2-(4-methoxyphenyl)-N1-methylbenzene-1,2-diamine 
(39 mg, 0.1 mmol) and Bromobenzene (21 µL, 0.20 mmol) using NaOtBu (19 mg, 0.20 
mmol) as the base and a reaction temperature of 125 °C for 12 h. This procedure 
afforded 37 mg (79%) of the title compound as a viscous white oil. This material was 
judged to be 96:4 er by chiral HPLC analysis (Chriacel ADH, 15 cm x 4.6 mm, 1.00% 
IPA/Hexanes, 1 mL/min, λ 254 nm, RT = 7.0 and 10.6 min), [α]23D  -19.51 (c 1.23, 
CH2Cl2); 
1H NMR (700 MHz, C6D6) δ 7.31 (t, J= 7.5 Hz, 2 H), 7.28-7.18 (m, 7 H), 7.16 
(d, J = 7.3 Hz, 2 H), 6.98-6.90 (m, 1 H), 6.86 (d, J = 8.9 Hz, 2 H), 6.69-6.64 (m, 2H), 
6.51 (t, J= 7.2 Hz, 1 H), 6.08 (d, J= 8.0 Hz, 1 H), 4.29 (d, J = 11.8 Hz, 1 H), 4.24 (d, J = 
11.8 Hz, 1 H), 3.82 (s, 3 H), 3.39 (d, J = 9.9 Hz, 1 H), 3.23 (d, J = 11.1 Hz, 1 H), 3.21 (d, 
J = 9.7 Hz, 1 H) 3.09 (d, J = 13.3 Hz, 1 H), 3.04 (d, J = 10.9 Hz, 1 H), 3.00 (d, J = 13.1 
Hz, 1 H), 2.92 (s, 3 H); 13C NMR (175 MHz, CDCl3) δ 158.1, 138.2, 138.1, 136.4, 136.0, 
135.8, 133.4, 132.8, 130.9, 128.3, 128.1, 127.5, 127.4, 126.3, 118.2, 117.6, 115.0, 
114.6, 114.2, 111.1, 72.9, 72.1, 60.6, 55.4, 54.1, 40.3, 39.2 (extra peaks at 132.8 and 
114.2 are present due to apparent slow bond rotation); IR (film) 2923, 2859, 1504 cm-1; 
MS (ESI+) 465.2536 (465.2537 calcd for C31H32N2O2, M + H
+).   
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(S)-(+)-Methyl 3-(4-methoxybenzyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (3-
40).  General Procedure D was employed for the coupling of (2-allylbenzyl)carbamate 
(51 mg, 0.25 mmol) and 4-bromoanisole (60 mg, 0.32 mmol) using NaOtBu (31 mg, 
0.32 mmol) as the base and a reaction temperature of 90 °C for 2 h. This procedure 
afforded 40 mg (51%) of the title compound as a colorless oil. This material was judged 
to be 93:7 er by chiral HPLC analysis (Chiracel ODH, 15 cm x 4.6 mm, 5% 
IPA/Hexanes, 1 mL/min, λ 215 nm, RT = 5.8 and 12.1 min), [α]23D +48.8 (c 0.86, 
CH2Cl2);  
1H NMR (700 MHz, d8-toluene, 95 °C) δ 7.01–6.95 (m, 2 H), 6.92 (d, J = 8.2 
Hz, 2 H), 6.88–6.83 (m, 2 H), 6.69 (d, J = 8.5 Hz, 1 H), 4.82 (d, J = 16.6 Hz, 1 H), 4.73 
(s, br, 1 H), 4.34 (d, J = 16.7 Hz, 1 H), 3.60 (s, 3 H), 3.49 (s, 3 H), 2.74–2.67 (m, 2 H), 
2.67 (d, J = 13.6 Hz, 1 H),  2.35 (dd, J = 9.0, 13.5, Hz 1 H); 13C NMR (175 MHz, d8-
toluene, 95 °C) δ 159.6, 156.4, 134.2, 134.9, 131.6, 130.8, 129.8, 127.3, 126.9, 126.8, 
114.9, 55.3, 52.7, 52.4, 44.3, 38.4, 32.5; IR (film) 2952, 1695 cm-1; MS (ESI+) 312.1589 
(312.1594 calcd for C19H21NO3, M + H
+).  
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(S)-(+)-Methyl 3-(2-methoxybenzyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (3-
41). General Procedure D was employed for the coupling of (2-allylbenzyl)carbamate 
(51 mg, 0.25 mmol) and 2-iodoanisole (85 mg, 0.32 mmol) using NaOtBu (31 mg, 0.32 
mmol) as the base and a reaction temperature of 90 °C for 2 h. This procedure afforded 
33 mg (42%) of the title compound as a white solid, mp 74-77 °C. This material was 
judged to be 80:20 er by chiral HPLC analysis (Chiracel ODH, 15 cm x 4.6 mm, 5% 
IPA/Hexanes, 1 mL/min, λ 215 nm, RT = 5.7 and 8.2 min), [α]23D +77.0 (c 0.67, CH2Cl2); 
1H NMR (700 MHz, d8-toluene, 95 °C) δ 7.02–6.92 (m, 5 H), 6.88–6.82 (m, 2 H), 6.73 (t, 
J = 7.5 Hz, 1 H), 6.56 (d, J = 8.1 Hz, 1 H), 4.88 (s, br, 1 H),  4.80 (d, J = 16.8 Hz, 1 H), 
4.32 (d, J = 16.8 Hz, 1 H), 3.44 (s, 3H ), 3.41 (s, 3 H), 2.80–2.72 (m, 2 H), 2.64 (dd, J = 
8.1, 13.2 Hz, 1 H), 2.46 (d, J = 15.9 Hz, 1 H); 13C NMR (175 MHz, d8-toluene, 95 °C) δ 
159.1, 156.7, 134.3, 134.2, 131.9, 130.0, 127.2, 126.9, 126.8, 121.3, 111.5, 55.6, 52.4, 
51.3, 44.3, 33.7, 33.4 (two aromatic carbon signals are missing due to incidental 
equivalence); IR (film) 2951, 1698 cm-1; MS (ESI+) 312.1593 (312.1594 calcd for 
C19H21NO3, M + H
+).  
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(S)-(+)-Methyl 3-[4-(trifluoromethyl)benzyl]-3,4-dihydroisoquinoline-2(1H)-
carboxylate (3-42). General Procedure D was employed for the coupling of (2-
allylbenzyl)carbamate (51 mg, 0.25 mmol) and 4-bromobenzotrifluoride (72 mg, 0.32 
mmol) using NaOtBu (31 mg, 0.32 mmol) as the base and a reaction temperature of 90 
°C for 2 h. This procedure afforded 63 mg (72%) of the title compound as a colorless oil. 
This material was judged to be 93:7 er by chiral HPLC analysis (Chiracel ODH, 15 cm x 
4.6 mm, 5% IPA/Hexanes, 1 mL/min, λ 215 nm, RT = 4.4 and 9.3 min), [α]23D +39.5 (c 
1.24, CH2Cl2); 
1H NMR (700 MHz, d8-toluene, 95 °C) δ 7.32 (d, J= 7.8 Hz, 2 H), 7.03–
6.94 (m, 2 H), 6.92 (d, J = 7.8 Hz, 2 H), 6.87–6.79 (m, 2 H), 4.67 (d, J = 16.6 Hz, 1 H), 
4.58 (s, br, 1 H), 4.19 (d, J = 16.7 Hz, 1 H), 3.47 (s, 3 H), 2.68–2.62 (m, 2 H), 2.34–2.26 
(m, 2 H); 13C NMR (175 MHz, d8-toluene, 95 °C) δ 156.3, 143.8, 133.9, 133.5, 130.3, 
129.7, 127.5, 127.2, 126.8, 125.8, 152.5, 152.3, 44.3, 39.1, 32.6 (two aromatic carbon 
signals are missing due to incidental equivalence); IR (film) 2954, 1695 cm-1. MS (ESI+) 
350.1365 (350.1362 calcd for C19H18F3NO2, M + H
+).  
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(S)-(+)-Methyl 3-[3-(4-fluorophenoxy)benzyl]-3,4-dihydroisoquinoline-2(1H)-
carboxylate (3-43). General Procedure D was employed for the coupling of (2-
allylbenzyl)carbamate (51 mg, 0.25 mmol) and 3-bromo-4’-fluorodiphenyl ether (85 mg, 
0.32 mmol) using NaOtBu (31 mg, 0.32 mmol) as the base and a reaction temperature 
of 90 °C for 2 h. This procedure afforded 60 mg (61%) of the title compound as 
colorless oil. This material was judged to be 93:7 er by chiral HPLC analysis (Chiracel 
ODH, 15 cm x 4.6 mm, 5% IPA/Hexanes, 1 mL/min, λ 215 nm, RT = 7.7 and 13.3 min), 
[α]23D  +48.3 (c 1.18, CH2Cl2); 
1H NMR (700 MHz, d8-toluene, 95 °C) δ 7.02–6.93 (m, 3 
H), 6.83–6.68 (m, 9 H), 4.68 (d, J = 16.8 Hz, 1 H), 4.62 (s, br, 1 H), 4.20 (d, J = 16.6 Hz, 
1 H), 3.46 (s, 3 H), 2.71–2.62 (m, 2 H), 2.39 (d, J = 15.9 Hz, 1 H), 2.31 (dd, J = 8.5, 13.5 
Hz, 1 H); 13C NMR (175 MHz, d8-toluene, 95 °C) δ 159.8 (d, J = 241 Hz), 158.8, 156.3, 
154.2, 141.8, 134.0, 133.6, 130.2, 129.7, 127.4, 127.0, 126.8, 124.9, 121.1 (d, J = 7 
Hz), 120.3, 117.2, 116.8 (d, J = 23 Hz), 52.5, 44.3, 39.2, 32.8 (one aliphatic carbon 
signal is missing due to incidental equivalence); IR (film) 2952, 1695, 1500  cm-1; MS 
(ESI+) 392.1658 (392.1656 calcd for C24H22FNO2, M + H
+). 
 
131 
 
 
(S)-(+)-Methyl 3-benzyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (3-45). General 
Procedure D was employed for the coupling of (2-allylbenzyl)carbamate (51 mg, 0.25 
mmol) and bromobenzene (51 mg, 0.32 mmol) using NaOtBu (31 mg, 0.32 mmol) as the 
base and a reaction temperature of 90 °C for 2 h. This procedure afforded 48 mg (68%) 
of the title compound as a colorless oil. This material was judged to be 94:6 er by chiral 
HPLC analysis (Chiracel ODH, 15 cm x 4.6 mm, 5% IPA/Hexanes, 0.5 mL/min, λ 
215nm, RT = 9.9 and 18.5 min), [α]23D +63.2 (c 1.28, CH2Cl2); 
1H NMR (700 MHz, d8-
toluene, 90 °C) δ 7.10–7.03 (m, 2 H), 7.03–6.95 (m, 5 H), 6.87–6.81 (m, 2 H), 4.72 (d, J 
= 16.7 Hz, 1 H), 4.66 (s, br, 1 H), 4.24 (d, J = 16.7 Hz, 1 H), 3.49 (s, 3 H), 2.72 (dd, J = 
5.8, 13.3 Hz, 1 H), 2.67 (dd, J = 5.6, 15.7 Hz, 1 H), 2.41 (d, J = 15.7 Hz, 1 H), 2.37 (dd, 
J = 8.9, 13.5 Hz, 1 H); 13C NMR (125 MHz, d8-toluene, 90 °C) δ 156.3, 139.7, 134.1, 
133.8, 130.0, 129.7, 129.0, 127.3, 126.9, 126.9, 126.8, 52.6, 52.4, 44.3, 39.3, 32.5; IR 
(film) 2953 1697 cm-1; MS (ESI+) 282.1491 (282.1489 calcd for C18H19NO2, M + H
+).  
 
(Z,S)-(+)-Methyl-3-[4-(trifluoromethyl)benzyl]-3,4-dihydroisoquinoline-2(1H)-
carboxylate (3-44). General Procedure D was employed for the coupling of (2-
allylbenzyl)carbamate (51 mg, 0.25 mmol) and (Z)-1-bromo-1-butene (43 mg, 0.32 
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mmol) using NaOtBu (31 mg, 0.32 mmol) as the base and a reaction temperature of 90 
°C for 2 h. This procedure afforded 36 mg (57%) of the title compound as a colorless oil. 
This material was judged to be 93:7 er by chiral HPLC analysis (ODH, 15 cm x 4.6 mm, 
1% IPA/Hexanes, 1 mL/min, λ 215 nm, RT = 6.7 and 22.1 min), [α]23D +46.7 (c 1.12, 
CH2Cl2);
 (The mixture was found to exist as a 2.5:1 mixture of rotomers in the nmr, with 
most of the minor rotomer peaks appearing partially in the major rotomer peaks, 
however coupling constants given are all for the major rotomer) 1H NMR (700 MHz, d8-
toluene, 95 °C) δ 6.98–6.93 (m, 2 H), 6.88–6.84 (m, 2 H), 6.83–6.79 (m, 2 H), 5.38–5.33 
(m, 1 H), 5.30–5.25 (m, 1 H), 4.78 (d, J = 16.7 Hz, 1 H), 4.48 (s, br, 1 H), 4.19 (d, J = 
16.7 Hz, 1 H), 3.55 (s, 3 H), 2.78 (dd, J = 6.1, 15.6 Hz, 1 H), 2.46 (d, J = 15.7 Hz, 1 H),  
2.20–2.15 (m, 1 H), 2.00–1.95 (m, 1 H), 1.90-1.84 (m, 0.63 H), 1.80 (quin, J = 7.30 Hz, 
1.45 H), 0.87 (t, J = 7.5 Hz, 0.76 H), 0.80 (t, J = 7.5 Hz, 2.22 H); 13C NMR (125 MHz, 
d8-toluene, 95 °C) δ 156.4, 134.5, 134.1, 133.9, 129.7, 127.2, 126.9, 126.6, 125.7, 52.6, 
51.1, 44.1, 33.1, 30.7, 21.2, 14.5; IR (film) 2958, 1699 cm-1; MS (ESI+) 260.1644 
(260.1645 calcd for C16H21NO2, M + H
+).  
Confirmation of product 3-44 structure. 
The NMR spectrum of 3-44 was complicated due to apparent rotomers. In order to rule 
out the presence of E:Z alkene stereoisomers the product was reduced with LiAlH4 to 
form the analogous N-methyl isoquinoline derivative 3-S4. 
 
(Z,S)-(–)-2-methyl-3-(pent-2-en-1-yl)-1,2,3,4-tetrahydroisoquinoline (3-S4). A flame-
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dried round-bottom flask equipped with a stirbar was cooled under a stream of nitrogen 
and charged with 3-44 (35 mg, 0.136 mmol) and THF (4 mL). The resulting solution was 
cooled to 0°C and after five minutes of stirring LiAlH4 (0.27 mL, 0.27 mmol, 1.0M in 
THF) was added dropwise. The resulting solution was heated to reflux for 1.5 h then 
cooled to rt and quenched with 0.1 mL H2O followed by 0.1 mL of a 15% aqueous 
NaOH solution. The mixture was filtered and the solid was washed with ether (2 x 5) 
mL. The combined organic solutions were dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography on 
silica gel using hexanes/EtOAc as the eluent to afford 20 mg (69%) of the product as a 
clear oil; [α]23D –24.7 (c 1.86, CH2Cl2).  
1H NMR (700 MHz, CDCl3) δ 7.13–7.09 (m, 2 H), 
7.08–7.05 (m, 1 H), 7.04–7.00 (m, 1 H), 5.53–5.48 (m, 1 H), 5.44–5.39 (m, 1 H), 3.82 (d, 
J = 15.5 Hz, 1 H), 3.68 (d, J = 15.6 Hz, 1 H), 2.79–2.72 (m, 1 H), 2.69–2.58 (m, 2 H), 
2.36 (s, 3 H), 2.32–2.27 (m, 1 H), 2.10–2.04 (m, 1H), 2.03 (quint, J = 7.5 Hz, 2 H), 0.97 
(t, J = 7.5 Hz, 3 H); 13C NMR (175 MHz, CDCl3
126.1, 125.6, 125.4, 59.1, 56.4, 41.0, 32.3, 28.3, 20.7, 14.2; IR (film) 2960, 1456 cm-1; 
MS (ESI+) 216.1747 (216.1747 calcd for C15H21N, M + H
+). 
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Chapter 4 
Development of Enantioselective Carboetherification Reactions for 
the Synthesis of Oxygen Heterocycles: Use of a Modular Chiral 
Alcohol Moiety to Access Rationally Designed Taddol Phosphite 
Ligands 
4.1 Introduction 
 Oxygen heterocycles are prominent moieties displayed in an array of natural 
products and biologically active compounds .1,2  Families of compounds, such as the as 
the annonaceous acetogenins, contain chiral 2,5-substitutued THF’s which are powerful 
inhibitors of the mitochondrial complex.1 Also, chiral 2-substituted oxygen heterocycles 
are noted in a variety of pharmaceuticals displaying an array of biological activities 
(Figure 4.1).2 As such, synthesizing THF’s in an enantioselective fashion is an 
interesting challenge in organic synthesis. 
Although many groups have shown the utility of adding amines enantioselectively 
onto alkenes with transistion metal catalyisis to access chiral amine heterocyles,3,4 
relatively few methods exist for the  analogous enantioselective synthesis of oxygen 
heterocycles.4b,5 Recently, we showed the importance of N-protecting groups in 
developing enantioselective carboamination reactions.3a,c Consequently, the lack of an 
interchangeable protecting group on the oxygen heteroatom may be a reason for the 
dearth of related enantioselective carboetherification reactions, as the lack of 
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this protecting group could make it hard to achieve high enantioselectivities. 
Figure 4.1 Biologically active chiral oxygen heterocycles 
 
 The ability to easily alter a portion of the substrate or catalyst system in 
enantioselective reactions is essential to the development of new methodology.6 Since 
the oxygen heteroatom in our substrates lacks an extra protecting group, we decided to 
alter the ligand in our reaction. As such, our strategy was to utilize modular ligand 
scaffolds which are easy to synthesize and manipulate, as we assumed these two 
criteria would be essential to our reaction development (Scheme 4.1). 
Scheme 4.1 Modular ligand scaffolds 
 
4.2 Previous Results 
 Previously in our group, Dr. Qifei Yang and Dr. Duy Mai both looked into the 
enantioselective synthesis of tetrahydrofurans.7 As shown in Table 4.1, a screen with a 
variety of different ligands failed to reveal a candidate that was promising. Furthermore, 
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irreproducible results were obtained when attempting similar reactions with ligand 
scaffold 4-L3. Although, even if this result had been reproducible, making analogues of 
this scaffold is time consuming and expensive.8 Thus, we decided to synthesize 
analogues of easily accessible modular ligand scaffolds (Figure 4.2). 
Table 4.1 Previous ligand screens 
 
4.3 Initial Screen of Synthesized Ligands 
 It was peculiar that ligand 4-L1 was unreactive in the system shown above 
(Table 4.1), as previously this scaffold afforded product in related carboamination 
reactions. Furthermore, similar ligands such as 4-L2 above provided the desired 
product, albeit in low yields. As such, we decided to run the reaction of 4-1a with ligand 
4-L1 under slightly different conditions with elevated temperatures. Gratifyingly, these 
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reaction conditions afforded the desired product 4-2a, albeit in low yield and er (Table 
4.2). Unfortunately, a variety of other BINOL ligands did not lead to desired levels of 
enantioselectivity. 
Table 4.2 Use of binol ligands with substrate 4-1aa 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv ArBr, 2.0 equiv NaO
t
Bu, 
toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to isolated 
compounds. 
 
 Since BINOL phosphoramidite ligands (Table 4.2) afforded poor 
enantioselectivities and yields, we decided to look at chiral ligands bearing scaffolds 
similar to racemic ligands that worked well for this reaction.9 As such, we tested electron 
rich chiral binaphthyl based ligands (Table 4.3). Unfortunately, poor results were 
obtained with 4-L16 and 4-L17 in our reaction. We also tested the electron rich PHOX 
ligand 4-L18, and it afforded poor results as well. However, PHOX ligand 4-L20 gave 
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better enantioselectivity, but slight modifications of this scaffold yielded inferior results 
for our reaction (4-L21). Since product 4-2b was better for HPLC analysis, it was utilized 
for further ligand screens. 
Table 4.3 Screen with binaphthyl and phox ligandsa 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv ArBr, 2.0 equiv NaO
t
Bu, 
toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to isolated 
compounds. A (-) in front of the er refers to the opposite enantiomer being formed. 
 
4.4 Ligand Design for Enantioselective Carboetherification Reactions 
 Due to the disappointing results that were obtained with the ligands above (Table 
4.3 and 4.2), we decided to take a different approach with our ligand synthesis. Two 
criteria were important for the new ligand design: 1.) The backbone needed to be easily 
accessible and amenable to alteration and 2.) The chiral alcohol or amine portion 
needed to be cheap and readily accessible. As such, we decided to test TADDOL 
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based ligands with our reaction, as these moieties are highly amenable to variation. 
TADDOL is also derived from tartaric acid, which makes it cheap and easy to 
synthesize. Additionally, chiral alcohols would be used in our ligand as well, since there 
are a variety of cheap and naturally occurring chiral alcohols to select from. We 
envisioned that we could exploit nature’s chemical diversity to identify a chiral alcohol 
framework that would be suitable for ligands used in our enantioselective 
carboetherification reactions.  
As such, we synthesized the ligands in Table 4.4 from commercially available 
chiral alcohols. 4-L22 and 4-L23, ligands bearing menthol as the chiral alcohol portion, 
afforded good yields and decent er’s for our reaction. Similar ligands, such as 4-L24 
and 4-L25 which possessed isopinocampheol as the chiral alcohol portion, yielded 
inferior results for this reaction. As an attempt to improve the enantioselectivity, ligands 
4-L26 and 4-L27 were synthesized to mimic the framework of the menthol ligand. These 
ligands afforded good yields and moderate enantioselectivities (better than 4-L22 and 4-
L23) for our reactions. In terms of enantioselectivity, the best ligand was 4-L8 with 
cinchonidine as the chiral alcohol, which afforded product 4-2b in 25% yield and 95:5 er. 
Lastly, TADDOL ligands bearing the chiral bisphenethylamine moiety gave poor results, 
and also a small amount of regioisomer (3-7%) was detected in most of the crude NMR 
mixtures.  
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Table 4.4 TADDOL ligand screena 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv ArBr, 2.0 equiv NaO
t
Bu, 
toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to isolated 
compounds.
c
 A slight amount of regioisomer was noted in the NMR. 
 
To test the substrate scope with the cinchona derived ligands 4-L8 and 4-L28, as 
they afforded the highest enantioselectivities (Table 4.4), reactions with these ligands 
were carried out with substrates 4-1a, 4-1c, and 4-1d (Table 4.5). As noted below, 
ligands 4-L8 and 4-L28 worked for substrate 4-1a, affording product 4-2a in low to 
moderate yields and decent enantioselectivities. However, these cinchona based 
ligands failed to afford any product under the reaction conditions with substrates 4-1c 
and 4-1d. Moreover, altering the cinchona alkaloid (4-L31 and 4-L32) or the TADDOL 
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back bone (4-L33, 4-L34, 4-L35, and 4-L36) failed to increase the yield or 
enantioselectivity of 4-2a. Synthesis of similar ligand scaffolds which resembled the 
cinchona alkaloid afforded poor results as well.10 
Table 4.5 Substrate scope with cinchona taddol ligandsa 
 
 a Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv ArBr, 2.0 equiv 
NaO
t
Bu, toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated compounds. A 
small amount (~5%) of regioisomer was detected by NMR in these reactions.  
 
 
 Since ligand 4-L27 afforded product 4-2b in 80% yield and -84:16 er, we wanted 
to test the substrate scope with this ligand. Additionally, we knew that the chiral 2-
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phenylcyclohexanol could be easily synthesized via an enzymatic resolution, which we 
imagined would lend itself to the facile synthesis of analogues bearing this scaffold as 
well.11 Gratifyingly, the carboetherification reactions of substrates 4-1a, 4-1c, and 4-1d 
all afforded their respective products in good yields and decent enantioselectivities 
(Table 4.6).  
Table 4.6 Substrate scope with 4-L27a 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 2.0 equiv ArBr, 2.0 equiv NaO
t
Bu, 
toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to isolated 
compounds. 
c
A small amount of regioisomer was detected by NMR for product 4-2a. 
 
4.5 Synthesis and Enzymatic Resolution of 2-substitutued Cyclohexanols 
 As part of our rational design of ligands, the chiral 2-phenylcyclohexanol scaffold 
was selected due to its similarity to menthol which worked well in ligands for our 
reactions (Table 4.4), and also due to the ease of synthesis for this compound.11 Use of  
chiral 2-phenylcyclohexanol/TADDOL-based phosphite ligands, afforded good yields 
and moderate enantioselectivities for a range of products (Table 4.6 and 4.4). To further 
explore this ligand scaffold, we imagined systematically accessing a variety of TADDOL 
ligands by modifying the aryl group of this chiral alcohol. 
To access these desired chiral alcohols, we needed to find a synthetic route that 
would afford these alcohols in good enantioselectivities. To this extent, we became 
interested in a resolution procedure, which had previously been used to afford 2-
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phenylcyclohexanol in perfect enantioselectivity.11 To our knowledge the scope of this 
specific resolution procedure to afford other 2-arylcyclohexanols has yet to be 
established. Thus, in Table 4.7 below, we display the complete scope of this enzymatic 
resolution procedure to afford an array of chiral 2-arylcyclohexanols. In most cases we 
only determined the er of the free alcohol (A Table 4.7), and as long as it was >99:1 er 
we did not test the corresponding er of the acetylated product (B Table 4.7). This 
methodology worked well to access variety of 2-arylcyclohexanols in excellent 
enantioselectivities. Additionally, the resolution of 2-phenylcyclopentanol yielded 4-A10 
in 39% yield and >97:3 er. The main limitation of this resolution is the use of sterically 
hindered groups as noted in 4-A8, 4-A9 and 4-A11. No resolution was observed in 
these cases even under increased catalyst loading and longer reaction times.  
To further determine the effects of the chiral cyclohexanol portion of our TADDOL 
ligands on the outcome of our carboetherification reactions, we decided to synthesize 
chiral cyclohexanols with different groups in the 2 position. As shown in Table 4.8, a 
handful of chiral cyclohexanols were synthesized bearing heteroatoms in the 2 position. 
The larger chiral alcohols, including 4-A13 and 4-A14, required increased reaction 
times, temperature, and catalyst loading. Even still, these reactions did not go to 
completion. Thus, we isolated the acylated products of these larger alcohols (B Table 
4.8) and deacylated them in the presence of K2CO3 and methanol to determine the 
enantioselectivity by HPLC analysis. These deacylated products were afforded in 
perfect enantioselectivity. Thus, with variety of new chiral alcohols in hand (Tables 4.7 
and 4.8), we synthesized a selection of new phosphite ligands to test in our 
enantioselective carboetherification reactions. 
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Table 4.7 Enzymatic resolution of 2-arylcyclohexanolsa 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 10 equiv vinyl acetate, 100 mg 
enzyme per 1 mmol substrate,  
t
BuOMe (0.30 M), RT, 2-3 days until complete by HPLC analysis. 
b
Yields 
and enantiomeric ratios refer to isolated compounds. 
c
ND means er not determined. 
d
NR means no 
resolution observed by HPLC under standard reaction conditions. 
 
Table 4.8 Enzymatic resolution other cyclohexanolsa 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate, 10 equiv vinyl acetate, 100 mg 
enzyme per 1 mmol substrate,  
t
BuOMe (0.30 M), RT, 2-3 days until complete by HPLC analysis. 
b
Yields 
and enantiomeric ratios refer to isolated compounds. 
c
ND means yield not determined, and the er was 
determined by taking an aliquot from the reaction. 
d 
Reaction was ran for 1 day at RT and 4 days at 37 °C, 
and on the 3
rd
 day an extra 50 mg of enzyme per 1mmol of substrate was added. 
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4.6 Evaluation of 2-substituted Cyclohexanol TADDOL Phosphite Ligands  
 As displayed in Table 4.9 below, we synthesized a diverse set of ligands with 
differing groups on the chiral cyclohexanol. Unfortunately, no clear trends were noticed 
in terms of substituents, and all ligands tested afforded similar results. The best result 
was determined when using the biphenyl substituted ligand 4-L41, which gave the 
product in 60% yield and 88:12 er. 
Table 4.9 Effect of 2-substituted cyclohexanol on enantioselectivitya 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.0 equiv ArBr, 2.0 equiv 
NaO
t
Bu, toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to 
isolated compounds.  
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 We also evaluated other ligands based on chiral cyclohexanols that we had 
synthesized, and also ligands from chiral cyclohexanols obtained by other means (Table 
4.10). Again, no clear trends were noted, but based on the result from 4-L54 compared 
to 4-L50 (Table 4.9), it seemed increasing the sterics of the ligand might increase the 
enantioselectivity (Table 4.10). As such we synthesized the ligands 4-L56-57 and 4-
L61-62. Ligands 4-L56-57 possessed an extra chiral center, but failed to increase the 
enantioselectivity of our products. Ligands 4-L61-62 possessed an even larger moiety in 
the 2-position of the chiral alcohol, but these ligands also failed to improve the reaction 
outcomes. Also, utilizing a cis isomer instead of the trans isomer failed to improve the 
results as well (4-L60). 
Table 4.10 Other chiral cyclohexanol based ligandsa 
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a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.0 equiv ArBr, 2.0 equiv 
NaO
t
Bu, toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to 
isolated compounds.  
 
Interestingly, for most ligand scaffolds screened in all of the tables above (with 
only a few exceptions) both diastereomers of the ligands yielded similar results. Thus, 
we wanted to test racemic variants of the 2-arylcyclohexanols in these TADDOL 
phosphite ligands. As shown in Table 4.11 below, we discovered that some racemic 
ligands gave similar er’s and yields when compared to their chiral counterparts. 
Consequently, we thought we might be able to increase the enantioselectivity of 4-2b 
without the need of chiral alcohol derivatives, as the use of racemic alcohols allows us 
to test other larger ligands that were inaccessible through the enzymatic resolution 
procedure. Unfortunately, we were unable to increase the enantioselectivity of product 
4-2b with these racemic ligands, and just like in Table 4.10 increasing the size of the 2- 
substituent on the cyclohexanol decreased the yield and er. However, potentially 1 of 
the 2 diastereomers of these bulky racemic ligands was reacting more rapidly than the 
other one, and the diastereomer that was affording the product was yielding lower 
enantioselectivities. As such, we separated the two diastereomers of racemic 4-L66 to 
150 
 
give us 4-L70 and 4-L71 in 5:1 and 10:1 dr respectively. We subjected both 
diastereomers to the reaction conditions, and disappointingly neither diastereomer 
afforded 4-2b in excellent enantioselectivity (Table 4.9). Thus, simply enhancing the 
steric bulk of these ligands seems to help the enantioselectivity to a slight extent (Table 
4.9), but too much steric bulk seems to lower the observed enantioselectivity for product 
4-2b as well (Tables 4.10 and 4.11). Other racemic ligands were also ineffective at 
improving the reaction outcomes (4-L72-75).  
Table 4.11 Effect of racemic cyclohexanols on enantioselectivitya 
 
151 
 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.0 equiv ArBr, 2.0 equiv 
NaO
t
Bu, toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to 
isolated compounds. 
C
 Absolute configuration of 4-L70 and 4-L71 was not determined. 
 
Ligands that possessed differing backbones were tested in these reactions too. 
Again, no changes we made to the ligands seemed to increase the enantioselectivity of 
our reactions (Table 4.12). The one exception was ligand 4-L77, but synthesis of this 
ligand was challenging and we decided against using it for our reactions. As such, the 
best ligand from our screens for enantioselective carboetherification reactions was 
ligand 4-L41 (Table 4.9).  
 
Table 4.12 Changes to the taddol backbonea 
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a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.0 equiv Ar-Br, 2.0 equiv 
NaO
t
Bu, toluene (0.10 M), 90 °C, 12-14 hrs. 
b
Yields refer to NMR yields and enantiomeric ratios refer to 
isolated compounds.  
 
4.7 Evaluation of Substrate and Electrophile Scope  
 Before we began testing the scope of this reaction, we wanted to make sure we 
had the optimal reaction conditions in hand. Thus, we tested a variety of different 
solvents, Pd sources, Pd:Ln ratios, and concentrations for our reaction. From Table 
4.13, the best set of conditions was entry 8 using Pd(COD)Cl2 and dioxane in the 
reactions. However, in subsequent reactions Pd(COD)Cl2 yielded isolated products that 
were not as clean when compared to the use of Pd2(dba)3 for substrate 4-2c. Thus it 
was not used in further screens. It was also shown that no reaction is observed in the 
absence of ligand. Moreover, the Pd:Ln ratio does not affect the enantioselectivity 
observed for the reaction products, meaning that a mono-ligated complex is likely for 
the enantiodetermining step. 
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Table 4.13 Optimization of reaction conditionsa 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.0 equiv ArBr, 2.0 equiv 
NaO
t
Bu, toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields and enantiomeric ratios refer to 
isolated compounds. ND means not determined. 
 
 In order to determine the robustness of the enantioselective carboetherification 
reactions with 4-L41, we decided to examine the scope of the reaction with different 
substrates (Table 4.14). Products 4-2a and 4-2b were afforded in moderate 
enantioselectivities, and a small amount of regioisomer was isolated with product 4-2b. 
The gem-diphenyl substrate 4-1c worked very well under our conditions, and the 
desired product 4-2c was afforded in moderate yield and good enantioselectivity (67% 
and 95:5 er). The gem-diphenyl substrate also gave >95:5 er for product 4-2h. In a few 
cases, interesting effects of the solvent were noted (Table 4.14). Morever, the 
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enantioselectivity appears to vary based on the nucleophilicity of the starting substrate 
as well (4-2e and 4-2f). Likewise, the position of the nitrogen in heteroaryl electrophile 
may be affecting the enantioselectivity as well (4-2i and 4-2j.) Studies are currently 
ongoing to determine the nature of all these effects. 
Table 4.14 Substrate scopea  
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.20 mmol), 1.8 equiv ArBr, 2.0 equiv 
NaO
t
Bu, dioxane (0.10 M), 90 °C, 12-14 h. 
b
Yields and enantiomeric ratios refer to isolated compounds. 
C 
1.4 equiv ArBr was used.
d
Small amount of regioisomer detected (from beta-hydride elimination after 
insertion).
e
 Yield and product:isomer ratio are from NMR. 
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4.8 Determination of Absolute Configuration 
 To determine the absolute configuration of our molecules, we synthesized 
product 4-2k to compare it to the known compound form the literature.5 Product 4-2k 
was afforded in 23% yield by NMR, and we were able to isolate pure material with the 
product matching spectral data in the literature perfectly. Under our conditions 4-2k was 
obtained in 79:21 er. The optical rotation of 4-2k was +4.54° (literature value was 
+8.30°). Thus, we determined that the configuration of our molecule matched that in the 
literature, and we were forming compounds with an (S) configuration. 
Scheme 4.2 Determination of absolute configuration 
 
4.9 Conclusions 
 We showed that a modular TADDOL ligand scaffold was key to designing a 
useful ligand for Pd-catalyzed enantioselective carboetherification reactions. We 
discovered that altering the TADDOL backbone was not beneficial, but changing the 
chiral alcohol in the ligand scaffold did have an impact on the reaction outcome. Using 
naturally occurring chiral alcohols as an inital guide in our ligand synthesis, we were 
able to synthesize a ligand framework (4-L41) that afforded our products in good yield 
and enantioselectivity (up to 95:5 er). Furthermore, ligand 4-L41 works for a variety of 
substrates as well, showing the robust nature of this scaffold. Work is currently ongoing 
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to unravel the full electrophile scope, and also the scope of alkene substitution that will 
be tolerated in these reactions. 
4.10 Experimental 
General: Reactions were carried out under nitrogen in flame-dried glassware. 
Tris(dibenzylideneacetone)dipalladium was purchased from Strem Chemical Co. and 
used without further purification. Xylenes were purified by distillation over CaH2 prior to 
use in reactions.  Methylene chloride and toluene were purified using a GlassContour 
solvent system. All other solvents and aryl halides were purchased from commercial 
sources and used as is. 1-(but-3-en-1-yl)cyclopentan-1-ol (4-1b)12 and 2-methylhex-5-
en-2-ol (4-1a)12 were synthesized by following literature procedures. Ligands in Table 
4.4 were all synthesized according to a literature procedure.6b All yields refer to isolated 
compounds that are estimated to be >95% pure as judged by 1H NMR or GC analysis. 
The yields reported in the supporting information describe the result of a single 
experiment. 
Synthesis of Substrates: 
 
1,1-diphenylpent-4-en-1-ol (4-1c): A flame dried round bottom flask  under nitrogen 
was equipped with a stir bar and charged with 4-pentenoyl chloride (5 mmol, 0.551 mL, 
1.0 equiv.) followed by the addition of 50 mL of dry diethyl ether. The mixture was 
cooled to 0 °C in an ice bath for five minutes, and then PhMgBr (1M in THF, 20 mL, 4 
equiv.) was added drop wise to the flask. After stirring for 12 hours, the flask was cooled 
to 0 °C in an ice bath and slowly quenched with 10 mL saturated ammonium chloride. 
The mixture was extracted 3x25 mL ethyl acetate and the combined organic layers were 
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dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
product was then purified by flash chromatography on silica gel using hexanes/EtOAc 
as the eluant. This procedure afforded 864 mgs (72%) of the title compound as a clear 
oil. 1H NMR (500 MHz, CDCl3) δ 7.43(d, J = 7.4 Hz, 4 H), 7.33 (t, J = 8.1 Hz, 4 H),  7.24 
(t, J = 6.6 Hz, 2 H), 6.85–6.78 (m, 2 H), 5.06–4.96 (m, 2 H), 2.44–2.38 (m, 2 H), 2.18 (s, 
1 H),  2.12–2.04 (m, 2 H). Spectroscopic data was consistent with that previously stated 
in the literature.13 
 
1,1-bis(4-(trifluoromethyl)phenyl)pent-4-en-1-ol (4-1e): A flame dried round bottom 
flask  under nitrogen was equipped with a stir bar and charged with freshly ground Mg 
turnings  (25 mmol, 0.607 g, 2.50 equiv.) followed by the addition of 15 mL of dry THF. 
To this was added 4-bromobenzotrifluoride (25 mmol, 3.50 mL, 2.5 equiv.) all at once. 
An ice bath was used to control the exothermic reaction, and it was allowed to stir until 
almost all of the Mg was gone. At the same time, a flame dried round bottom flask  
under nitrogen was equipped with a stir bar and charged with 4-pentenoic acid (10 
mmol, 1.02 mL, 1.0 equiv.) followed by the addition of 20 mL of dry benzene. The 
mixture was cooled to 0 °C in an ice bath for five minutes and then oxallyl chloride (20 
mmol, 1.75 mL, 2.0 equiv.) was slowly added to the flask. It was allowed to warm to 
room temperature and stir for one hour. After this time, the solvent was removed in 
vacuo, and the round bottom flask was placed under nitrogen and equipped with a stir 
bar.  15 mL of dry THF was added to this crude 4-pentenoyl chloride and it was cooled 
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to 0 °C in an ice bath.  The freshly prepared grignard reagent from above was added 
drop wise to the flask containing the crude 4-pentenoyl chloride. It was allowed to warm 
to room temperature and after stirring for 12 hours the flask was cooled to 0 °C in an ice 
bath and slowly quenched with 10 mL saturated ammonium chloride. The mixture was 
extracted 3x25 mL ethyl acetate and the combined organic layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude product was 
then purified by flash chromatography on silica gel using hexanes/EtOAc as the eluant. 
This procedure afforded 1.25 g (34%) of the title compound as a light yellow oil. 1H 
NMR (700 MHz, CDCl3) δ 7.61 (d, J = 8.2 Hz, 4 H), 7.56 (d, J = 8.3 Hz, 4 H),  5.94–5.83 
(m, 1 H), 5.10–4.99 (m, 2 H), 2.51–2.42 (m, 2 H), 2.35 (br., s, 1 H),  2.15–2.06 (m, 2 H); 
13C NMR (125 MHz CDCl3) δ 158.9, 158.7, 158.5, 141.8, 139.6, 139.0, 137.5, 135.9, 
132.5, 131.0, 128.6, 127.4, 124.8, 115.0, 114.8, 113.7, 113.6, 113.5, 77.9, 55.4, 41.4, 
34.3, 28.6 (C-F couplings for this compound were not taken into account and peaks 
were listed as displayed in the spectra) ; IR (film) 3473.3, 2357.5, and 1617.2 cm-1; MS 
(EI+) 374.1107 (374.1105 calcd for C19H16F6O, M
+).   
 
1,1-bis(4-methoxyphenyl)pent-4-en-1-ol (4-1f): A flame dried round bottom flask  
under nitrogen was equipped with a stir bar and charged with freshly ground Mg 
turnings  (8.68 mmol, 0.211 g, 3.10 equiv.) followed by the addition of 8 mL of dry THF. 
To this was added 4-bromoanisole (8.42 mmol, 1.05 mL, 3.0 equiv.) all at once. One 
drop of dibromoethane was added to the reaction, and it was allowed to stir until almost 
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all of the Mg was gone. The grignard was cooled to 0 °C in an ice bath for five minutes, 
and then 4-pentenoyl chloride (2.80 mmol, 0.310 mL, 1.0 equiv.) in 5 mL of dry THF 
was added drop wise to this flask. It was allowed to warm to room temperature and after 
stirring for 12 hours, the flask was cooled to 0 °C in an ice bath and slowly quenched 
with 5 mL saturated ammonium chloride. The mixture was extracted 3x15 mL ethyl 
acetate and the combined organic layers were dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel using hexanes/EtOAc as the eluant. This procedure 
afforded 200 mgs (25%) of the title compound as a clear oil. 1H NMR (500 MHz, CDCl3) 
δ 7.31 (d, J = 8.7 Hz, 4 H), 6.84 (d, J = 9.0 Hz, 4 H),  5.90–5.80 (m, 1 H), 5.03–4.92 (m, 
2 H), 3.74 (s, 6 H) 2.35–2.30 (m, 2 H), 2.09–2.02 (m, 3 H); 13C NMR (125 MHz CDCl3) δ 
158.3, 139.4, 138.8, 127.2, 114.6, 113.4, 55.2, 41.2, 28.5. 
 
General Procedure A: Synthesis of Racemic 2-Arylcyclohexanols 
Freshly ground magnesium turnings (1.45 equiv.) were added to a flame dried 2-neck 
round bottom flask under nitrogen, and it was equipped with a reflux condenser. Dry 
THF (1 M) was added to the flask. The appropriate aryl bromide (1.50 equiv.) was 
added in THF (3 M). If the reaction commenced to auto-reflux, it was controlled with an 
ice bath. If the reactions failed to initiate, the reactions were heated under conditions 
that allowed for a controlled reflux until the magnesium turnings were gone. Once the 
magnesium turnings had disappeared, the reaction was cooled to -20 °C for 10 minutes. 
After this time, 8 mol% CuCl was added to the reaction, immediately followed by the 
addition of cyclohexene oxide (1.0 equiv.) in THF (2 mL THF: 1mL oxide). The mixture 
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was allowed to slowly warm to room temperature and then stirred at that temperature 
for 4 hours. The reaction was then cooled to 0 °C and quenched with saturated 
ammonium chloride (1mL/mmol). The mixture was filtered through a pad of celite, and 
added to a separatory funnel. It was extracted 3x with ethyl acetate (1mL/mmol) and 
then dried over sodium sulfate. The solvent was then evaporated in vacuo and the 
crude residue was purified by flash chromatography on silica gel to afford the desired 
product. 
General Procedure B: Synthesis of Enantiomerically Pure 2-Arylcyclohexanols 
To a flame dried round bottom flask under nitrogen was added PS  30 Amano   Lipase 
(100 mgs / 1 mmol alcohol). To this was added the appropriate (+/-) trans-2-
arylcyclohexanol (1.0 equiv.)  followed by tert-Butyl methyl ether (3 mL / 1 mmol). To 
this mixture was added vinyl acetate (10 equiv.) and the reactions were allowed to stir 
1-3 days until completed based on chiral HPLC analysis. When complete, the mixture 
was filtered on a fritted funnel and the enzyme was washed with diethyl ether and then 
recycled for future use if desired. The solvent was then evaporated in vacuo and the 
crude residue was purified by flash chromatography on silica gel to afford the desired 
products. Typically although the acetylated product was isolated the enantioselectivity of 
this product was not determined by HPLC except when noted. 
 
(1S,2R)-2-phenylcyclohexan-1-ol (4-A1): The title compound was synthesized as 
previously noted in the literature, and all spectroscopic data matched as well.11 This 
material was judged to be >99:1 er by chiral HPLC analysis (Chiracel OJH, 25 cm x 4.6 
mm, 4.00% IPA/Hexanes, 0.75 mL/min, λ 215 nm, RT= 12.4 and 13.3 min). 
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(1S,2R)-2-(naphthalen-2-yl)cyclohexan-1-ol (4-A2): According to general procedure A 
the grignard reagent was formed with Mg (43.5 mmol, 1.05 g) and 2-Bromonaphthalene 
(45 mmol, 9.31 g). Then CuCl (2.4 mmol, 0.238 g) was added followed by cyclohexene 
oxide (30 mmol, 3.04 mL). This procedure afforded 3.30 g (48 %) of racemic 4-A2 as a 
white solid.  
PS 30 Amano Lipase (662 mgs), racemic 4-A1 (6.62 mmol, 1.50 g), tBuOMe (18 mL), 
and vinyl acetate (6.1 mL, 66.2 mmol) were reacted according to general procedure B 
for 3 days. This procedure afforded 678 mgs (45%) of the title compound as a white 
solid. Spectroscopic data matched the reported data in the literature.16 This material 
was judged to be >99:1 er by chiral HPLC analysis (Chiracel OJH, 25 cm x 4.6 mm, 
4.00% IPA/Hexanes, 0.75 mL/min, λ 225 nm, RT= 35.0 and 43.0 min). 
 
(1S,2R)-2-(3,5-dimethylphenyl)cyclohexan-1-ol (4-A3): According to general 
procedure A the grignard reagent was formed with Mg (29 mmol, 0.704 g) and 5-Bromo-
m-xylene (30 mmol, 4.08 mL). Then CuCl (1.6 mmol, 0.158 g) was added followed by 
cyclohexene oxide (20 mmol, 2.02 mL). This procedure afforded 3.00 g (73 %) of 
racemic 4-A3 as a white solid.  
PS 30 Amano Lipase (662 mgs), racemic 4-A3 (6.62 mmol, 1.35 g), tBuOMe (18 mL), 
and vinyl acetate (6.1 mL, 66.2 mmol) were reacted according to general procedure B 
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for 3 days. This procedure afforded 634 mgs (47%) of the title compound as a white 
solid, mp 57–60 °C. This material was judged to be >99:1 er by chiral HPLC analysis 
(Chiracel OJH, 25 cm x 4.6 mm, 4.00% IPA/Hexanes, 0.50 mL/min, λ 225 nm, RT= 8.4 
and 9.1 min). [α]23D  -39.0 (c 2.50, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 6.91–6.88 (m, 
3 H), 3.66 (td, J = 10.2, 4.2 Hz, 1 H), 2.37 (td, J = 11.2, 3.6 Hz, 1 H), 2.33 (s, 6H), 2.15–
2.10 (m, 1 H), 1.89–1.83 (m, 2 H), 1.76 (app. d, J = 13.6 Hz, 1 H), 1.62 (s, 1H), 1.56–
1.30 (m, 4 H); 13C NMR (175 MHz CDCl3) δ 143.3, 138.4, 128.7, 125.9, 74.5, 53.3, 34.6, 
33.5, 26.3, 25.3, 21.5; IR (film) 3445.7, 2925.4, and 1603.4 cm-1; MS (ESI+) 227.1410 
(227.1406 calcd for C14H20O, M + Na
+).  
 
(1S,2R)-2-([1,1'-biphenyl]-4-yl)cyclohexan-1-ol (4-A4): According to general 
procedure A the grignard reagent was formed with Mg (48.2mmol, 1.17 g) and 4-
Bromobiphenyl  (50 mmol,11.65 g). Then CuCl (2.66 mmol, 0.257 g) was added 
followed by cyclohexene oxide (33.3 mmol, 3.36 mL). This procedure afforded 4.00 g 
(48 %) of racemic 4-A4 as a white solid.  
PS 30 Amano Lipase (1.50 g), racemic 4-A4 (14.8 mmol, 3.74 g), tBuOMe (40 mL), and 
vinyl acetate (13.6 mL, 148 mmol) were reacted according to general procedure B for 3 
days. This procedure afforded 1.72 (46%) of the title compound as a white solid, mp 
122–125 °C. This material was judged to be >99:1 er by chiral HPLC analysis (Chiracel 
OJH, 25 cm x 4.6 mm, 4.00% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 21.8 and 25.0 
min). [α]23D  -13.99 (c 3.38, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.62–7.57 (m, 4 H), 
7.45 (t, J = 7.7 Hz, 2 H), 7.37–7.34 (m, 3 H), 3.72 (td, J = 10.0, 4.2 Hz, 1 H), 2.51 (td, J 
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= 11.1, 3.6 Hz, 1 H), 2.1–2.15 (m, 1 H), 1.95–1.88 (m, 2 H), 1.81 (app. d, J = 13.2 Hz, 1 
H), 1.64–1.35 (m, 5 H); 13C NMR (175 MHz CDCl3) δ 142.6, 141.1, 140.0, 128.9, 128.5, 
127.7, 127.3, 127.2, 74.6, 53.1, 34.5, 33.5, 26.2, 25.3; IR (film) 3548.0, 2918.6, and 
1490.0 cm-1; MS (ESI+) 270.1850 (270.1852 calcd for C18H20O, M + NH4
+).  
 
(1S,2R)-2-(4-methoxyphenyl)cyclohexan-1-ol (4-A5): According to general procedure 
A the grignard reagent was formed with Mg (8.03 mmol, 195 mg) and 4-Bromoanisole  
(8.31 mmol,1.04 mL). Then CuCl (0.44 mmol, 0.045 g) was added followed by 
cyclohexene oxide (5.54 mmol, 0.560 mL). This procedure afforded 0.800 g (70 %) of 
racemic 4-A5 as a white solid.  
PS 30 Amano Lipase (0.335 g), racemic 4-A5 (3.35 mmol, 0.692 g), tBuOMe (9 mL), 
and vinyl acetate (3.08 mL, 33.5 mmol) were reacted according to general procedure B 
for 2 days. This procedure afforded 330 mgs (48%) of the title compound as a white 
solid, mp 73–76 °C. This material was judged to be >99:1 er by chiral HPLC analysis 
(Chiracel OJH, 25 cm x 4.6 mm, 5.00% IPA/Hexanes, 1.00 mL/min, λ 225 nm, RT= 15.7 
and 17.3 min). [α]23D  -107.0 (c 1.17, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.62–7.57 
(m, 4 H), 7.45 (t, J = 7.7 Hz, 2 H), 7.37–7.34 (m, 3 H), 3.72 (td, J = 10.0, 4.2 Hz, 1 H), 
2.51 (td, J = 11.1, 3.6 Hz, 1 H), 2.18–2.15 (m, 1 H), 1.95–1.88 (m, 2 H), 1.81 (app. d, J 
= 13.2 Hz, 1 H), 1.64–1.35 (m, 5 H); 13C NMR (175 MHz CDCl3) δ 142.6, 141.1, 140.0, 
128.9, 128.5, 127.7, 127.3, 127.2, 74.6, 53.1, 34.5, 33.5, 26.2, 25.3; IR (film) 3411.9, 
2926.7, and 1611.5 cm-1; MS (ESI+) 229.1196 (229.1199 calcd for C13H18O2, M + Na
+).  
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(1S,2R)-2-(4-(dimethylamino)phenyl)cyclohexan-1-ol (4-A6): According to general 
procedure A the grignard reagent was formed with Mg (14.5 mmol, 352 mg) and4-
Bromo-N,N-dimethylaniline (15.0 mmol,3.01 g). Then CuCl (0.80 mmol, 0.079 g) was 
added followed by cyclohexene oxide (10.0 mmol, 1.01 mL). This procedure afforded 
1.50 g (68 %) of racemic 4-A6 as a white solid.  
PS 30 Amano Lipase (0.455 g), racemic 4-A6 (4.45 mmol, 1.00 g), tBuOMe (14 mL), 
and vinyl acetate (4.19 mL, 45.5 mmol) were reacted according to general procedure B 
for 2 days. This procedure afforded 493mgs (49%) of the title compound as a white 
solid, mp 63–66 °C. This material was judged to be >99:1 er by chiral HPLC analysis 
(Chiracel ODH, 15 cm x 4.6 mm, 2.50% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 8.5 
and 9.4 min). [α]23D  -31.8 (c 2.55, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.15 (d, J = 8.7 
Hz, 2 H), 6.75 (d, J = 8.5 Hz, 2 H),  3.60 (td, J = 10.2, 4.5 Hz, 1 H), 2.95 (s, 6H), 2.34 
(td, J = 11.3, 3.8 Hz, 1 H), 2.15–2.10 (m, 1 H), 1.88–1.82 (m, 2 H), 1.76 (app. d, J = 
13.1 Hz, 1 H), 1.65 (s, br, 1 H), 1.54–1.30 (m, 4 H); 13C NMR (175 MHz CDCl3) δ 149.9, 
131.0, 128.7, 113.3, 74.8, 52.4, 40.9, 34.4, 33.5, 26.4, 25.3; IR (film) 3403.9, 2922.7, 
and 1613.1 cm-1; MS (ESI+) 220.1694 (220.1696 calcd for C14H21NO, M + H
+).  
 
(1S,2R)-2-(2-methoxyphenyl)cyclohexan-1-ol (4-A7): According to general procedure 
A the grignard reagent was formed with Mg (24.2 mmol, 585 mg) and 2-Bromoanisole 
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(25.0 mmol, 3.11 mL). Then CuCl (1.32 mmol, 0.132 g) was added followed by 
cyclohexene oxide (16.66 mmol, 1.65 mL). This procedure afforded 1.39 g (41 %) of 
racemic 4-A7 as a clear oil.  
PS 30 Amano Lipase (0.491 g), racemic 4-A7 (4.91 mmol, 1.00 g), tBuOMe (12 mL), 
and vinyl acetate (4.52 mL, 49.2  mmol) were reacted according to general procedure B 
for 3 days. This procedure afforded 490 mgs (48%) of the title compound as a clear oil. 
This material was judged to be 99:1 er by chiral HPLC analysis (Chiracel ADH, 25 cm x 
4.6 mm, 4.0% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 12.4 and 13.3 min). [α]23D  -
62.4 (c 1.65, CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.24 (d, J = 8.2 Hz, 1 H), 7.20 (t, J = 
8.2 Hz, 1 H), 6.96 (t, J = 7.5 Hz, 1 H), 6.89 (d, J = 8.2 Hz, 1 H),  3.82 (s, 3H), 3.73 (td, J 
= 10.0, 4.9 Hz, 1 H), 3.04–2.96 (m, 1 H), 2.16–2.02 (m, 1 H), 1.88–1.70 (m, 4 H), 1.53–
1.31 (m, 4 H); 13C NMR (175 MHz CDCl3) δ 157.9, 131.7, 127.6, 127.5, 121.2, 111.0, 
74.2, 55.7, 45.3, 35.4, 32.5, 26.4, 25.3; IR (film) 3420.3, 2928.4, and 1599.4 cm-1; MS 
(ESI+) 229.1154 (229.1199 calcd for C13H18O2, M + H
+).  
 
General Procedure C: Synthesis of Chiral Phosphite 2-Arylcyclohexanol Ligands 
The following ligands were synthesized according to a slightly modified literature 
procedure.6b A flame dried round bottom flask was charged with the appropriate chiral 
2-arylcyclohexanol (1.05 equiv.) and dry DCM (0.50 M). To this flask containing the 
stirring chiral 2-arylcyclohexanol was added PCl3 (1.05 equiv.) and this mixture was 
allowed to stir for 1 hour at room temperature. After this time, dry NEt3 (4.0 equiv.) was 
added drop wise and the mixture stirred for thirty minutes. Next, the appropriate Taddol 
precursor (1.00 equiv.) was added to the mixture in dry DCM (0.50 M). The reaction was 
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allowed to stir 12 to 14 hours and then diethyl ether was added 5 mL/ mmol and the 
mixture was filtered through celite. The solvent was evaporated in vacuo and the crude 
residue was purified by flash chromatography on silica gel to afford the desired 
products. 
 
(3aR,8aR)-6-(((1S,2R)-2-(3,5-dimethylphenyl)cyclohexyl)oxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (4-L40): 
According to general procedure C (1S,2R)-2-(3,5-dimethylphenyl)cyclohexan-1-ol 
(0.337 mmol, 69 mgs) was stirred with PCl3 (0.337 mmol, 30 µL) for 1 hour. Next, NEt3 
(1.48 mmol, 180 µL) was added. After 30 minutes, (R,R)-Taddol (0.321 mmol, 150 mgs) 
was added and the reaction stirred for 12-14 hours. This procedure afforded 120 mgs 
(53%) of the title compound as a white foamy solid, mp 73–76 °C. [α]23D  -243.5 (c 1.20, 
CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.57 (d, J = 7.8 Hz, 2 H), 7.36 (t, J = 7.7 Hz, 4 H), 
7.29–7.25 (m, 4 H),  7.24–7.11 (m, 8 H), 7.00 (d, J = 6.9 Hz, 2 H), 6.84 (s, 2H), 6.73 (s, 
1H), 4.87 (s, 2H), 4.65 (app. qd, J = 10.1, 4.2 Hz, 1 H), 2.59–2.54 (m, 1 H), 2.33–2.28 
(m, 1 H), 1.98 (s, 6H), 1.90–1.85 (m, 1 H), 1.79–1.72 (m, 2 H), 1.67–1.60 (m, 1 H), 
1.56–1.49 (m, 1 H), 1.42–1.27 (m, 2 H),  1.22 (s, 3 H), 0.27 (s, 3 H); 13C NMR (175 MHz 
CDCl3) δ 146.6, 146.1, 143.7, 141.7, 141.3, 137.5, 129.2, 129.0, 128.9, 128.1, 127.9, 
127.8, 127.53, 127.48, 127.4, 127.3, 127.27, 127.22, 127.20, 126.4, 111.9, 83.0, 82.8, 
82.7, 82.29, 82.27, 81.8, 81.7, 77.8, 35.8, 33.9, 27.6, 26.1, 25.4, 25.3, 21.2 (Due to the 
complexity of the spectra all the peaks are listed without taking into consideration C-P 
couplings); 31P NMR (283 MHz CDCl3) δ 139.0; IR (film) 2935.2, 1601.9, and 1447.3 cm
-
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1; MS (ESI+) 699.3226 (699.3234 calcd for C45H47O5P, M + H
+).  
 
(3aS,8aS)-6-(((1S,2R)-2-(3,5-dimethylphenyl)cyclohexyl)oxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (4-L39): 
According to general procedure C (1S,2R)-2-(3,5-dimethylphenyl)cyclohexan-1-ol 
(0.337 mmol, 69 mgs) was stirred with PCl3 (0.337 mmol, 30 µL) for 1 hour. Next, NEt3 
(1.48 mmol, 180 µL) was added. After 30 minutes, (S,S)-Taddol (0.321 mmol, 150 mgs) 
was added and the reaction stirred for 12-14 hours. This procedure afforded 110 mgs 
(50%) of the title compound as a white foamy solid, mp 70–73 °C. [α]23D  -56.7 (c 0.95, 
CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.38 (d, J = 7.5 Hz, 2 H), 7.35–7.29 (m, 8 H),  
7.27–7.15 (m, 10 H), 6.79 (s, 2H), 6.76–6.74 (m, 1 H),  5.02 (d, J = 8.3 Hz, 1 H), 4.90 (d, 
J = 8.3 Hz, 1 H),  4.65 (app. qd, J = 9.8, 4.3 Hz, 1 H), 2.54–2.59 (m, 1 H), 2.23–2.19 (m, 
1 H), 2.02 (s, 6H), 1.90–1.86 (m, 1 H), 1.84–1.79 (m, 1 H), 1.77–1.72 (m, 1 H), 1.63–
1.56 (m, 1 H), 1.46–1.40 (m, 2 H), 1.34–1.26 (m, 1 H),  1.10 (s, 3 H), 0.28 (s, 3 H); 13C 
NMR (175 MHz CDCl3) δ 146.5, 146.2, 143.5, 142.1, 141.4, 137.4, 129.0, 128.8, 128.2, 
127.9, 127.8, 127.6, 127.5, 127.4, 127.34, 127.27, 127.2, 127.1, 126.4, 83.1, 82.5, 
82.44, 82.38, 82.02, 81.99, 77.82, 77.77, 51.65, 51.63, 35.5, 33.4, 27.5, 26.0, 25.6, 
25.4, 21.3 (Due to the complexity of the spectra all the peaks are listed without taking 
into consideration C-P couplings); 31P NMR (283 MHz CDCl3) δ 137.8; IR (film) 2925.2, 
1602.3, and 1446.8 cm-1; MS (ESI+) 699.3226 (699.3234 calcd for C45H47O5P, M + H
+). 
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(3aR,8aR)-6-(((1S,2R)-2-([1,1'-biphenyl]-4-yl)cyclohexyl)oxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (4-L40): 
According to general procedure C (1S,2R)-2-([1,1'-biphenyl]-4-yl)cyclohexan-1-ol (0.337 
mmol, 85 mgs) was stirred with PCl3 (0.337 mmol, 30 µL) for 1 hour. Next, NEt3 (1.48 
mmol, 180 µL) was added. After 30 minutes, (R.R)-Taddol (0.321 mmol, 150 mgs) was 
added and the reaction stirred for 12-14 hours. This procedure afforded 85 mgs (35%) 
of the title compound as a white foamy solid, mp 180–183 °C. [α]23D  -130.6 (c 3.81, 
CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.55 (d, J = 8.1 Hz, 2 H), 7.42–7.06 (m, 27 H),  
4.98–4.95 (m, 1 H), 4.92 ( d, J = Hz, 8.5 Hz, 1 H),  4.63–4.57 (m, 1 H), 2.75–2.70 (m, 1 
H), 2.32 (app. d, J = 13.4 Hz, 1 H), 1.98 (app. d, J = 13.6 Hz, 1 H), 1.89–1.76 (m, 2 H), 
1.72–1.56 (m, 2 H), 1.45–1.34 (m, 2 H), 1.22 (s, 3 H), 0.33 (s, 3 H); 13C NMR (175 MHz 
CDCl3) δ 146.6, 146.1, 143.0, 141.8, 141.3, 141.2, 139.4, 129.4, 129.0, 128.91, 128.88, 
128.6, 128.0, 127.8, 127.53, 127.47, 127.44, 127.37, 127.33, 127.29, 127.2, 127.14, 
127.11, 127.1, 126.88, 112.0, 82.9, 82.7, 82.6, 82.12, 82.10, 81.91, 81.87, 78.10, 78.08, 
51.39, 51.37, 35.7, 33.8, 27.6, 26.0, 25.5, 25.3  (Due to the complexity of the spectra all 
the peaks are listed without taking into consideration C-P couplings); 31P NMR (283 
MHz CDCl3) δ 140.7; IR (film) 2932.0, and 1446.9 cm
-1; MS (ESI+) 747.3232 (747.3234 
calcd for C49H47O5P, M + H
+). 
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(3aS,8aS)-6-(((1S,2R)-2-([1,1'-biphenyl]-4-yl)cyclohexyl)oxy)-2,2-dimethyl-4,4,8,8-
tetraphenyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepine (4-L41): 
According to general procedure C (1S,2R)-2-([1,1'-biphenyl]-4-yl)cyclohexan-1-ol (1.01 
mmol, 255 mgs) was stirred with PCl3 (1.01 mmol, 86 µL) for 1 hour. Next, NEt3 (4.04 
mmol, 534 µL) was added. After 30 minutes, (S,S)-Taddol (0.963 mmol, 450 mgs) was 
added and the reaction stirred for 12-14 hours. This procedure afforded 520 mgs (72%) 
of the title compound as a white foamy solid, mp 115–118 °C. [α]23D  -226.2 (c 1.11, 
CH2Cl2); 
1H NMR (700 MHz, CDCl3) δ 7.51 (d, J = 7.9 Hz, 2 H), 7.38–7.02 (m, 27 H), 
4.94–4.90 (m, 1 H), 4.88 ( d, J = Hz, 8.4 Hz, 1 H),  4.56 (app. qd, J = 9.9, 3.7 Hz, 1 H), 
2.71–2.66 (m, 1 H), 2.28 (app. d, J = 13.8 Hz, 1 H), 1.95 (app. d, J = 13.2 Hz, 1 H), 
1.81–1.73 (m, 2 H), 1.69–1.50 (m, 2 H), 1.41–1.31 (m, 2 H), 1.19 (s, 3 H), 0.30 (s, 3 H); 
13C NMR (175 MHz CDCl3) δ 146.6, 146.1, 143.0, 141.8, 141.25, 141.23, 139.4, 129.4, 
129.0, 128.92, 128.89, 128.6, 128.0, 127.8, 127.54, 127.48, 127.45, 127.38, 127.34, 
127.30, 127.18, 127.15, 127.12, 127.06, 126.9, 112.0, 82.9, 82.7, 82.6, 82.12, 82.10, 
81.92, 81.88, 78.10, 78.09, 51.39, 51.37, 35.7, 33.8, 27.6, 26.0, 25.5, 25.3 (Due to the 
complexity of the spectra all the peaks are listed without taking into consideration C-P 
couplings); 31P NMR (202 MHz CDCl3) δ 140.6; IR (film) 2931.7, 1486.2, and 1446.7 
cm-1; MS (ESI+) 747.3224 (747.3234 calcd for C49H47O5P, M + H
+). 
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4-((1R,2S)-2-(((3aS,8aS)-2,2-dimethyl-4,4,8,8-tetraphenyltetrahydro[1,3]dioxolo[4,5-
e][1,3,2]dioxaphosphepin-6-yl)oxy)cyclohexyl)-N,N-dimethylaniline (4-L45): 
According to general procedure C (1S,2R)-2-(4-(dimethylamino)phenyl)cyclohexan-1-ol 
(0.675 mmol, 148 mgs) was stirred with PCl3 (0.675 mmol, 59 µL) for 1 hour. Next, NEt3 
(2.57 mmol, 356 µL) was added. After 30 minutes, (S,S)-Taddol (0.642 mmol, 300 mgs) 
was added and the reaction stirred for 12-14 hours. This procedure afforded 166 (35%) 
of the title compound as a white foamy solid, mp 91–94 °C. 1H NMR (700 MHz, CDCl3) 
δ 7.50–7.44 (m, 7 H), 7.42 (t, J = Hz, 7.6 Hz, 2 H), 7.38–7.25 (m, 11 H), 7.16 (d, J = Hz, 
8.7 Hz, 2 H), 6.56 (d, J = Hz, 8.7 Hz, 2 H), 5.14–5.12 (m, 1 H), 5.08 (d, J = Hz, 8.3 Hz, 1 
H),  4.55–4.49 (m, 1 H), 2.81 (s, 6 H), 2.63–2.58 (m, 1 H), 2.30–2.25 (m, 1 H), 2.02–
1.96 (m, 1 H), 1.92–1.80 (m, 2 H), 1.73–1.66 (m, 1 H), 1.58–1.47 (m, 2 H), 1.43–1.35 
(m, 1 H),1.21 (s, 3 H), 0.42 (s, 3 H); 13C NMR (175 MHz CDCl3) δ 149.3, 146.5, 146.0, 
142.02, 142.01, 141.4, 131.7, 129.1, 129.0, 128.93, 128.91, 128.1, 127.7, 127.6, 127.5, 
127.31, 127.30, 127.26, 127.2, 127.10, 127.06, 112.8, 112.2, 83.02, 83.00, 82.5, 82.4, 
82.33, 82.31, 81.92, 81.90, 78.33, 78.30, 50.45, 50.43, 40.9, 35.40, 33.3, 27.5, 26.0, 
25.6, 25.4  (Due to the complexity of the spectra all the peaks are listed without taking 
into consideration C-P couplings); 31P NMR (283 MHz CDCl3) δ 138.4; IR (film) 2931.9, 
1613.3, and 1520.8 cm-1. 
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4-((1R,2S)-2-(((3aR,8aR)-2,2-dimethyl-4,4,8,8-tetraphenyltetrahydro 
[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepin-6-yl)oxy)cyclohexyl)-N,Ndimethylaniline 
(4-L46): According to general procedure C (1S,2R)-2-(4-
(dimethylamino)phenyl)cyclohexan-1-ol (0.675 mmol, 148 mgs) was stirred with PCl3 
(0.675 mmol, 59 µL) for 1 hour. Next, NEt3 (2.57 mmol, 356 µL) was added. After 30 
minutes, (R,R)-Taddol (0.642 mmol, 300 mgs) was added and the reaction stirred for 
12-14 hours. This procedure afforded 235 (51%) of the title compound as a white foamy 
solid, mp 94–97 °C. 1H NMR (700 MHz, CDCl3) δ 7.61 ( d, J = Hz 7.2 Hz, 2 H),  7.47 ( d, 
J = Hz, 7.3 Hz, 2 H), 7.43 ( d, J = Hz, 7.3 Hz, 2 H),   7.34–7.28 (m, 4 H), 7.27–7.17 (m, 
12 H), 6.53 ( d, J = Hz, 8.7 Hz, 2 H), 5.02–4.98 (m, 1 H), 4.95 ( d, J = Hz, 8.3 Hz, 1 H),  
4.57–4.51 (m, 1 H), 2.68 (s, 6H), 2.64–2.59 (m, 1 H), 2.33–2.29 (m, 1 H), 1.95 (app. d, J 
= 13.1 Hz, 1 H), 1.83–1.74 (m, 2 H), 1.69–1.57 (m, 2 H), 1.44–1.32 (m, 2 H), 1.27 (s, 3 
H), 0.36 (s, 3 H); 13C NMR (175 MHz CDCl3) δ 149.3, 146.7, 146.0, 141.8, 141.1, 131.9, 
129.1, 129.0, 128.90, 128.88, 128.08, 127.63, 127.61, 127.5, 127.29, 127.27, 127.23, 
127.2, 127.1, 127.0, 112.7, 112.2, 82.99, 82.97, 82.4, 82.33, 82.30, 82.28, 81.89, 81.87, 
78.31, 78.27, 50.43, 50.40, 40.8, 35.4, 33.3, 27.5, 26.0, 25.6, 25.3(Due to the 
complexity of the spectra all the peaks are listed without taking into consideration C-P 
couplings); 31P NMR (283 MHz CDCl3) δ 140.7; IR (film) 2931.7, 1614.1, and 1520.9 
cm-1. 
General procedure for asymmetric Pd-catalyzed carboetherification reactions of 
172 
 
alcohol derivatives. A flame-dried Schlenk tube equipped with a stirbar was cooled 
under a stream of nitrogen and then charged with Pd2(dba)3 (2 mol %), 4-L41 (5 mol %), 
the alcohol substrate (1.0 equiv), and NaOtBu (1.50-2.0 equiv). The flask was purged 
with N2, then the aryl or alkenyl halide (1.40-2.0 equiv), and dioxane or toluene (0.10 M) 
was added. The resulting mixture was heated to 90 °C with stirring until the starting 
material had been consumed as judged by TLC analysis (ca. 12 h). The reaction 
mixture was then cooled to rt, saturated aqueous ammonium chloride (6mL/mmol 
substrate) was added, and the mixture was transferred to a separatory funnel. The 
mixture was extracted with ethyl acetate (3 x 5 mL) then the combined organic layers 
were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude 
product was purified by flash chromatography on silica gel. 
 
(S)-2,2-dimethyl-5-(naphthalen-2-ylmethyl)tetrahydrofuran (4-2a): The general 
procedure was employed for the coupling of 2-methylhex-5-en-2-ol (0.20 mmol, 22.8 
mg) and 2-bromonaphthalene (0.1.80 mmol, 75.0 mg) using a catalyst composed of 
Pd2(dba)3 (0.004 mmol, 3.7 mg) and 4-L41 (0.010 mmol 7.5 mg), a reaction temperature 
of 90 °C and a reaction time of 12 h. This procedure afforded the title compound (21.1 
mg, 44%) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.85–7.76 (m, 3 H), 7.67 (s, 1H), 
7.50–7.37 (m, 3 H),  4.35–4.27 (m, 1 H), 3.17 (dd, J = 5.3, 13.3Hz, 1 H), 2.88 (dd, J = 
7.7, 13.3 Hz, 1 H), 1.97–1.91 (m, 1 H), 1.78–1.68 (m, 3 H), 1.29 (s, 3 H), 1.27 (s, 3H). 
Other spectral data matched that of the literature.12 The enantiopurity was determined to 
be 75:25 er by chiral HPLC analysis (chiralcel OJH, 25 cm x 4.6 mm, 1.00% 
IPA/Hexanes, 1.50 mL/min, λ 254 nm, RT= 7.0 and 7.5 min). 
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(S)-2-(naphthalen-2-ylmethyl)-1-oxaspiro[4.4]nonane (4-2b): The general procedure 
was employed for the coupling of 1-(but-3-en-1-yl)cyclopentan-1-ol (0.20 mmol, 28.0 
mg) and 2-bromonaphthalene (0.38 mmol, 75.0 mg) using a catalyst composed of 
Pd2(dba)3 (0.004 mmol, 3.7 mg) and 4-L41 (0.010 mmol 7.5 mg), a reaction temperature 
of 90 °C and a reaction time of 12 h. This procedure afforded the title compound (31.1 
mg, 58%, 10:1 dr) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.85–7.79 (m, 3 H), 7.67 
(s, 1 H), 7.49–7.35 (m, 3 H),  4.29–4.22 (m, 1 H), 3.15 (dd, J = 5.0, 13.6 Hz, 1 H), 2.87 
(dd, J = 7.7, 13.3 Hz, 1 H), 1.95–1.87(m, 1 H), 1.86–1.49 (m, 11 H); 13C NMR (125 
MHz, CDCl3) δ136.6, 133.7, 132.3, 128.4, 127.84, 127.79, 127.75, 127.7, 91.6, 79.2, 
43.0, 39.4, 38.6, 36.6, 24.2; IR (film) 2953.3, 2360.5, 2338.1, 1508.1 cm-1. The 
enantiopurity was determined to be 89:11 er by chiral HPLC analysis (chiralcel OJH, 25 
cm x 4.6 mm, 1.00% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 10.5 and 12.8 min). 
 
(S)-5-(naphthalen-2-ylmethyl)-2,2-diphenyltetrahydrofuran (4-2c): The general 
procedure was employed for the coupling of 1,1-diphenylpent-4-en-1-ol (0.20 mmol, 
47.7 mg) and 2-bromonaphthalene (0.28 mmol, 58.0 mg) using a catalyst composed of 
Pd2(dba)3 (0.004 mmol, 3.7 mg) and 4-L41 (0.010 mmol 7.5 mg), a reaction temperature 
of 90 °C and a reaction time of 12 h. This procedure afforded the title compound 
(48.7mg, 67%) as a white solid, mp 83–86 °C. 1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 
7.2 Hz, 1 H), 7.81 (d, J = 8.6 Hz, 2 H), 7.74 (s, 1 H), 7.55–7.44 (m, 7 H), 7.37–7.31 (m, 
4 H), 7.28–7.21 (m, 2 H), 4.53 (app. quin, J = 6.7 Hz, 1 H), 3.34 (dd, J = 6.0, 13.6 Hz, 1 
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H), 3.02 (dd, J = 7.0, 13.6 Hz, 1 H), 2.71–2.64 (m, 1 H), 2.58–2.51 (m, 1 H), 2.03–1.95 
(m, 1 H), 1.89–1.81 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 147.4, 146.9, 136.6, 133.7, 
132.3, 128.31, 128.25, 128.2, 127.88, 127.87, 127.8, 127.6, 126.76, 126.74, 126.1, 
126.0, 125.4, 88.5, 79.9, 42.8, 38.8, 31.0; IR (film) 2933.8, 1600.9, 1446.4 cm-1. The 
enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 2.00% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 5.2 and 6.3 min). 
 
(S)-5-(naphthalen-2-ylmethyl)-2,2-bis(4-(trifluoromethyl)phenyl)tetrahydrofuran (4-
2e): The general procedure was employed for the coupling of 1,1-bis(4-
(trifluoromethyl)phenyl)pent-4-en-1-ol (0.20 mmol, 74.8 mg) and 2-bromonaphthalene 
(0.38 mmol, 75.0 mg) using a catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and 
4-L41 (0.010 mmol 7.5 mg), a reaction temperature of 90 °C and a reaction time of 12 h. 
This procedure afforded the title compound (58.0 mg, 58%) as a clear oil. 1H NMR (500 
MHz, CDCl3) δ 7.86–7.74 (m, 3 H), 7.69 (s, 1 H), 7.61–7.53 (m, 8 H), 7.51–7.44 (m, 2 
H), 7.41 (d, J = 8.2 Hz, 1 H), 4.51 (app. quin, J = 6.6 Hz, 1 H), 3.26 (dd, J = 6.0, 13.6 
Hz, 1 H), 3.02 (dd, J = 6.6, 13.7 Hz, 1 H), 2.68–2.59 (m, 1 H), 2.55–2.46 (m, 1 H), 2.03–
1.94 (m, 1 H), 1.90–1.80 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 150.5, 150.2, 136.0, 
133.7, 132.4, 129.55, 129.48, 129.29, 129.22, 128.1, 128.03, 127.97, 127.8, 127.7, 
126.3, 126.2, 125.6, 125.5 (q, J= 3.8 Hz), 125.4 (q, J= 3.8 Hz), 87.8, 80.4, 42.6, 38.7, 
30.8  (Other than the 2 reported quartets, C-F couplings for this compound were not 
taken into account and peaks were listed as displayed in the spectra); IR (film) 2953.3, 
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2360.5, 2338.1, and 1508.1cm-1. The enantiopurity was determined to be 90:10 er by 
chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 2.50% IPA/Hexanes, 1.00 
mL/min, λ 254 nm, RT= 5.0 and 5.5 min). 
 
(S)-2,2-bis(4-methoxyphenyl)-5-(naphthalen-2-ylmethyl)tetrahydrofuran (4-2f): The 
general procedure was employed for the coupling of 1,1-bis(4-methoxyphenyl)pent-4-
en-1-ol (0.20 mmol, 59.7 mg) and 2-bromonaphthalene (0.38 mmol, 75.0 mg) using a 
catalyst composed of Pd2(dba)3 (0.004 mmol, 3.7 mg) and 4-L41 (0.010 mmol 7.5 mg), 
a reaction temperature of 90 °C and a reaction time of 12 h. This procedure afforded the 
title compound (42.0 mg, 50%) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.84 
(d, J = 7.2 Hz, 1 H), 7.80 (d, J = 8.1 Hz, 2 H), 7.71 (s, 1 H), 7.50–7.41 (m, 3 H), 7.40–
7.33 (m, 4 H), 6.88–6.81 (m, 4 H), 4.48 (app. quin, J = 6.7 Hz, 1 H), 3.81 (s, 3 H), 3.79 
(s, 3H), 3.31 (dd, J = 5.9, 13.7 Hz, 1 H), 2.99 (dd, J = 7.1, 13.4 Hz, 1 H), 2.62–2.54 (m, 
1 H), 2.49–2.41 (m, 1 H), 2.00–1.92 (m, 1 H), 1.87–1.79 (m, 1 H); 13C NMR (125 MHz, 
CDCl3) δ 158.3, 139.9, 139.1, 136.6, 133.7, 132.3, 128.3, 127.9, 127.74, 127.67, 127.3, 
127.2, 126.0, 125.4, 113.6, 113.4, 88.0, 79.8, 55.4, 42.8, 39.0, 31.1; IR (film) 2935.9, 
1608.1, and 1507.7 cm-1. The enantiopurity was determined to be 94:6 er by chiral 
HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5.00% IPA/Hexanes, 1.00 mL/min, λ 
254 nm, RT= 10.7 and 19.5 min). 
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(S)-2-(naphthalen-2-ylmethyl)tetrahydrofurantetrahydrofuran (4-2g): The general 
procedure was employed for the coupling of pent-4-en-1-ol (0.20 mmol, 17.2 mg) and 2-
bromonaphthalene (0.28 mmol, 58.0 mg) using a catalyst composed of Pd2(dba)3 (0.004 
mmol, 3.7 mg) and 4-L41 (0.010 mmol 7.5 mg), a reaction temperature of 90 °C and a 
reaction time of 12 h. This procedure afforded the title compound (9.9 mg, 23%) as a 
light yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.83–7.75 (m, 3 H), 7.68 (s, 1 H), 7.48–
7.36 (m, 3 H), 4.18 (app. quin, J = 6.5 Hz, 1 H), 3.95–3.89 (m, 1 H), 3.79–3.73 (m, 1 H), 
3.08 (dd, J = 6.4, 13.5 Hz, 1 H), 2.92 (dd, J = 6.4, 13.7 Hz, 1 H), 1.98–1.82 (m, 3 H), 
1.66–1.57 (m, 1 H). Other spectral data matched that of the literature.12 The 
enantiopurity was determined to be 60:40 er by chiral HPLC analysis (chiralcel OJH, 25 
cm x 4.6 mm, 1.00% IPA/Hexanes, 1.50 mL/min, λ 254 nm, RT= 19.8 and 26.1 min). 
 
(S)-5-(naphthalen-2-ylmethyl)-2,2-diphenyltetrahydrofuran (4-2h): The general 
procedure was employed for the coupling of 1,1-diphenylpent-4-en-1-ol (0.20 mmol, 
47.7 mg) and 2-bromonaphthalene (0.38 mmol, 75.0 mg) using a catalyst composed of 
Pd2(dba)3 (0.004 mmol, 3.7 mg) and 4-L41 (0.010 mmol 7.5 mg), a reaction temperature 
of 90 °C and a reaction time of 12 h. This procedure afforded the title compound ( 52.0 
mg, 66%) as a white solid, mp 93–96 °C. 1H NMR (500 MHz, CDCl3) δ 7.69 (app. dd, J 
= 3.2, 8.6 Hz, 2 H), 7.65 (s, 1 H), 7.53–7.46 (m, 4 H), 7.69 (d, J = 8.4 Hz, 1 H), 7.36–
7.28 (m, 4 H), 7.27–7.13 (m, 4 H), 4.50 (app. quin, J = 6.7 Hz, 1 H), 3.94 (s, 3H), 3.29 
(dd, J = 5.9, 13.7 Hz, 1 H), 2.97 (dd, J = 7.1, 13.7 Hz, 1 H), 2.69–2.61 (m, 1 H), 2.55–
2.48 (m, 1 H), 2.00–1.93 (m, 1 H), 1.87–1.79 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 
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157.4, 147.4, 146.9, 134.2, 133.3, 129.2, 128.6, 128.3, 128.2, 127.7, 126.74, 126.72, 
126.1, 126.0, 118.8, 105.8, 88.5, 80.0, 55.4, 42.6, 38.8, 30.9; IR (film) 2936.5, 1604.9, 
and 1447.5 cm-1. The enantiopurity was determined to be 95:5 er by chiral HPLC 
analysis (chiralcel ADH, 25 cm x 4.6 mm, 2.00% IPA/Hexanes, 1.00 mL/min, λ 254 nm, 
RT= 7.5 and 8.9 min). 
 
(S)-5-(naphthalen-2-ylmethyl)-2,2-diphenyltetrahydrofuran (4-2i): The general 
procedure was employed for the coupling of 1,1-diphenylpent-4-en-1-ol (0.20 mmol, 
47.7 mg) and 2-bromo-5-trifluoromethylpyridine (0.40 mmol, 90.0 mg) using a catalyst 
composed of Pd2(dba)3 (0.009 mmol, 3.7 mg) and 4-L41 (0.020 mmol 15.0 mg), a 
reaction temperature of 90 °C and a reaction time of 12 h in 2 mL of toluene. This 
procedure afforded the title compound ( 71.0 mg, 92%) as a light yellow oil. 1H NMR 
(500 MHz, CDCl3) δ 8.81 (s, 1 H), 7.81 (dd, J = 2.1, 8.2 Hz, 1 H), 7.43–7.38 (m, 5 H), 
7.31–7.25 (m, 4 H), 7.22–7.16 (m, 2 H), 4.61 (app. quin, J = 6.5 Hz, 1 H), 3.26 (dd, J = 
7.1, 13.7 Hz, 1 H), 3.13 (dd, J = 5.6, 13.7 Hz, 1 H), 2.68–2.61 (m, 1 H), 2.55–2.48 (m, 1 
H), 2.10–2.02 (m, 1 H), 1.90–1.82 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 163.5, 147.1, 
146.6, 146.2 (q, J= 3.8 Hz), 133.3 (q, J= 2.8), 128.3, 128.2, 126.9, 126.8, 126.0, 125.9, 
124.0, 88.6, 78.4, 45.0, 38.7, 31.1; IR (film) 2948.3, 1607.9, and 1326.8 cm-1. The 
enantiopurity was determined to be 51:49 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 1.00% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 8.0 and 9.2 min). 
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(S)-5-(naphthalen-2-ylmethyl)-2,2-diphenyltetrahydrofuran (4-2i): The general 
procedure was employed for the coupling of 1,1-diphenylpent-4-en-1-ol (0.10 mmol, 
23.8 mg) and 4-bromoisoquinoline (0.14 mmol, 29.0 mg) using a catalyst composed of 
Pd2(dba)3 (0.002 mmol, 1.8 mg) and 4-L41 (0.005 mmol 3.7 mg), a reaction temperature 
of 90 °C and a reaction time of 12 h. This procedure afforded the title compound (19%, 
7.0 mg) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ 9.18 (s, 1 H), 8.47 (s, 1 H),  
8.12 (d, J = 8.5 Hz, 1 H), 8.02 (d, J = 8.3 Hz, 1 H),  7.74 (t, J = 7.6 Hz, 1 H), 7.64  (d, J = 
8.1 Hz, 1 H), 7.45 (d, J = 7.4 Hz, 2 H),  7.41 (d, J = 7.4 Hz, 2 H), 7.32–7.15 (m, 6 H), 
4.57 (app. quin, J = 6.6 Hz, 1 H), 3.55 (dd, J = 6.0, 14.3 Hz, 1 H), 3.22 (dd, J = 6.8, 13.9 
Hz, 1 H), 2.70–2.58 (m, 2 H), 2.02–1.83 (m, 2 H). The enantiopurity was determined to 
be 63:37 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 1.50% 
IPA/Hexanes, 1.25 mL/min, λ 254 nm, RT= 39.1 and 42.1 min). 
 
(S,E)-5-(3-(4-methoxyphenyl)allyl)-2,2-diphenyltetrahydrofuran (4-2k): The general 
procedure was employed for the coupling of 1,1-diphenylpent-4-en-1-ol (0.20 mmol, 
47.7 mg) and (E)-1-(2-bromovinyl)-4-methoxybenzene15 (0.40 mmol, 85.0 mg) using a 
catalyst composed of Pd(COD)Cl2 (0.008 mmol, 2.3 mg) and 4-L41 (0.012 mmol 8.9 
mg), a reaction temperature of 90 °C and a reaction time of 12 h. This procedure 
afforded the title compound (18%, 14.0 mg) as a clear oil. [α]23D  4.54 (c 0.22, CHCl3);
1H 
NMR (400 MHz, CDCl3) δ 7.46 (d, J = 7.5 Hz, 4 H), 7.33–7.23 (m, 6 H), 7.22–7.15 (m, 2 
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H),  6.83 (d, J = 8.8 Hz, 2 H), 6.40 (d, J = 16.0 Hz, 1 H), 6.83 (dt, J = 7.0, 15.7 Hz, 1 H), 
4.31–4.21 (m, 1 H), 3.80 (s, 3H), 2.70–2.58 (m, 2 H), 2.57–2.40 (m, 2 H), 2.06–1.86 (m, 
1 H), 1.81–1.70 (m, 1 H).  Other spectral data matched that of the literature.5 The 
enantiopurity was determined to be 79:21 er by chiral HPLC analysis (chiralcel ADH, 25 
cm x 4.6 mm, 0.50% IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 17.5 and 18.8 min). 
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Chapter 5 
Synthesis of Benzo-fused Oxygen Heterocycles 
5.1 Introduction and Importance of Benzo-fused Oxygen Heterocycles 
 Enantiopure benzo-fused oxygen heterocycles are displayed in a variety of 
natural products, biologically active compounds, and pharmaceuticals.1 These 
biologically active oxygen heterocycles include compounds of different ring sizes 
(Figure 5.1) including isochromans (A),1a isobenzofurans (B),1b and oxepines (C).1c 
These compounds display interesting and diverse biological activities serving as 
antidepressants, antifungal agents, and also squalene synthase inhibitors. 1 
Figure 5.1 Biologically active benzo-fused oxygen heterocycles 
 
Due to the array of interesting biological activities possessed by these chiral 
benzo-fused oxygen heterocycles, accessing these compounds from simple precursors 
is of interest to the synthetic community. One such method of obtaining chiral benzo-
fused oxygen heterocycles would be the addition of a heteroatom across an alkene via 
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transition metal catalysis. As mentioned in chapter 4, similar enantioselective 
methodologies exist for the synthesis of amine heterocycles, but only a few of these 
methods exist for the related synthesis of oxygen heterocycles.2,3 
 We envisioned that benzo-fused oxygen heterocycles could be accessed through 
an enantioselective carboetherification reaction. Previously in our group, Dr. Amanda 
Ward demonstrated the utility of synthesizing chromans in a racemic manner to afford 
an array of benzofused oxygen heterocycles.5 Also, unpublished work by Dr. Ward 
showed that a screen of chiral ligands failed to afford these chroman products in high 
enantioselectivities (Scheme 5.1). After initial attempts at improving the chroman 
system with different ligands and reactions conditions, we decided to synthesize a 
slightly different class of benzo-fused oxygen heterocycles. 
Scheme 5.1 Previous reactions to afford enantiopure chromans 
 
5.2 Initial Substrate Synthesis and Ligand Screen 
 Previous work in our group demonstrated that enantioselectivity was influenced 
by the electronics of the cyclizing heteroatom.5 Thus, we decided to alter the electronics 
of the chroman system mentioned above (Scheme 5.1) by moving the oxygen 
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heteroatom one carbon unit away from the ring. Based on literature pKa values,6 this 
change should have a substantial effect on the electronics of our cyclizing oxygen, 
making it considerably more electron rich. Furthermore, substrates of this nature would 
allow us to access isochromans, which are attractive synthetic targets as well (Figure 
5.1).1a To test our hypothesis that altering the electronics might increase 
enantioselectivity, we synthesized substrate 5-1 in a straightforward manner from 
readily available 2-bromobenzylalcohol (Scheme 5.2).  
Scheme 5.2 Synthesis of substrate 5-1 
 
 With substrate 5-1 in hand, we undertook a ligand screen with conditions similar 
to those noted in the previous chapters. Parallel to our approach in chapter 4, we were 
interested in initially testing ligand scaffolds that were modular, and as such we 
screened various TADDOL and BINOL based ligands (Table 5.1). All of the non-
TADDOL based ligand systems in Table 5.1 afforded isochroman product 5-2 in poor 
yields and enantioselectivities. However, we were excited to see product 5-2 was 
afforded in good enantioselectivity (94:6 er), albeit poor yield (15%), when 5-L7 was 
used as the ligand. Part of the reason for the poor yield arises from a side reaction 
forming the oxidized product 5-3. Although starting material was noted in the crude 
NMR (10%), heating the reaction to a higher temperature only afforded 5-2 in 20% yield, 
and side product 5-3 was still observed in the crude reaction mixture in 25% yield. Due 
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to the poor yield of product 5-2, we decided to examine different reaction conditions for 
this transformation. 
Table 5.1 Initial ligand screen of substrate 5-1a 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 1.50 equiv Ar-Br, 1.50 
equiv NaO
t
Bu, toluene (0.10 M), 90 °C, 12-14 h. 
b
Yields refer to NMR yields, and enantiomeric ratios refer 
to isolated compounds.  
 
 Initially, we tested different bases in this reaction to observe how the nature of 
the base affects the yield of oxidation product. As shown in Table 5.2, the base is 
important for the formation of the oxidation product 5-3, but the choice of base can also 
affect the isomerization of 5-1 to the conjugated alkene 5-4. A clear trend on how 
different bases affect the reaction outcome was not observed, and slight differences in 
the nature of the base led to varied results. For instance, the use of K2CO3 (entry 2) led 
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to no formation of desired product 5-2, and the only noted product was the isomerized 
alkene 5-4 in 45% yield. On the other hand, the use of Cs2CO3 (entry 3) led to formation 
of desired product 5-2 in 10% yield, and also the formation of the oxidized product 5-3 in 
35% yield. Furthermore, lowering the reaction temperature (entry 5) with ligand 5-L7 led 
to no formation of any of the products. Changing the ligand to 5-L6 and using a lower 
temperature did afford 5-2 in 15% yield (entry 6), but the enantioselectivity was almost 
unchanged compared to the normal reaction conditions in Table 5.1.  
Table 5.2 Effects of changing reaction conditions on yielda 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 1.50 equiv Ar-Br, 1.50 
equiv base, solvent (0.10 M), 45-90°C, 12 h. 
b
Yields refer to NMR yields, and enantiomeric ratios refer to 
isolated compounds. 
c
A product arising from a suspected heck reaction was noticed in the crude nmr. 
d
ND means not determined for the reaction, as we were more concerned with improving yields.  
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 The combination of a specific base in different solvents also has drastic effects 
on the reaction selectivity. For instance (entries 11, 12, 13) Cs2CO3 in DCE yields the 
isomerized product 5-4 in 50% yield. Cs2CO3 in dioxane affords the desired product 5-2 
and the oxidized product 5-3 both in 30% yield. Cs2CO3 in CF3Ph does not favor any of 
the products being formed and starting material 5-1 still remains in 30%. In some 
reactions Heck products appeared in quantities of up to 15%. While some of the mass 
balance is still unaccounted for, it is possible other side products and decomposition 
products were washed away during the standard workup for these reactions.  
To try and eliminate one of the side reactions during the formation of product 5-2 
above, substrate 5-5 (Scheme 5.3) was synthesized as it would not be able to undergo 
the oxidation to an aldehyde. Unexpectedly, this reaction was unproductive and no 
desired product was noted in the crude reaction mixtures and/or the isolated material. 
Although some apparent Heck product was isolated from this reaction, the rest of the 
mass balance is unknown at this time. 
Scheme 5.3 Reaction of 5-5 under the standard conditions 
 
 Although we were unable to afford isochroman 5-2 in high yields, we were still 
interested in the synthesis of other benzo-fused oxygen heterocycles. Additionally, we 
can use what we learned from the synthesis of isochroman 5-2 and apply that 
knowledge to access new substrates that will not undergo facile isomerization or 
oxidation reactions. To this extent, we synthesized substrate 5-6, which would allow us 
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to access chiral isobenzofurans. Notably, this heterocyclic motif is utilized in the 
Lexapro (Figure 5.1), which was the 12th bestselling pharmaceutical in the USA in 
2010.1b 
 To access isobenzofurans enantioselectivly, we were interested in screening 
ligands that afforded good enantioselectivities for the isochroman system. However, as 
noted in Table 5.3, 5-L6 and 5-L7 were poor ligands for this transformation. Fortunately, 
the chiral PHOX ligand 5-L9 afforded the product in excellent yield, albeit in fairly low 
enantioselectivity. Changing the isopropyl group in 5-L9 to the tert-butyl group in 5-L12 
did increase the enantioselectivity. Unfortunately, other changes to the system, such as 
altering the phosphine, had a deleterious effect on the enantioselectivity. Furthermore, 
other ligand systems, such as the chiral binaphthyl ligands 5-L16 and 5-L17, failed to 
afford the product in higher enantioselectivities as well. 
 To improve the substrate scope of these reactions, we wanted to attempt 
the synthesis of isobenzofuran products that contained a quaternary center in the 
molecule, as these compounds would resemble the antidepressant Lexapro (Figure 
5.1). Additionally, our group has a general interest in forming products bearing 
quaternary centers, as these motifs are typically difficult to access by heteroatom 
additions to 1,1-disubstituted alkenes with transition metals.5c As such, we synthesized 
substrate 5-8 and subjected it to our carboetherification reaction conditions. Product 5-9 
was afforded in good yield albeit in poor enantioselectivity (Table 5.4).  
 
 
 
188 
 
Table 5.3 Ligand screen with substrate 5-6a 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.00 equiv Ar-Br, 2.00 
equiv NaO
t
Bu, toluene (0.10 M), 100 °C, 12 h. 
b
Yields refer to NMR yields, and enantiomeric ratios refer 
to isolated compounds. 
c
A product arising from a suspected heck reaction was noticed in the crude nmr.  
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Table 5.4 Formation of an enantioenriched quaternary centera 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.00 equiv Ar-Br, 2.00 
equiv NaO
t
Bu, xylenes (0.10 M), 135 °C, 12 h. 
b
Yields refer to NMR yields, and enantiomeric ratios refer 
to isolated compounds 
 
 We also wanted to look back into the synthesis of isochromans, as we 
realized the potential to generate the other isomer of isochroman with our 
carboetherification reactions. The substrate 5-10 to access this new isomer bears a 
styrenyl group (Table 5.5). Thus, we decided to use a PHOX ligand for this reaction, as 
these ligands performed well with the styrenyl substrates in Tables 5.3 and 5.4. 
Unfortunately, subjecting substrate 5-10 to our reaction conditions failed to afford 
isochroman 5-11 in good yield or enantioselectivity. 
We were also interested in the synthesis of seven membered ring oxepines, 
which are noted in interesting biologically active motifs (Figure 5.1). Unfortunately, the 
reaction of substrate 5-12 under the conditions in Table 5.6 failed to yield any desired 
product with the chiral ligands tested. However, product was noted in the case of the 
racemic ligand DPEPhos (by crude NMR analysis), and different reaction conditions and 
chiral ligands need to be tested for this substrate in the future. 
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Table 5.5 Synthesis of isochroman 5-11a 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.00 equiv Ar-Br, 2.00 
equiv NaO
t
Bu, toluene (0.10 M), 100 °C, 12 h. 
b
Yields refer to NMR yields, and enantiomeric ratios refer 
to isolated compounds. 
 
 
Table 5.6 Synthesis of 7-membered ringsa 
 
a
 Conditions: Reactions were conducted using 1.0 equiv substrate (0.10 mmol), 2.00 equiv Ar-Br, 2.00 
equiv NaO
t
Bu, toluene (0.10 M), 110 °C, 12 h. 
b
Yields refer to NMR yields. 
C
5-12 was no longer present in 
the crude nmr.  
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5.3 Conclusions 
 The work described above demonstrates the potential of these enantioselective 
carboetherification reactions to afford a variety of different compounds. The formation of 
the isochroman 5-2 is especially promising as it already affords products in up to 94:6 
er. However, optimization of this reaction needs to be re-examined. PHOX ligands 
should be investigated further, as they might be able to hinder the oxidation side 
product. Furthermore, the formation of isobenzofurans (5-7 and 5-9) is interesting as it 
is the first Pd-catalyzed carboamination or carboetherification reaction to take place with 
a styrene in high yields. Moreover, altering the electronics of these systems could lead 
to better enantioselectivity, and it would be useful to determine how the nucleophilicity 
of the oxygen atom affects the enantioselectivity of the products mentioned in chapter 5 
(Figure 5.2). Lastly, some ideas for new ligands for these transformations are shown 
below in Figure 5.2, as these ligands resemble scaffolds that were effective for the 
reactions in chapter 5. 
Figure 5.2 New substrates and ligand scaffolds  
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5.4 Experimental 
General: Reactions were carried out under nitrogen in flame-dried glassware. 
Tris(dibenzylideneacetone)dipalladium was purchased from Strem Chemical Co. and 
used without further purification. All other reagents including all aryl and alkenyl 
bromides were purchased from commercial sources and used as received unless 
otherwise noted. 2-(2-vinylphenyl)propan-2-ol7 and 1-bromo-2-(1-phenylvinyl)benzene8 
were prepared according to literature procedures. Xylenes were purified by distillation 
over CaH2 prior to use in reactions.  Toluene was purified using a GlassContour solvent 
system. All yields refer to isolated compounds that are estimated to be >90% pure as 
judged by 1H NMR or GC analysis unless otherwise noted. The yields reported herein 
chapter 5 describe the result of a single experiment, and in some cases only NMR 
yields are noted as some products were difficult to separate and accurate isolated yields 
could not be determined. Absolute configurations of the molecules in this chapter have 
yet to be determined. 
 
((2-allylbenzyl)oxy)trimethylsilane (5-S1): Butylmagnesium chloride (2.0 M THF, 4.00 
mmol, 2.0 mL) was added to a flame dried round bottom flask that was equipped with a 
stir bar. 8 mL of dry THF was added to this and the solution was stiffed at 0 °C for 5 
minutes. To this, was added nBuLi (2.5 M Hexanes, 8.1 mmol, 3.24 mL) and it was 
stirred at 0 °C for 10 minutes. After this time, the mixture was cooled to -42 °C in a dry 
ice/acetonitrile bath. To this mixture was then added ((2-
bromobenzyl)oxy)trimethylsilane in 30 mL dry THF and it was stirred for 30 minutes. 
After this time a mixture of CuCN (30%, 2.43 mmol, 217 mgs) and LiCl (60%, 4.86 
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mmol, 206 mgs) was added in 5 mL dry THF immediately followed by the addition of 
allyl bromide (32.4 mmol, 2.80 mL). This mixture was allowed to stir for 30 minutes and 
it was then quenched by adding 80 mL of EtOAc and 10 mL of saturated ammonium 
chloride. This mixture then stirred for 30 minutes and it was added to a separatory 
funnel and the organics were collected and washed 1x 20 mL brine. The organics were 
dried with sodium sulfate and the solvent was evaporated in vacuo. The crude product 
was purified by flash chromatography on silica gel to afford the title compound in 775 
mgs (43%) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.45–7.40 (m, 1 H), 7.26–7.22 
(m, 2 H), 7.20–7.16 (m, 1 H), 6.03–5.93 (m, 1 H), 5.08 (d, J = 10.3 Hz, 1 H), 5.01 (d, J = 
17.1 Hz, 1 H), 4.72 (s, 2H), 3.43 (d, J = 6.03 Hz, 2 H), 0.17 (s, 9H). 
 
(2-allylphenyl)methanol (5-1): To a solution of ((2-allylbenzyl)oxy)trimethylsilane (775 
mgs, 3.52 mmol) in 8 mL dry THF was added TBAF (1M THF, 7.04 mL). This mixture 
was allowed to stir for 2 hours at room temperature and then the THF was removed in 
vacuo. The crude residue was dissolved in 40 mL diethyl ether and washed 1 x 10 mL 
brine. The organics were dried with sodium sulfate and the solvent was evaporated in 
vacuo. The crude product was purified by flash chromatography on silica gel to afford 
the title compound in 395 mgs (76%) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.43–
7.38 (m, 1 H), 7.31–7.24 (m, 2 H), 7.24–7.20 (m, 1 H), 6.07–5.98 (m, 1 H), 5.12–5.07 
(m, 1 H), 5.05–4.99 (m, 1 H), 4.73 (d, J = 5.9 Hz, 2 H), 4.73 (d, J = 5.9 Hz, 2 H), 3.50 (d, 
J = 6.1 Hz, 2 H), 1.65-1.62 (m, 1H). 
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Methyl 2-allylbenzoate (5-S2): Starting with Methyl 2-bromobenzoate (5mmol, 0.72 
mL) and following the procedure for 5-S1 above, the title compound was afforded in 440 
mgs (50%) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 7.4 Hz,  H), 
7.45 (t, J = 7.7 Hz,  H), 7.33–7.28 (m, 2 H), 6.07–5.98 (m, 1 H), 5.09–5.00 (m, 2 H), 3.90 
(s, 3 H), 4.73 (d, J = 6.3 Hz, 2 H). 
 
2-(2-allylphenyl)propan-2-ol (5-5): Methyl 2-allylbenzoate (480 mgs, 2.72 mmol) was 
added to a flame dried flask with 30 mL diethyl ether. The flask was cooled to 0 °C while 
the mixture stirred. MeMgBr (3 M Et2O, 3.60 mL) was added dropwise to this solution. 
After 5 hours it was quenched with 5 mL of a satured ammonium chloride solution. The 
aqueous layer was extracted 3 x 20 mL diethyl ether and the organic layers were 
combined, dried with sodium sulfate, and the solvent was removed in vacuo. The crude 
product was purified by flash chromatography on silica gel to afford the title compound 
in 265 mgs (55%) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.45–7.41 (m, 1 H), 7.27–
7.16 (m, 3 H), 6.12–6.03 (m, 1 H), 5.10–4.96 (m, 2 H), 3.85–3.80 (m, 2 H), 1.67 (s, 6H). 
 
2-(2-(1-phenylvinyl)phenyl)propan-2-ol (5-8): 1-bromo-2-(1-phenylvinyl)benzene8 
(2.31 mmol, 600 mgs) was added to a flame dried flask under nitrogen with 5 mL dry 
diethyl ether. This solution was cooled to 0 °C and then nBuLi (2.5M hexanes, 0.92 mL) 
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was added slowly. This mixture was stirred at 0 °C for one hour and then acetone (4.62 
mmol, 0.34 mL) was added slowly in 2 mL dry diethyl ether. This was allowed to stir for 
30 minutes at 0 °C and then 30 minutes at room temperature before it was quenched by 
the addition of 5 mL of a saturated ammonium chloride solution. It was extracted 3 x 10 
mL diethyl ether, dried over sodium sulfate, and concentrated in vacuo. The crude 
product was purified by flash chromatography on silica gel to afford the title compound 
in 320mgs (58%) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.55–7.53 (m, 1 H), 7.39–
7.23 (m, 7 H), 7.16–7.14 (m, 1 H), 5.90 (s, 1H), 5.13 (s, 1H), 1.49 (s, 6H). 
 
2-methyl-1-(2-vinylphenyl)propan-2-ol (5-10): 2-bromostyrene (16 mmol, 2mL) was 
added to a flame dried flask with 45 mL dry THF. It was cooled to -78 °C. nBuLi (2.5 M 
hexanes, 7.0 mL) was added drop wise over 15 minutes with a syringe pump. After 
stirring for 1.5 hours at this temperature, isobutylene oxide (17 mmol, 1.50 mL) was 
added over 5 minutes. The solution was allowed to stir at this temperature for 30 
minutes and then it was allowed to stir at room temperature for 1 hour. The reaction was 
quenched by the addition of 20 mL of a saturate ammonium chloride solution. It was 
extracted 3 x 25 mL diethyl ether, dried over sodium sulfate, and evaporated in vacuo. 
The crude product was purified by flash chromatography on silica gel to afford the title 
compound in 813 mgs (29%) as a white solid.  
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2-(2-(but-3-en-1-yl)phenyl)propan-2-ol (5-12): 1-bromo-2-(but-3-en-1-yl)benzene 
(4.73 mmol, 1.00 g) was added in 0.50 mL diethyl ether to a flame dried flask containing 
freshly ground magnesium turnings (6.15 mmol, 150 mgs). Once the Grignard reagent 
starts forming 5 mL of diethyl ether is slowly added. Stir for 1 hour. Cool to 0 °C and add 
acetone (14.2 mmol, 1.04 mL) in 1 mL dry diethyl ether. Stir for 4 hours and then 
quench with 3 mL of a saturated ammonium chloride solution. Extract 3 x 15 mL diethyl 
ether, dry sodium sulfate, and evaporate in vacuo. The crude product was purified by 
flash chromatography on silica gel to afford the title compound in 550 mgs (61%) as a 
clear oil. 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 7.88 Hz,  1H), 7.27–7.14 (m, 3 H), 
6.01–5.91 (m, 1 H),  5.15–4.99 (m, 2 H), 3.14–3.05 (m, 2 H), 2.46–2.38 (m, 2 H),  1.78–
1.65 (m, 7 H). 
General Procedure A: Asymmetric Pd-catalyzed carboamination reactions. A 
flame dried Schlenk flask equipped with a stir bar was cooled under a stream of 
nitrogen and charged with Pd2(dba)3 (2 mol %), Ligand (6 mol %), the aryl or alkenyl 
halide (1.0–2.0 equiv.), NaOtBu (1.3–2.0 equiv.), and the oxy alkene substrate. The 
flask was purged with nitrogen, and toluene (0.1 M) was added (xylenes was used as 
solvent in cases where reactions were heated over 110 °C). The resulting mixture was 
heated to 80–125 °C with stirring for 12–15 hrs. The reaction mixture was then cooled to 
rt, saturated aqueous ammonium chloride (6 mL/mmol) was added, and the mixture was 
transferred to a separatory funnel. The mixture was extracted with ethyl acetate and the 
combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
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concentrated in vacuo. The crude product was then purified by flash chromatography on 
silica gel using hexanes/Et2O as the eluant. 
 
3-(naphthalen-2-ylmethyl)isochromane (5-2): According to general procedure A (2-
allylphenyl)methanol (0.10 mmol, 14.8 mgs), Pd2(dba)3 (2%, 0.002 mmol, 1.8 mgs), 5-
L7 (6%, 0.006 mmol, 4.7 mgs), NaOtBu (0.15 mmol, 14.4 mgs), and 2-
bromonaphthalene (0.15 mmol, 31.0 mgs) were all reacted to afford the title compound 
in 15 % yield (according to NMR) as a clear oil. Isolated material was determined to be 
94:6 er by chiral HPLC analysis (chiralcel ODH, 15 cm x 4.6 mm, 1.00% IPA/Hexanes, 
1.00 mL/min, λ 225 nm, RT= 8.9 and 11.1 min). 1H NMR (500 MHz, CDCl3) δ 7.86–7.80 
(m, 3 H), 7.75 (s, 1H), 7.51–7.42 (m, 3 H), 7.17–7.13 (m, 2 H), 7.07–6.98 (m, 2 H), 4.90 
(d, J = 15.2 Hz,  1H), 4.83 (d, J = 15.2 Hz,  1H), 4.09–4.02 (m, 1 H), 3.26 (dd, J = 6.8, 
13.7 Hz,  1H), 3.04 (dd, J = 6.3, 13.9 Hz,  1H), 2.84 (dd, J = 11.0, 16.1 Hz,  1H),  2.71 
(dd, J = 2.7, 16.4Hz,  1H). 
 
1,1-dimethyl-3-(naphthalen-2-ylmethyl)-1,3-dihydroisobenzofuran (5-7): According 
to general procedure A 2-(2-vinylphenyl)propan-2-ol7 (0.10 mmol, 16.2 mgs), Pd2(dba)3 
(2%, 0.002 mmol, 1.8 mgs), (S)-tBuPHOX (6%, 0.006 mmol, 2.3 mgs), NaOtBu (0.20 
mmol, 19.2 mgs), and 2-bromonaphthalene (0.20 mmol, 41.0 mgs) were all reacted to 
afford the title compound in 19.0 mgs (65 %) as a clear oil. The product was determined 
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to be 81:19 er by chiral HPLC analysis (chiralcel ODH, 15 cm x 4.6 mm, 1.00% 
IPA/Hexanes, 1.00 mL/min, λ 254 nm, RT= 4.1 and 5.0 min). 1H NMR (500 MHz, 
CDCl3) δ 7.85–7.78 (m, 3 H), 7.72 (s, 1H), 7.50–7.42 (m, 3 H), 7.31–7.26 (m, 1 H), 7.21 
(t, J = 7.4 Hz,  1H), 7.11 (d, J = 7.4 Hz,  1H), 6.95 (d, J = 7.6 Hz,  1H), 5.60 (app. t, J = 
6.2 Hz,  1H), 3.34 (dd, J = 6.4, 13.7 Hz,  1H), 3.24 (dd, J = 6.2, 13.9 Hz,  1H), 1.50 (s, 
3H), 1.49 (s, 3H). 
 
1,1-dimethyl-3-(naphthalen-2-ylmethyl)-3-phenyl-1,3-dihydroisobenzofuran (5-9): 
According to general procedure A 2-(2-(1-phenylvinyl)phenyl)propan-2-ol (0.15 mmol, 
36.0 mgs), Pd2(dba)3 (2%, 0.002 mmol, 1.8 mgs), (S)-
iPrPHOX (6%, 0.006 mmol, 2.3 
mgs), NaOtBu (0.20 mmol, 19.2 mgs), and 2-bromonaphthalene (0.20 mmol, 41.0 mgs) 
were all reacted to afford the title compound in 40.0 mgs (73 %) as a clear oil. The 
product was determined to be 67:33 er by chiral HPLC analysis (chiralcel ODH, 15 cm x 
4.6 mm, 1.00% IPA/Hexanes, 0.500 mL/min, λ 254 nm, RT= 6.8 and 7.5 min). 1H NMR 
(500 MHz, CDCl3) δ 7.76–7.65 (m, 4 H), 7.61–7.57 (m, 2 H),  7.50 (s, 1H), 7.42–7.32 
(m, 5 H), 7.29–7.23 (m, 2 H), 7.16 (d, J = 8.5 Hz,  1H), 6.95 (d, J = 7.6 Hz,  1H), 3.60 
(app. s, 2H), 1.40 (s, 3H), 1.17 (s, 3H). 
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3,3-dimethyl-1-(naphthalen-2-ylmethyl)isochromane (5-11): According to general 
procedure A 2-methyl-1-(2-vinylphenyl)propan-2-ol (0.15 mmol, 17.6mgs), Pd2(dba)3 
(2%, 0.002 mmol, 1.8 mgs), (S)-tBuPHOX (6%, 0.006 mmol, 2.3 mgs), NaOtBu (0.20 
mmol, 19.2 mgs), and 2-bromonaphthalene (0.15 mmol, 31.0 mgs) were all reacted to 
afford the title compound as a clear oil (25 % yield by NMR, product co-eluted with ArBr 
and an accurate isolated yield was not obtained). A small amount of isolated product 
was determined to be 57:43 er by chiral HPLC analysis (chiralcel OJH, 25 cm x 4.6 mm, 
0.00% IPA/Hexanes, 1.00 mL/min, λ 225 nm, RT= 36.0 and 48.8 min). 1H NMR (500 
MHz, CDCl3) δ 7.82–7.73 (m, 2 H), 7.71 (d, J = 8.5 Hz,  1H),  7.64 (s, 1H), 7.45–7.36 
(m, 3 H), 7.21–7.12 (m, 3 H), 6.99 (d, J = 7.3 Hz,  1H), 5.15 (app. t, J = 5.4 Hz,  1H), 
3.40 (dd, J = 4.3, 14.0 Hz,  1H), 3.22 (dd, J = 6.6, 14.3 Hz,  1H), 2.62 (d, J = 15.4 Hz,  
1H),  2.42 (d, J = 15.6 Hz,  1H),  1.34 (s, 3H), 1.11 (s, 3H). 
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